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Human  papillomaviruses  (HPV)  activate  a  number  of  host  factors  to  control  their  
differentiation-­dependent   life   cycles.   The   manipulation   of   these   host   cell  
signalling   pathways   can   result   in   the   developement   of   cancer   and   HPV   is  
responsible   for   around   5%   of   all   cancers   worldwide.   Gaining   a   better  
understanding  of  these  virus:  host  interactions  is  critical  for  the  development  of  
treatments   for  HPV   infection  and  associated  cancers.  The  transcription   factor  
signal   transducer   and  activator   of   transcription   (STAT)-­3   is   important   for   cell  
cycle  progression  and  cell  survival  in  response  to  cytokines  and  growth  factors.  
STAT3  requires  phosphorylation  on  Ser727,   in  addition   to  phosphorylation  on  
Tyr705   to  be   transcriptionally  active.  Although  STAT3  has  been  shown   to  be  
hyperactive   in  many   cancers,   including   cervical   cancer,   there   is   a   paucity   of  
information  on  the  role  of  STAT3  during  the  productive  HPV  life  cycle  and  HPV-­
associated  cancers.  Utilising  a  primary  keratinocyte  system  to  study  the  full  HPV  
life  cycle,   this  study  demonstrates   that  STAT3   is  essential   for   the  HPV18   life  
cycle  in  both  undifferentiated  and  differentiated  keratinocytes.  Furthermore,  the  
HPV   E6   oncoprotein   is   identified   to   be   sufficient   to   induce   the   dual  
phosphorylation   of   STAT3   at   Ser727   and   Tyr705   by   a  mechanism   requiring  
Janus   kinases   and   members   of   the   MAPK   family.   Importantly,   silencing   of  
STAT3  protein  expression  by  siRNA  or  inhibition  of  STAT3  activation  by  small  
molecule   inhibitors,   or   by   expression   of   dominant   negative   STAT3  
phosphorylation   site   mutants,   results   in   blockade   of   cell   cycle   progression.  
Organotypic   raft   cultures   of   HPV18   containing   keratinocytes   expressing   a  
phosphorylation  site  STAT3  mutant  display  a  profound  reduction  in  suprabasal  
hyperplasia,  which  correlates  with  a  loss  of  cyclin  B1  expression  and  increased  
differentiation.   Finally,   increased   STAT3   expression   and   phosphorylation   is  
observed  in  HPV  positive  cervical  disease  biopsies  compared  to  normal  cervical  
tissue,   highlighting   a   role   for   STAT3  activation   in   cervical   carcinogenesis.   In  
confirmation   of   this,   STAT3   phosphorylation   was   demonstrated   to   be   in  
increased  in  HPV+  cervical  cancer  cells  when  compared  to  HPV-­  cervical  cancer  
cells.  Detailed  mechanistic  study  identified  that  this  was  due  to  an  increase  in  
IL-­6  auto/paracrine  signalling  induce  by  HPV  E6  in  an  NFk-­dependent  manner.  
Finally,  STAT3  was  demonstrated  to  essential  for  the  proliferation,  migration  and  
invasion   of   HPV+   cervical   cancer   cells.   Utilisation   of   a   clinically   available  
inhibitor   of   JAK2,   an   upstream   kinase   for   STAT3,   also   resulted   in   a   similar  
impairment  of  proliferation,  migration  and  invasion.    
In  summary,  our  data  provides  evidence  of  a  critical  role  for  STAT3  in  the  HPV18  
life  cycle  and  in  HPV+  cervical  cancer  cells.  This  suggests  a  possible  therapeutic  
target  for  both  HPV  infection  and  in  the  treatment  HPV+  cervical  cancer   
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STAT   signal  transducer  and  activator  of  transcription    
STING   stimulator  of  interferon  genes  
SV40   simian  vacuolating  virus  40  
T  or  t   thymine  
TAD   transactivation  domain  
TBK1   TANK-­binding  protein  1  
TAE   Tris-­Acetic  acid-­EDTA  buffer  
TAP   transporter  associated  with  antigen  processing  
TBS   Tris  buffered  saline  
TBST   Tris  buffered  saline  containing  Tween-­20  
TCR   T-­cell  receptor  
TEMED   tetramethylethylenediamine  
TGF   transforming  growth  factor  
TLR9     toll-­like  receptor  9  
TRIM   tripartite  motif-­containing  protein    
TopBP1   topoisomerase  IIb-­binding  protein  1  
UK   United  Kingdom  
URR   upstream  regulatory  region  
USA   United  States  of  America  
USP   ubiquitin  specific  protease  
UV   ultraviolet  radiation  
UV  B   ultraviolet  B  radiation  
vDNA   viral  deoxyribonucleic  acid  
VEGF   vascular  endothelial  growth  factor  
v/v   volume  per  volume  
v-­ATPase   vacuolar  ATPase  
VLP   virus-­like  particle  
w/v   weight  per  volume  
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Chapter  1.  Introduction  
1.1  Papillomaviridae     
The  Papillomavirdae   (PV)  are  an  ancient   taxonomic   family  of  double  stranded  DNA  
viruses   that   infect   almost   all  mammals   and  other   amniotes   such  as   birds,   fish   and  
reptiles  (1).  A  distinctive  feature  of  the  PV  is  their  genotype-­specific  tropism,  which  is  
host  restrictive,  and  the  preference  for  certain  PV  types   to   infect  specific  anatomical  
regions  (2).  The  first  papillomavirus  was  isolated  in  1933  in  cottontail  rabbits  (3),  with  
the   latest   identified   from   a   cervical   swab   in   2018   (4).   Over   300   types   of  
papillomaviruses,  including  225  types  of  human  papillomaviruses  (HPVs),  have  been  
identified   to   date,  and   these  are  arranged   in   52  different   genera.   The   classification  
system  used  is  by  the  Reference  Centre  for  Papillomaviruses  initiated  in  Heidelberg  (5)  
in  1985,  but  now  managed  from  the  Karolinska  Institute.  Papillomavirus  classification  is  
based  on  the  nucleotide  sequence  of  the  gene  coding  for  the  L1  capsid  protein;;  HPV  
that  belong  to  different  genera  have  less  than  60%  similarity.  The  most  common  HPV  
genera   are   α-­,   β-­,   γ-­,   µ-­genera,   with   the   α-­   genera   having   the   highest   clinical  
significance  (Fig  1.1).     
There  are  currently  5  genera  of  HPV,  split  into  individual  species  that  share  between  
60  and  70%  similarity   (6).  Each  species  comprises  of  several  HPV   types   that  have  
similar  biological  properties.  The  αPV-­9  species  includes  HPV16,  31,  33,  35,  52,  58  
and   67.   These   viruses   infect   the  mucosal   epithelium   and   are   associated   with  
malignancies  (7)  and  are  therefore  often  referred  to  as  ‘high-­risk’  HPV  types.  Infection  
with  the  ‘low-­risk’  HPV  types,  such  as  HPV6  and  11  of  the  αPV-­10  species,  leads  to  
the  development  of  benign   legions   in   the  mucosal  epithelium.  Collectively,  these  
species  of  HPV  are  called  ‘mucosal’  PVs,  as  they  infect  the  mucosal  epithelium.  PVs  
that   cause   legions   of   the   skin,   such   as   HPV49   of   the   βPV-­3   species,   are   called  
‘cutaneous’  PVs.  Although  these  viruses  are  mostly  linked  with  the  development  of  
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warts  (flat,  plantar  or  genital),  growing  evidence  suggests  they  may  also  contribute  
to  skin  carcinogenesis    as  a  co-­factor  together  with  UV  irradiation  (8,9).    
  
  
Figure   1.1.  Evolutionary   Relationship   between   Human   Papillomaviruses.  
The  human  papillomaviruses  types  found  in  humans;;  α-­,  β-­,  γ-­,  µ-­  and  v-­.  HPV  
types   from   the   α-­PV   genus   are   often   classified   as   low-­risk   cutaneous   (light  
brown);;   low-­risk   mucosal   (yellow);;   or   high-­risk   (pink)   according   to   their  
association  with  malignancies.  The  ‘high-­risk’  types  highlighted  with  red  text  are  
confirmed  as   “human   carcinogens”   on   the   basis   of   epidemiological   data.   The  




1.2  HPV  Transmission    
HPV  is  the  most  commonly  sexually  transmitted  disease  in  the  world  (10).  Infection  
occurs   through  micro   abrasions   in   the   epidermis   of   the   recipient,  most   commonly  
through  direct  contact  with  an   infected  person.  Mucosal  HPV   types  are   transferred  
horizontally  (i.e.  through  sexual  contact)  or  vertically  (i.e.  from  other  to  child),  with  the  
primary  infection  route  being  sexual  contact  (11).  HPV  can  also  be  transmitted  in  utero;;  
the  virus  can  spread  through  the  placenta,  amniotic  fluid  or  during  delivery  (12).  
Cutaneous  HPVs  that  cause  warts  are  often  spread  in  children  due  to  the  increased  
frequency  of  person  to  person  contact  and  the  tendency  to  have  mouth  to  contaminated  
surface   contact   (13).   Despite   the   high   rate   of   infant   infection,   these   are   generally  
cleared  with  a  year.     
  
1.3  HPV  associated  disease     
1.3.1  Cutaneous  lesions     
The  most  well  studied  HPV  types  that  infect  the  cutaneous  epithelia  are  those  of  the  β-­
genus   (8).   These   viruses  are  most   commonly   associated  with   the   development   of  
planta  warts  (HPV1,  2  and  4)  and  flat  warts  (HPV3,  10  and  49) (14).  These  warts  are  
characterised  by   the   hyperkeratosis   throughout   the   dermis.  Although   these   viruses  
establish   a   persistent   infection,   the   warts   are   benign   and   cause   relatively   minor  
discomfort  to  patients,  with  80%  of  cutaneous  warts  spontaneously  resolving.     
A  rare  disorder  called  Epidermodysplasia  verruciformis  (EV),  which  is  characterised  
by   an   impaired   innate   immune   system   due   to   homozygous  mutations   in  EVER  
genes,  results  in  an  increased  susceptibility  to  β-­HPV  infection  (15).  This  leads  to  
the  development  of  skin  lesions  and  often  to  squamous  cell  carcinomas  induced  by  
HPV5  and  8  (16).  Recent  studies  have  demonstrated  that  the  loss  of  the  EVER2  gene  
allows  constitutive  Protein  Kinase  C  (PKC)α-­dependent  c-­Jun  phosphorylation  and  
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this  drives  HPV5  long  coding  region  (LCR)  activation  and  viral  replication  (17).  This  
can  lead  to  viral  persistence  and  the  potential  to  develop  skin  cancer.  
Despite  little  research  into  the  role  of  the  cutaneous  HPVs  in  skin  cancer  development,  
the  contribution  of  other  HPV  species  in  the  β-­genus  to  cancer  formation  has  been  
demonstrated(8).  The  E6  and  E7  proteins  encoded  by  HPV  49,  a  β-­3  species,  have  
been  shown  to  have  similar  functionality  to  the  ‘high-­risk’  mucosal  HPV  types,  with  
co-­expression  of  both  HPV49  E6  and  E7  able  to  induce  the  immortalisation  of  primary  
human  keratinocytes  (18).  Furthermore,  HPV49  E6  and  E7  expressing  transgenic  mice  
were  highly  susceptible  to  upper  digestive  tract  carcinogenesis  upon  initiation  with  
4-­nitroquinoline  1-­oxide  (4NQO) (19).  Additionally,  expression  of  HPV  38  E6  and  E7  
in   a   transgenic   mouse   model   makes   them   more   susceptible   to   UV-­induced   skin  
carcinogenesis  and  induces  the  accumulation  of  UV-­induced  DNA  mutations  (20).  
 
1.3.2  Mucosal  lesions  
Infections  caused  by  the  α-­HPV  types  are  much  more  common  than  those  of   the  
cutaneous  HPVs;;  however,  many  of  these  infections  are  symptomless.  The  most  
common  anatomical  site  of  symptomatic  α-­HPV  types  is  the  genital  mucosa  and  the  
oropharyngeal   tract;;  HPV6  and  11  are   the  most  common  cause  of  genital  warts  
(21).   However,   many   of   these   warts   regress   and   spontaneously   resolve   within   6  
months.   Additionally,   HPV6   and   11   can   also   cause   Recurrent   Respiratory  
Papillomatosis  if  they  infect  the  laryngeal  mucosa  (22).  This  is  a  rare  medical  condition  
that  causes  the  appearance  of  benign  tumours  called  papillomas  in  the  aerodigestive  
tract  and   this  may  cause  a  narrowing  of   the  airways.  Although   the  development  of  
Recurrent   Respiratory   Papillomatosis   is   often   easily   treated;;   however,   in   very   rare  
cases  the  benign  legions  can  turn  malignant  (23).    
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HPV13  and  32  are  strongly  associated  with  development  of  focal  epithelial  hyperplasia  
or   Heck’s   disease,   a   rare   benign   legion   of   the   oral   mucosa   (24).   This   is   often  
characterised  by  multiple  whitish  or  normal  coloured  papules   in   the  oral  cavity  and  
primarily  occurs  in  children,  with  most  cases  spontaneously  regressing  over  time.  
The   ‘high-­risk’   HPV   types   are   the   cause   of   several  malignant   cancers   of   different  
anatomical  sites,  the  most  common  being  anogenital  sites  and  head  and  neck  cancers  
(2).  HPV  infection  of  the  mucosal  epithelia  has  been  shown  to  be  a  contributing  factor  
for  cancers  of  the  uterine  cervix,  penis,  vagina,  vulva,  anus  and  the  oropharynx.  The  
role  of  HPV   in   the  development  of  cervical  cancer  has  been  the  most  studied  HPV  
cancer  to  date,  with  Professor  Harold  Zu  Hausen  winning  the  Nobel  prize  for  his  work  
in  identifying  the  association  of  HPV  with  cervical  cancer  (25).  Currently,  there  are  13  
‘high-­risk’  HPV  types  associated  with  cervical  cancer  –  HPV16,  18,  31,  33,  35,  39,  45,  
51,  52,  56,  58,  59  and  68  –  although  HPV16  and  18  account  for  almost  70%  of  all  cases  
(2).  Most  HPV  infections  of  the  cervix  resolve  on  their  own  and  pre-­cancerous  legions  
often  spontaneously  revert  to  normal;;  however,  persistent  HPV  infections  can  develop  
further  in  to  cervical  intraepithelial  neoplasia  (CIN).  Although  symptomless,  progression  
through  the  CIN  grades  from  CIN  I,  abnormal  cells  of  the  cervix,  to  CIN  3,  all  cells  of  
the  cervix  are  highly  abnormal,  can  result  in  the  progression  to  invasive  carcinoma  (2).  
Cervical   cancers   are   characterised   from   the   anatomical   site   in   which   they   arise.  
Cancers  that  start  in  the  transformation  zone  of  the  cervix  are  squamous  cell  carcinoma  
(SCCs),  with  the  other  cervical  cancer  being  adenocarcinomas  (26).  
HPV  was  first  identified  as  a  causal  agent  in  head  and  neck  cancers  (HNCs)  in  1983  
(27)and  over   the   past   15   years,   the   number  of  HPV+  HNC  has   rapidly   increased,  
reaching  epidemic  levels  in  the  western  world  (28).  HNC  are  a  diverse  group  of  tumours  
and  the  role  of  HPV  in  HNC  is  sub-­type  specific;;  whilst  around  25%  of  HNC  is  attributed  
to  HPV  infection,  60%  of  oropharyngeal  cancers  are  associated  with  HPV  infection,  in  
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certain  geographical  locations.  The  overwhelming  majority  of  HPV+  HNC  are  caused  
by  HPV16,  with  HPV18,  31,  33  and  35  playing  a  minor  role  (29).    
HPV   is  also  associated  with  rarer  cancers  of   the  anogenital   regions;;   it  accounts   for  
approximately  50%  of  penile  cancers,  66%  of  vaginal  cancers,  35%  of  vulvar  cancers  
and  90%  of  anal  cancers  (29).  Again,  the  most  commonly  associated  HPV  type  in  these  
cancers  is  HPV16  (29).  
  
1.4  Epidemiology  of  Papillomaviridae  
HPV   associated   disease   has   a   high   impact   worldwide,   with   HPV   associated  
cancers  accounting   for  ~  5%  of  all  cancers  worldwide  and  having  a  significant  
level  of  morbidity  and  economic  burden,  particularly  in  developing  countries  (30).  
The  prevalence  rate  of  HPV  infection  is  high,  with  80-­90%  of  female  adults  likely  to  
contract  HPV  during  their  life  time  (31).  However,  the  risk  of  contracting  HPV  is  much  
greater  for  women  in  Africa  and  Central  American  when  compared  with  Europe  (32).  
Furthermore,  despite  the  fact  that  the  burden  of  HPV-­associated  cancers  is  higher  in  
developing  countries,  the  prevalence  of  HPV  infection  with  ‘high-­risk’  types  does  not  
differ  greatly.     
  
1.4.1.  Epidemiology  of  HPV  malignancies  
Cervical   cancer   is   the   fourth   most   common   cause   of   female   cancer   death  
worldwide  (33).  Developing  countries  account  for  85%  of  all  cancer  cases  (Fig  1.2),  
with  around  50%  leading  to  death.  Almost  100%  of  cervical  cancer  cases  are  attributed  
to  HPV  infection,  with   54%  caused  by  HPV16  and  16.5%  by  HPV18   (26).  HPV  
infection  also   accounts   for   a   larger   proportion  of   other   female   cancers,  with  ~  
35%  of  vulvar  and  66%  of  vaginal  cancers  caused  by  HPV  infection.  Additionally,  
HPV  is  responsible  for  over  90/%  of  anal  cancers  in  both  men  and  women  (34).  Again,  
these  cancers  are  much  more  prevalent  in  developing  countries,  likely  due  to  the  lack  
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of  contraceptive  use  and  inadequate  vaccine  programmes  (35).  Penile  cancer  is  a  rare  
cancer,  accounting  for  only  0.5%  of  cancers  in  men.  HPV  accounts  for  50%  of  all  penile  
cancers.  The  rates  of  penile  cancer  worldwide  correlate  with  cervical  cancer  and  are  




Figure   1.2.   Age   standardised   rate   of   cervical   cancer   worldwide.   Age  
standardised  rates  (ARS)  indicated  are  per  100,  000  women  per  year.  Adapted  
from  WHO  and  ICO,  2012.  
  
Head  and  neck  squamous  cell  carcinoma  (HNSCC)  is  the  6th  most  common  cancer  
worldwide  and  has  been  on  the  rise  in  the  past  20  years  (29).  HPV-­  HNSCC  are  
most  commonly  caused  by  excessive  smoking  and  drinking,  or  poor  dental  hygiene  
(37).  The  prevalence  of  HPV-­  HNSCC  is  higher  is  Asian  countries  such  as  China  and  
India,  whereas   in  Europe  and   the  US,  HPV+  HNSCC   is   currently   undergoing  an  
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epidemic.  In  the  1980’s,  around  20%  of  HNSCC  were  associated  with  HPV  infection,  
whereas  today,  around  70%  are  positive  for  HPV  (38).  
  
  
Figure   1.3.   The   distribution   and   incidences   of   HPV   and   Non-­HPV   cases   in  
selected  HPV  associated  cancers.  The  HPV  associated  cancer  cases  (dark  blue)  
are  contrasted  with  non-­HPV  cancer  cases  (light  blue).  
  
1.5  Prevention  and  treatment  of  HPV  associated  disease  
There  are  currently   three  approved  prophylactic  vaccines  against  HPV;;  all  of   these  
vaccines  are  composed  of  self-­assembled,   recombinant  L1  major  capsid  protein  as  
virus-­like  particles  (39).  The  three  vaccines  offer  protection  against  different  HPV  types;;  
Ceravix  (GlaxoSmithKline,  UK)  is  a  bivalent  vaccine  and  offers  protection  against  the  
most   common   HPV   types   associated   with   malignancy,   HPV16   and   18.   Gardasil  
(Merck,  USA),  a  quadrivalent  vaccine,  also  offers  protection  against  these  HPV  types  
but  offers  additional  protection  against   the   ‘low-­risk’  HPV   types  6  and  11,   the  most  
common   cause  of   genital   warts.   The  most   recently   developed   vaccine,  Gardasil   9  
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(Merck)  offers  the  same  protection  as  Gardasil,  but  also  protects  against  HPV31,  33,  
45,  52  and  58,  which  account  for  around  20%  of  cervical  cancers  (40).    
Since   the   development   of   these   vaccines,   many   governments   have   installed  
vaccination  programmes  for  young  females  (41).  In  the  UK,  girls  aged  between  12-­13  
years  old  receive  the  vaccine  through  secondary  education  programmes.  In  July  2018,  
it  was  announced  that,  in  the  UK,  boys  in  the  same  age  bracket  will  also  receive  the  
vaccine  (42).  This  is  likely  due  to  the  increase  in  HPV+  oropharyngeal  cancer  cases  
worldwide.     
  
Despite  the  efficacy  of  these  vaccines,  there  are  several   limitations.  Firstly,  the  high  
cost   of   these   vaccines   means   that   it   is   difficult   to   initiate   successful   vaccination  
programmes   in   poorer,   developing   countries,   where   cases   of   HPV   infection   and  
associated  cancers  are  highest  (43).     
  
Another  limitation  of  these  vaccines  is  that  they  are  not  therapeutic  and  thus  are  not  a  
treatment   option   for   people   already   infected  with   the   virus.  Currently,   there   are   no  
specific  anti-­viral   compounds   targeting  PVs.  This  means   that  current   treatments   for  
HPV  associated  disease   rely  on  non-­specific  approaches   that   results   in  many  side  
effect  (44).  For  patients  with  CIN   lesions,  clinicians   treat   the  symptoms  and  not   the  
virus;;  these  include  cryotherapy,  loop  electrosurgical  excision  and  cone  biopsies  (45).  
For  invasive  cervical  cancers,  hysterectomy  or  generic  chemoradiotherapy  treatments  
are  the  only  options  (46).  In  some  HPV  associated  cancers,  such  as  HNSCC,  surgery  
combined  with  chemoradiotherapy  is  also  an  option  (47).  In  the  benign  HPV  induced  
lesions,  such  as  genital  warts,  generic  anti-­virals  such  as  cidofovir  are  often  used  (48).  
Additionally,  genital  warts  can  be  treated  with  cryotherapy  (49).     
Cervical  cancers  have  shown  a  steady  decline  worldwide  over  the  past  30  years  (50).  
This  is  due  to  the  introduction  of  cervical  screening  programmes  in  many  countries.  
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These  screening  assays  often   involve  a  cytology-­based  Papanicolaou   (Pap)  smear  
test,  which  detects  abnormalities  in  patients’  cells  to  identify  the  presence  of  CIN.  If  CIN  
is   identified,   a   small   biopsy   is   taken   to   check   for   HPV   DNA   or   RNA   (51).   These  
programmes  are  still  not  widely  used  in  developing  countries;;  this  is  mostly  due  to  the  
cost  of  initiating  country  wide  programmes  and  is  likely  why  cervical  cancer  risk  is  much  
greater   in   these   countries   (52).   Therefore,   the   current   treatment   options   for   HPV  
infection  and  associated  disease  are  non-­specific  and  expensive,  limiting  their  used  to  
developed  countries.  Basic  research  is  still  required  to  identify  novel  therapeutic  targets  
for   HPV   infection   and  malignancies   to   reduce   the   burden   of   these   cancers   in   the  
developing  world.  
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1.6  Papillomavirus  Virology  
1.6.1  Genome  organisation  
Papillomaviruses  are  small,  non-­enveloped,  double-­stranded  DNA  viruses  with  a  
circular  genome  of  approximately  8000  bp  packaged  into  an  icosahedral  capsid  of  
around  60  nm   (7).  The  genome   is   comprised  of   three   regions;;   the  early   region  
encodes  6  open  reading  frames  (ORFs)  for  the  E1,  E2,  E4,  E5,  E6  and  E7  proteins  
(some   papillomavirus   types,   such   as   HPV31   and   BPV,   also   encode   for   an   E8  
protein  (53))  (Fig  1.44A).  The  late  region  encodes  for  the  major  structural  protein  
L1  and  the  minor  structural  protein  L2.  The  upstream  regulatory  region  (URR)  or  
long  control  region  (LCR)  contains  the  origin  of  replication  (ori)  and  binding  sites  
for  a  number  of  host  transcription  factors  and  several  early  proteins  responsible  for  
the  control  of  viral   replication  (Fig  1.4A).  The  HPV18  genome  also  contains   two  
promoter  regions;;  p105  (p97  in  HPV16  and  31),  contained  upstream  of  the  E6  open  
reading   frame   (ORF)   in   the   URR,   that   facilitates   early   gene   expression,   and   a  
differentiation   dependant   promoter   at   p811,  p765  or   p829   (p670   in  HPV16  and  
p742   in   HPV31)   that   is   contained   within   the   E7   ORF   and   this   is   active   during  
productive  viral  replication  (54).  
  
1.6.2  Papillomavirus  life  cycle  
Productive  viral  infection  requires  the  proliferation  and  differentiation  of  the  basal  
epithelial  host  cell,  the  keratinocyte  (55);;   infected  cells  must  remain  active  in  the  
cell   cycle   upon   cellular   differentiation   for   proficient   virus   production.   Infection  
requires  entry  of  HPV  into  the  basal  epithelial  cell  layer  via  microlesions  to  the  skin  
or  mucosa;;  the  tropism  of  HPV  is  biased  towards  keratinocytes  in  the  basal  layer  
of  the  stratified  squamous  epithelia  (56).    
HPV  entry   is  mediated  via   interactions  with  a  range  of  putative  host  cell  surface  
receptors  including  heparan  sulphate  proteoglycans  and  α-­6  integrins  (57-­59)  and  
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the  viral  major  capsid  protein  L1.  Binding  of  L1  to  these  receptors  leads  to  exposure  
of  the  N-­terminus  of  the  L2  protein;;  L2  is  then  cleaved  by  the  host  protease  furin,  
further   exposing   a   segment   of   L1   to   interact   with   an   unidentified   cell   receptor  
(60,61).  
The  virus  can  then  enter  the  cell  via  a  range  of  endocytic  routes  depending  on  the  
specific  papillomavirus  (62).  These  include  clathrin-­mediated  or  caveolin-­mediated  
endocytosis;;  however,   the   ‘high-­risk’  HPV   types  enter  via  an  endocytic  pathway  
that  is  clathrin,  caveolin,  lipid  raft,  and  dynamin  independent  and  instead  depends  
on   highly   regulated   actin   dynamics   and   an   association   with   CD151-­containing  
tetraspanin-­enriched   microdomains   (63,64).   Disassembly   of   the   viral   capsid   is  
initiated   by   the   acidic   endosomal   lumen,   and   L1,   L2,   and   viral   DNA   traffic   via  
retrograde  pathways   to   the  Golgi   apparatus  and  endoplasmic   reticulum  prior   to  
nuclear  entry   (65).  This   trafficking   is  mediated  by   direct  binding  of   the   retromer  
complex  to  L2  (66).  
  
Delivery   of   the   viral   genome   to   the   nucleus allows   it to   be   expressed   as   an  
autonomous  replicating  episomal  element.  Upon  nuclear  entry,  the  viral  genome  is  
rapidly   replicated   to   between   100-­200   copies   per   cell   (2).   After   initial   viral  
replication,  one  daughter  cell   remains   in   the  basal   layer   to  serve  as  an  episome  
reservoir,  while   the  other  daughter  cell  migrates   to   the  suprabasal   layers  of   the  
epithelium,  where  HPV  prevents   the   cell   from  exiting   from   the   cell   cycle. In   the  
suprabasal  layers,  early  viral  gene  (E5,  E6,  E7)  expression  (Fig  1.4B)  allows  the  
infected  cell  to  remain  in  an  active  cell  cycle.  This  induces  viral  DNA  replication  and  
genome  amplification;;  as  the  progeny  move  up  the  epithelial  layer,  E4  is  expressed  
alongside  the  late  genes  (L1,  L2)  and  capsid  proteins  are  formed  in  the  upper  layers  
of  the  suprabasal  epithelium.  The  E2  protein  recruits  the  viral  genome  to  sites  of  
virion  assembly  and  this  is  directed  by  the  L2  minor  capsid  protein  (67,68).  This  is  
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followed   by   viral   capsid   assembly   and   virion   release,   allowing   infection   of  





Figure  1.4.  HPV  genome  organization  and  viral   life  cycle.  A)  Organisation  of  
the  HPV18  genome,  showing  the  relative  positions  of  the  six  early  genes  (E1,  E2,  
E4,  E5,  E6,  E7),  the  two  late  genes  (L1  and  L2)  and  the  upstream  regulatory  region  
(URR).  Additionally,  the  early  and  late  promoter  regions  are  shown,  as  are  the  E2  
(cyan  circles)  and  E1   (blue   rectangle)  binding  sites   in   the  URR   (image  adapted  
from  (69)).  B)  Schematic  of  the  skin  architecture  and  HPV  viral  gene  expression.  
Stages  of  the  viral  life  cycle  and  viral  gene  expression  at  these  stages  are  outlined  
(70).  
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1.7  Papillomavirus  proteins  
1.7.1  E1  and  E2  regulatory  proteins  
The  papillomavirus  E1  protein  is  the  most  conserved  viral  protein  and  forms  a  homo-­
hexameric  DNA  helicase  (71).  It  is  the  only  viral  protein  with  enzymatic  function  and  they  
are   highly   modulated   by   the   host   cell,   through   phosphorylation,   SUMOylation   and  
caspase-­dependent  cleavage  (72).  The  E1  proteins  are  highly  unstable  and  are  degraded  
by  the  ubiquitin-­proteasome  pathway;;  the  formation  of  the  hexameric  structure  increases  
the  stability  of  the  protein  (73).  The  E1  ORF  is  expressed  from  the  early  viral  promoter  
(71).     
The  E1  protein  consists  of  three  distinct  regions;;  the  regulatory  domain  at  the  N-­terminus  
control  the  nuclear  import/export  of  E1  through  a  nuclear  localisation  signal  (NLS),  which  
is  essential  for  the  control  of  viral  replication  (74).  Phosphorylation  of  the  NLS  by  the  host  
kinase  cyclin  dependent  kinase  2  (CDK2)  and  prevents  nuclear  translocation  of  E1  and  
subsequent   DNA   replication   (75).   E1   phosphorylation   by   mitogen-­activated   protein  
kinases   (MAPK)  Extracellular  signal-­Related  Kinase   (ERK)  and  Jun  N-­terminal  Kinase  
(JNK)  promotes  nuclear   translocation  and   thus  viral   replication  (76).  The  DNA-­binding  
domain  (DBD)  is  adjacent  to  the  N-­terminal  domain  and  recognises  the  viral  ori  site  on  the  
LCR(77).  The  DBD  also   facilitates   the  dimerization  of  E1  proteins  (77).  Finally,   the  C-­
terminal   domain   contains   the   helicase   domain,   consisting   of   three   sub-­domains;;   the  
adenosine  triphosphate  (ATP)-­binding  domain,  the  oligomerisation  domain  and  the  brace  
domain,   which   stabilises   the   homo-­hexamer   during   DNA   unwinding   (78).  
E1  helicase  activity  is  required  for  the  establishment  of  viral  genome  episome  pools  upon  
infection  and  to  promote  genome  amplification  during  the  later  stages  of  infection.  Host  
modulation  of  E1  by  caspase-­dependent  cleavage  promotes  E1-­dependent  amplification  
of  the  viral  genome  (79).     
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The  E2  protein  is  an  essential  viral  protein  that  forms  stable  homo-­dimers  in  the  nucleus  
(80).  Like  the  E1  protein,  E2  proteins  contain  an  NLS  and  are  inherently  unstable.  Their  
stability  is  regulated  by  phosphorylation  and  SUMOylation  (81).  Unusually,  the  E2  ORF  is  
expressed  from  both  the  early  and  late  promoter,  depending  on  the  stage  of  the  virus  life  
cycle  (82).  As  E2  is  essential  for  the  productive  stages  of  the  life  cycle,  E2  expression  from  
the  late  promoter  results  in  a  higher  level  of  E2  protein  expression  (83).  
  
The  E2  proteins  contain  three  domains;;  the  N-­terminal  transactivation  domain  (TAD)  plays  
essential   roles   in  genome  replication  and  the  control  of  viral   transcription  (82).  The  C-­
terminal  domain  is  the  dimerization  domain  and  the  DBD,  which  recognises  the  consensus  
sequence   ACCN6GGT.   These   two   domains   are   linked   by   an   unstructured,   poorly  
conserved  hinge  region  and  this  controls  nuclear  localisation  (84).  
E2  proteins  interact  with  viral  and  host  cell  proteins  to  establish  successful  infection  and  
promote  viral  replication.  E2  binding  to  the  minor  capsid  protein  L2  is  required  to  establish  
initial  viral  replication  (85).  E2  also  plays  the  major  role  in  controlling  the  transcription  of  
viral  genes  by  recruiting  the  cellular  transcriptional  machinery  to  both  activate  or  supress  
gene  transcription.  An  important  role  of  E2  is  the  tethering  of  the  viral  episomes  to  mitotic  
chromosomes  to  ensure   the  episomes  remain  in  daughter  cells  upon  cell  division;;   this  
requires  he  binding  of  E2  to    bomodomain-­containing  4  (BRD4)  (86-­89).  E2  is  loaded  on  
to  mitotic  chromosome  by  binding  to  the  host  cell  protein  ChlR1  (90).  These  processes  
are  essential  for  the  maintenance  of  viral  genomes.     
  
Importantly,  the  E2  ORF  is  often  lost  or  disrupted  during  viral  genome  integration  into  the  
host   genome.   This   removes   the   control   of   viral   transcription   by   E2,   resulting   in   the  
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uncontrolled   expression   of   HPV   E6   and   E7,   promoting   tumourigenesis   (91).  
  
Both  the  E1  and  E2  regulatory  proteins  are  essential  for  the  initiation  and  maintenance  
of  viral  replication  upon  infection.  The  viral  ori  site  contains  palindromic  binding  sites  for  
E1  and  2-­3  E2  binding  sites  (92);;  these  allow  the  correct  assembly  of  the  E1  hexamer  in  
the  correct  orientation  on  the  DNA.  To  initiate  replication,  the  E2  protein  first  recruits  E1  to  
the  ori  site,   forming  a   ternary  complex  (72).  Conformational  changes   then  result   in   the  
ATP-­dependant  melting  of  the  DNA  at  the  ori  site  (77).  The  resultant  single  stranded  DNA  
allows  the  formation  of  two  E1  hexamers  to  bind  and  further  unwind  the  DNA.  This  allows  
for  the  recruitment  and  binding  of  host  cell  DNA  replication  machinery  to  the  viral  DNA,  
including  topoisomerase  I  {Clower:2006en}.  
  
1.7.2  L1  and  L2  structural  proteins  
The  papillomavirus  capsid  consists  of  two  proteins,  the  major  capsid  protein  L1  and  the  
minor  capsid  protein  L2  (93).  In  the  mature  virion,  360  L1  proteins  are  arranged  into  72  
pentameric  capsomers  alongside  an  unknown  number  of  L2  proteins,  however  this  may  
be  up  to  72  (93).  The  L1  pentameric  capsomers  are  connected  by  di-­sulphide  linkages  
between  cysteine  residues;;  these  are  highly  conserved  between  HPV  types  (94).     
The  entire  surface  of  the  virion  consists  of  the  L1  protein,  with  the  N-­  and  C-­termini  facing  
into  the  lumen  of  the  virus.  This  results  in  the  L1  protein  facilitating  the  entry  of  virions  into  
the  host  cell  via  the  interaction  with  heparin  sulphate  proteoglycans  (59,95).  This  receptor  
binding  induces  conformational  changes  in  the  virion  capsid,  exposing  the  L2  protein  and  
allowing  its  cleavage  by  the  host  protease  furin  (60,61).  Further  conformational  changes  
results   in   the   binding   of   the   virion   to   an   as   of   yet   unidentified   receptor   (96).  
  
 35 
After  cell  entry,  the  virus  traffics  through  the  endocytic  pathway,  first  entering  early  and  
then   late  endosomes  (97).  Disassembly   of   the   viral   capsid   is   initiated   by   the   acidic  
endosomal   lumen,   mediated   by   L2   (98)   and   the   L2/viral   DNA   (vDNA)   traffics   via  
retrograde   pathways   to   the   Golgi   apparatus   and   endoplasmic   reticulum   prior   to  
nuclear  entry.  Entry  of  the  virus  to  the  trans-­golgi  network  requires  the  previous  cleavage  
of  L2  by  furin  (61).  The  trafficking  is  mediated  by  direct  binding  of  the  retromer  complex  
to  L2  (66).  The  L2/vDNA  complex  is  then  trafficked  to  the  nucleus  by  interacting  with  the  
motor  protein  dynein  (99)  and  entry   to   the  nucleus   requires  breakdown  of   the  nuclear  
envelope  during  mitosis  (100,101).  Recently,  a  central  region  of  the  L2  protein  has  been  
demonstrated  to  be  essential  for  the  tethering  of  the  viral  genome  and  mitotic  nuclear  entry  
(101).     
  
Both  the  L1  and  L2  proteins  are  transcribed  from  the  late  viral  protein  during  the  productive  
stages  of  the  virus  life  cycle(102).  Upon  the  completion  of  the  life  cycle,  the  proteins  are  
expressed   in   the  cytoplasm  and  L1   is  pre-­assembled   into  pentameric  capsomers  (94).  
These  capsomers,  along  with  L2,  are  then  imported  into  the  nucleus  via  NLS  sequences,  
and  viral  assembly  occurs.  
  
1.7.3  E4  proteins    
The  papillomavirus  E4  proteins  are  not  well  conserved  among  papillomavirus  types  and  
their   functions   are   relatively   poorly   understood   (103).   The   E4   protein   of   most  
papillomaviruses  localise  to  the  cytoplasm  where,  during  the  late,  productive  stages  of  the  
virus  life  cycle,  they  bind  to  cytokeratins  and  form  fibrous,  amyloid-­like  structures  (104).  
The  E4  ORF  is  part  of  the  early  region  of  the  viral  genome  within  the  E2  ORF;;  however,  
E4   is  expressed   from  the   late  viral  promoter   (102).  The  E4  protein   is  expressed  as  a  
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spliced  transcript,  containing  the  initiating  codon  of  the  E1  ORF  and  the  whole  E4  ORF.  
The   protein,   therefore,   is   also   termed   E1^E4   (termed   E4   here)   (105).  
The  functions  of  E4  are  regulated  by  post  translation  modification  by  host  cell  kinases  and  
proteases  (103).  Phosphorylation  of  E4  by  the  MAP  kinase  ERK  results  in  the  stabilisation  
of  E4  and  enhances  binding   to  cytokeratins  (106).  E4  has  also  been  demonstrated   to  
induce  cell  cycle  arrest  in  the  G2  phase  of  the  cell  cycle,  promoting  viral  amplification  (107).  
E4  has  recently  been  shown  to  enhance  E1  nuclear  localisation  and  replication  efficiency;;  
this   is   in   a   HPV   type-­dependent  manner,   with   HPV16   being  more   dependent   on   E4  
functions  than  HPV18  (108).  Additionally,  E4  enhances  the  activation  of  the  MAP  kinases  
p38,  ERK  and   JNK,   further  enhancing  genome  amplification   (108).   The  production   of  
infections   virions   only   occurs   in   cell   expressing   E4,   demonstrating   its   role   in   virion  
production  (109).  
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1.7.4  Papillomavirus  oncoproteins  E5,  E6  and  E7  
1.7.4.1  E5  oncoprotein  
The  E5  oncoprotein  is  the  least  well  understood  oncoprotein  in  human  papillomaviruses.  
Not  all  papillomaviruses  encode  an  E5  protein:   it   is,  however,  expressed  in  all  clinically  
relevant  α–  genus  HPV  types  and  is  the  main  transforming  protein  of  the  carcinogenic  
Bovine  papillomaviruses  (BPV)  (110).  The  E5  ORF  is  located  at  the  3’  end  of  the  early  
region  of  the  viral  genome;;  however,  it  is  the  second  ORF  present  on  transcripts  from  the  
late  viral  promoter,  suggesting  it  may  play  important  roles  in  the  differentiation-­dependent  
stages  of  the  viral  life  cycle  (111).     
     
The  most  studied  E5  proteins  are  from  the  ‘high-­risk’  HPV  types  16  and  31  (112,113)  and  
BPV  E5  (110).  E5  proteins  are  integral  membrane  proteins  that  localise  to  the  endoplasmic  
reticulum   and   Golgi   apparatus   (114,115).   These   proteins   can   induce   anchorage  
independent   growth   in   fibroblasts   and   are   weakly   transforming   in   keratinocytes,  
suggesting  a  role  in  transformation  (116).  Furthermore,  mouse  studies  have  demonstrated  
that  E5  expression  results  in  epithelia  hyperplasia  and  the  spontaneous  development  of  
tumours  (117).     
  
As  E5  has  no  enzymatic  activity,  it  manipulates  the  host  cell  through  binding  to  several  
proteins   and  modulating   their   functions   (111).   A   key   pathway   targeted   by   E5   is   the  
epidermal   growth   factor   receptor   (EGFR)   signalling   pathway.   Mouse   studies   have  
demonstrated   that   the  oncogenic  potential  of  E5   is  minimised  upon   inhibition  of  EGFR  
(117).  The  mechanism  E5  uses  to  modulate  EGFR  and  downstream  mitogenic  signalling  
is  controversial.  The  initial  hypothesis  was  that  the  binding  of  E5  to  the  16K  subunit  of  the  
vacuolar  H+-­ATPase  inhibited  the  acidification  of  endosomes,  resulting  in  reduced  EGFR  
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degradation.  However,  some  groups  have  demonstrated  that  the  amount  of  E5  bound  to  
the  16K  subunit  of   the  vacuolar  H+-­ATPase   is   insufficient   to  account   for   the   increased  
EGFR  signalling  observed  (118).    Alternative  theories  have  arisen  through  the  discovery  
of  novel  E5  functions.  E5  can  inhibit  the  interaction  of  EGFR  with  the  ubiquitin  ligase  c-­
Casitas   B-­lineage   Lymphoma   (c-­Cbl),   resulting   in   increased   receptor   cycling   to   the  
membrane  and  prolonged  mitogenic  signalling   (119).  E5  expression  can  also   regulate  
mitogenic  signalling  independent  of  the  EGFR;;  E5  expression  promotes  PKC  expression  
at  the  cell  membrane,  resulting  in  EGF-­independent  MAPK  activation  (120).     
Additionally,   the   ‘high-­risk’  HPV  E5  proteins  have  been  demonstrated   to  have  channel  
forming  potential  and  thus  can  be  classified  as  viroporins  (121).  The  viroporin  function  of  
E5  is  required  for  the  activation  of  the  mitogenic  signalling  induced  by  E5  expression.  E5  
activity  can  been  inhibited  with  alkyl-­imino  sugars  and  classic  ion  channel  inhibitors  such  
as  rimantadine  (122);;  therefore,  E5  may  be  a  potential  therapeutic  target  for  HPV  infection  
and  associated  cancer.       
  
Another  major  function  of  E5  that  contributes  to  its  oncogenic  potential  is  the  manipulation  
of  the  immune  response.  A  number  of  E5  proteins  have  been  demonstrated  to  induce  the  
down  regulation  of  Major  histocompatibility  class  I  (MHC  I),  a  key  mediator  of  the  adaptive  
immune  response  (123,124).  This  regulation  is  highly  specific  as  only  certain  MHC  class  
I   alleles,   such  as  HLA-­A  and   -­B  are   targeted.  The  mechanism  E5  uses   for   the   down  
regulation  of  MHC  I  is  not  fully  understood  but  may  involve  the  retention  of  MHC  class  I  in  
the  Golgi   apparatus   (125).   This   could   additionally   involve   the   binding   of   E5   to   B-­cell  
receptor-­associated  protein  31  (BAP31)  and  its  binding  partner  A4  (126,127).     
In  contrast  to  Human  papillomaviruses,  E5  is  the  major  transforming  protein  in  BPV  (110).  
The  main  transforming  function  of  BPV  E5  is  through  modulation  of  the  platelet-­derived  
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growth   factor   b   receptor   (PDGFb-­R).   BPV   E5   dimerises   and   binds   to   two   PDGFb  
receptors,  inducing  receptor  dimerisation  and  activation.  The  activation  of  the  receptor  is  
ligand  independent  and  results  in  the  activation  of  downstream  mitogenic  signalling  (128).  
  
As  E5  is  not  expressed  by  all  papillomaviruses,  it  is  assumed  to  not  be  essential  for  viral  
infection.  During  the  virus  life  cycle,  E5  is  not  required  by  the  virus  in  undifferentiated  cells,  
with  no  difference  in  the  early  maintenance  of  genome  copy  number  noted  upon  loss  of  
E5  expression  (112,113).  However,  loss  of  HPV31  E5  led  to  a  reduced  expression  of  E4  
and  a  reduction  in  viral  transcription  from  the  late  promoter  and  genome  amplification  in  
differentiating  cells  (113),  with  a  subtler  effect  seen  in  HPV16  (112).  Recently,  it  has  been  
shown   that   HPV18   E5   supports   cell   cycle   progression   and   impairs   keratinocyte  
differentiation   by   enhancing   EGFR   signalling,   whilst   suppressing   keratinocyte   growth  
factor   receptor   (KGFR)   signalling   (129).   Additionally,   the   viroporin   function   of   E5   is  
required  for  the  expression  of  cyclin  B1,  a  key  cell  cycle  protein  required  for  maintenance  
of   the   cell   cycle   in   suprabasal   keratinocytes,   which   is   essential   for   viral   genome  
amplification  (122).  Further  studies  on  the  role  of  E5  during  the  productive  virus  life  cycle  
are  required  to  understand  the  molecular  mechanisms  involved.    
  
1.7.4.2  E7  oncoprotein  
The   E7   protein   of   the   ‘high-­risk’   HPV   types   is   the  major   virus   coded   transforming  
protein   (130);;   however,   not   all   papillomaviruses   encode   an   E7   protein.   E7   localises  
primarily   to   the   nucleus   of   infected   keratinocytes   but   often   shuttles   between   the  
nucleus  and  cytoplasm  (131).  E7  proteins  have  a  flexible  N-­terminus  and  a  structured  
C   terminus   (132);;   the   N-­   terminus   share   characteristics   of   other   well   known   viral  
oncogenes,  simian  vacuolating  virus  40  (SV40)  Large  T  antigen  and  the  adenovirus  E1A  
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through  two  conserved  regions,  CR1  and  CR2(133).  E7  has  also  been  shown  to  share  
some  characteristics  with  polyomavirus  small  t  antigen  and  can  compensate  for  small  t  
loss  in  transformation  assays  when  co  expressed  with  Large  T  (134).  The  CR2  region  
contains  the  LXCXE  motif  that  harbours  an  essential  function  of  E7;;  this  motif  mediates  
binding  to  the  pocket  proteins  pRb,  p107  or  p130  (135).  However,  residues  in  CR3  are  
also   required   for   optimal   binding   of   the   pocket   proteins   (136).   The   binding   of   pRb  
facilitates   the   release   of   the   transcription   factor   E2F,   which   then   constitutively  
activates   DNA   synthesis   and   cell   proliferation(137).   Rb   normally   binds   E2F   and  
inactivates  it;;  ‘high-­risk’  E7  induces  the  destabilisation  and  proteasomal  degradation  
of  Rb.  The  ‘low-­risk’  E7  proteins  bind  pRb  with  much  lower  affinity  than  ‘high-­risk’  E7  
proteins  as  determined  by  radiolabelled  co-­immunoprecipitation  experiements  and  this  
may  contribute  to  their  lack  of  transforming  ability  {Munger:1989un}.    E7  proteins  are  
also  phosphorylated  at  serine  residues  by  casein  kinase  II  in  the  CR2  domain  (138);;  the  
binding  of  Rb  and  the  phosphorylation  of  E7  by  CKII  are  critical  for  S  phase  entry.  An  
additional  phosphorylation  of  E7  by  dual-­specificity  tyrosine  phosphorylation-­regulated  
kinase  1A  (DYRK1A)  at  threonine  5  and  7  increases  the  stability  of  E7  and  thus  its  
transforming  potential   (139).   ‘High-­risk”  E7  can  also   inactivate   the  cyclin  dependent  
kinase  (Cdk)  inhibitors,  p21Cip1  and  p27Kip1	  (140,141).  
  
Other  key  transforming  activities  of  E7  include  activation  of  the  ataxia-­telangiectasia  
mutated  (ATM)   protein   DNA   damage   response   pathway   via   STAT5   activation	    
{Hong:2013fh}   and   this   can   lead   to   an   increase   in   genome   instability   that   might  
promote   transformation.   Induction   of   DNA   damage   can   cause   an   increase   in  
apoptosis;;  E7  can  counteract  anoikis,  or  apoptosis  due  to  lack  of  cell  attachment,  by  
interacting   with   p600   –   this   also   increases   anchorage   dependant   growth   and  
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contributes  to  malignant  progression  (142).  E7  also  induces  chromosomal  instability  
by  several  mechanisms.  Recent  work  demonstrated  that  E7  enhances  the  expression  
of  Chromatin  licensing  and  DNA  replication  1  (Cdt1),  a  DNA  replication  initiation  factor  
(143).  This  induces  an  arrest  in  the  cell  cycle  at  the  G2  phase  and  host  cell  replication  in  
the  absence  of  mitosis,  which  induces  genomic  instability  and  promotion  of  viral  genome  
integration.     
  
E7  proteins  are  also  involved  in  immune  evasion  strategies  employed  by  HPV.  E7  induces  
the   down   regulation   of   the   innate   immune   sensor   toll-­like   receptor   9   (TLR9)   through  
epigenetic  regulation  (144).  Furthermore,  E7  binds  to  the  Interferon  Regulatory  Factor  9  
(IRF9),   the  DNA-­binding   region  of   the   IFN-­stimulated  gene   factor  3   (ISGF3)   complex,  
disrupting   IFN-­a   signalling   (145).  E7   can  also   bind   to   IRF1,   inhibiting   IRF-­1  mediated  
activation  of  the  IFN-­b  promoter  (146).  In  addition  to  the  E5  oncoprotein,  E7  can  down  
regulate  MHC  class   I   from   the   cell   surface,   therefore  modulating   both   the   innate   and  
adaptive  immune  response  against  HPV  (147).     
  
E7  proteins  also  play  a  key  role  during  the  productive  virus  life  cycle.  E7  contributes  to  the  
inhibition  of  keratinocyte  differentiation  and  the  maintenance  of  the  cell  cycle  in  suprabasal  
keratinocytes  (148).  In  addition,  E7  inhibits  STAT1  phosphorylation  and  increases  STAT5  
phosphorylation;;  these  two  activities  of  E7  are  required  for  viral  genome  amplification  upon  
epithelial  differentiation  (149,150).    
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1.7.4.2  E6  oncoprotein  
1.7.4.2.1  a-­genus  E6  proteins  
As  with   the  E7  proteins,  E6  proteins   from   the  a-­genus  papillomaviruses  are  major  
contributors   to   transformation   (151).   The   E6   ORF   is   expressed   from   the   early   viral  
promoter  in  all  papillomaviruses  and  the  protein  remains  at  low  levels  upon  initial  infection.  
The   localisation   of   E6   protein   is   dependent   on   the   papillomavirus   type;;   ‘high-­risk’   E6  
proteins  are  localised  throughout  the  cytoplasm  and  nucleus,  with  ‘low-­risk’  E6  proteins  
primarily   localised   to   the  nucleus  (152).  The  E6  proteins  consist  of  N-­terminal  and  C-­
terminal  zinc  binding  domains  and  a  helix  linker  (153).  E6  proteins  from  the  ‘high-­risk’  
HPV   types   also   contain   an   eight   amino   acid   PDZ   (post   synaptic   density   protein,  
Drosophila  disc  large  tumour  suppressor,  zonula  occludens-­1  protein)  binding  ligand  
motif  at   the  C-­terminus.  The  sequence  of  this  PDZ  binding  motif  differs  between  HPV  
types  and  this  results  in  a  different  affinity  of  HPV  types  towards  different  PDZ  containing  
host  proteins  (154).     
  
The  E6  proteins  are  only  moderately  transforming  alone;;  the  transforming  ability  of  E6  
proteins   is   greatly   enhanced   in   the   presence   of   E7   (18).   Indeed,   transgenic   mice  
expressing  E6  alone  does  not   result   in   tumour   formation   (155).  E6  proteins   from  both  
mucosal  and  cutaneous  HPV  genera  recognise  and  bind  host  cell  proteins  containing  an  
acidic  leucine  rich  motif  (LXXLL)  (156).  Recently,  a  structural  study  has  demonstrated  that  
the   LXXLL  motif   binds   to   a   conserved   pocket   of   E6   (157).   One  major   target   of   this  
interaction  by  the  ‘high  risk’  HPV  types  is  the  tumour  suppressor  p53.  E6  binds  the  LXXLL  
of   the   host   cell   E3   ubiquitin   ligase   E6AP   and   the   subsequent   E6/E6AP   heterodimer  
induces   the   proteasomal   degradation   of   p53   (158).   Recent   structural   work   has  
demonstrated  that  the  binding  of  the  LXXLL  motif  on  E6AP  renders  the  conformation  of  
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E6  able  to  interact  with  p53,  which  is  essential  for  p53  degradation  (153).  This  function  of  
E6  is  especially  important  give  that  the  down  regulation  of  pRb  by  HPV  E7  leads  to  an  
increase  in  apoptosis  in  infected  cells  due  to  reduced  growth  and  an  increase  in  p53  
levels.   As   a   further   mechanism   of   p53   functional   inhibition,   E6   proteins   also   bind  
directly   to   p53   and   lead   to   a   block   in   p53-­dependant   transcriptional   activity   by  
interfering  with  its  DNA-­binding  activity  (159).  The  ‘low  risk’  HPV  types  can  also  interact  
with  E6AP  and  activate   its  ubiquitin   ligase  activity;;  however,   this  does  not   result   in   the  
degradation  of  p53.  ‘Low  risk’  HPV  type  E6  proteins  can,  however,  relocate  p53  to  the  
cytoplasm  (160).  These  proteins  interact  with  p300,  reducing  p53  acetylation  and  inhibiting  
p53-­dependent  apoptosis  in  response  to  DNA  damage  (161).  E6  binds  to  p53  through  two  
distinct  E6  binding  sites  of  p53  (162).  The  binding  of  E6  proteins   to   the  core  of  p53   is  
required  for  p53  degradation;;  however,  the  primary  site  of  E6  is  in  the  C  terminus  of  p53  
and  is  bound  by  most  E6  proteins  and  thus  has  no  role  in  p53  degradation.  Instead,  the  
‘low   risk’  HPV   type  E6  proteins   inhibit  p53  acetylation,   resulting   in   a   reduction   in   p53  
dependent  transcription  and  the  induction  of  pro-­apoptotic  genes  (161).  E6  has  also  been  
shown  to  degrade  p53  in  an  E6AP  independent  manner  (163).  E6AP  deficient  mice  can  
still  induce  the  degradation  of  p53  in  the  presence  of  E6,  suggesting  an  E6AP  independent  
mechanism  of  E6  mediated  p53  degradation  through  an  unknown  mechanism.     
  
The  degradation  of  p53  results  in  a  deregulation  of  the  cell  cycle  in  infected  cells  and  the  
promotion   of   cell   proliferation.   The   ‘high   risk’   HPV   E6   proteins   can   also   use   other  
mechanisms   to   promote   cell   cycle   progression   and   proliferation;;   E6   prolongs   EGFR  
signalling  by  enhancing  receptor  internalisation,  driving  downstream  mitogenic  signalling  
(164).  E6  proteins  can  also  induce  eIF4E  transcription  in  order  to  promote  proliferation  
(165).  E6,  as  with  E7,  can  also  inhibit  anoikis,  in  this  instance  by  increasing  activation  
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of  the  tyrosine  kinase  FAK,  causing  phosphorylation  and  activation  of  its  downstream  
target  paxillin,  resulting  in  cytoskeletal  rearrangements  that  allow  proliferation  in  the  
absence  of  cell  adherence  to  the  extracellular  matrix  (166).  Another  primary  function  of  
some   ‘high   risk’   HPV   E6   proteins   is   to   increase   telomerase   activity,   resulting   in  
increased   cell   proliferation   and   survival(167).The   mechanism   employed   by   E6   to  
induce  telomerase  activation   is  not   fully  understood;;   it  occurs   independently  of  p53  
degradation  and  E6AP  binding,  and  interactions  with  the  transcription  factor  Myc  and  
the  transcription  factor  NFX1-­91  are  thought  to  play  key  roles  (168).    
The  ‘low  risk’  E6  proteins  are  weak  transforming  proteins;;  this  is  primarily  due  to  their  poor  
efficiency  in  down  regulating  p53  function,  and  the  fact  that  ‘low  risk’  E6  proteins  cannot  
activate  telomerase  {Klingelhutz:1996js}.  
  
Additionally,   E6   proteins   from   ‘high-­risk’   HPV   types   that   have   lost   their   ability   to  
degrade  p53  can  still   immortalize  cells   through   their   interactions  with  host  proteins  
containing  PDZ  domains  including  the  putative  tumour  suppressor  proteins  Dlg  and  
Scribble  (169).    Mutation  of  the  residues  in  E6  necessary  for  binding  to  PDZ  binding  
domains  within  the  context  of  a  whole  HPV  genome  leads  to  reduced  host  cell  growth  
and  loss  of  viral  episomes  (170).  Recently,  a  study  has  demonstrated  a  striking  link  
between  the  number  of  PDZ  proteins  bound  by  E6  and  the  oncogenic  potential  of  the  
HPV  type  (154),  with  the  interaction  of  the  host  protein  Scribble  directly  correlating  with  
oncogenic  potential.  Moreover,  transgenic  mice  expressing  these  E6  mutants  are  no  
longer  able  to  develop  tumours  (170).  ‘Low  risk’  HPV  E6  proteins  do  not  contain  the  
PDZ  binding  motif  found  in  the  ‘high  risk’  E6  proteins,  preventing  them  from  binding  to  
this  group  of  proteins.     
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E6  proteins  also  play  a  role  in  the  inhibition  of  cell  apoptosis.  E6  proteins  from  both  
‘high   risk’   and   ‘low   risk’,   as  well   as  b   papillomaviruses,   can  bind   the   pro-­apoptotic  
protein  Bak;;  this  leads  to  the  degradation  of  Bak  (171).  Furthermore,  E6  proteins  can  
interact   with   Fas-­associated   protein   with   death   domain   (FADD)   and procaspase   8,  
preventing  downstream  apoptotic  signalling  (172).  E6  proteins  are  also  able  to  modulate  
the  NFkB  pathway  to  promote  cell  survival  and  transformation;;  this   is   regulated  by   the  
ability  of  E6  to  induce  the  degradation  of  the  deubiquitinase  Cylindromatosis  (CYLD)  in  a  
proteasome  dependent  manner  and   is  heightened  under  hypoxic  conditions   (173).  E6  
proteins  also  activate  mammalian  target  of  rapamycin  (mTOR)  (164);;  this  kinase  controls  
cell  proliferation  in  the  absence  of  nutrients  and  growth  signalling.  The  promotion  of  mTOR  
activity   by   E6   drives   downstream   signalling   through   the   kinases   AKT   and   3-­
phosphoionositide-­dependent   protein   kinase1   (PDK1)   to   allow   continued   cell  
proliferation.   Furthermore,   the   NFkB   and   B-­Cell   lymphoma   3   (BCL3)   target   gene  
KIAA1199  promotes  cell  survival  through  the  stabilisation  of  EGFR  and  the  maintenance  
of  EGFR  signalling  (174).     
  
In  addition  to  E5  and  E7,  E6  proteins  also  play  a  role  in  immune  evasion;;  E6  binds  to  IRF3,  
inhibiting  its  transactivation  and  preventing  the  transcription  of  IFN-­b  (175).  E6  proteins  
also  bind  to  the  non-­receptor  tyrosine  kinase  TYK2,  inhibiting  the  phosphorylation  of  TYK2  
and  the  subsequent  activation  of  STAT1  and  STAT2  (176).  HPV  E6  proteins  can  also  bind  
to   Ubiquitin   Specific   Protease   15   (USP15),   a   deubiquitinase   that   is   involved   in   the  
regulation  of  tripartite  motif-­containing  protein  25  (TRIM25),  an  E3  ubiquitin  ligase.  TRIM25  
is   important   in   the   activation   of   retinoic   acid-­inducible   gene   I   (RIG-­I),   a   pattern  
recognition  receptor  (PRR)  that  sense  viral  RNA(177).  E6  binds  to  USP15  and  TRIM25,  
increasing  TRIM25  ubiquitination  and  degradation.  This  results  in  the  suppression  of  RIG-­
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I  mediated  IFN-­b  induction  and  the  induction  of  IFN-­stimulated  genes  (ISGs)  (177).     
  
E6  proteins  are  also  important  during  the  productive  life  cycle  of  HPV.  E6  is  required  for  
efficient  viral  genome  amplification,  as  mutant  E6  that  are  deficient  in  destabilising  p53  
show  a  reduction  in  productive  virion  production  due  to  a  defect  in  viral  genome  assembly  
(170).  Additionally,  the  PDZ  binding  function  of  E6  proteins  is  required  for  mitotic  stability  
of  HPV  infected  cells  and  the  maintenance  of  stable  viral  episomes  (178).    
  
1.7.4.2.2  b-­genus  E6  proteins  
The  E6  proteins  of  the  cutaneous  HPV  types  of  the  b-­genus  share  many  characteristics  
with  the  a-­genus  E6  proteins,  but  several  key  differences  do  exist.  In  general,  these  E6  
proteins  do  not  degrade  p53.  However,  HPV38  E6  can  supress  the  transactivation  ability  
of  p53.  HPV38  E6  increases  p53  expression  but  attenuates  its  activity  through  promoting  
the  transcription  of  the  p53  suppressor  Dp73  (179,180).  Additionally,  HPV38  E6  can  inhibit  
p21  induction,  a  key  p53  responsive  gene  (181).  Furthermore,  E6  proteins  from  HPV5,  8  
and  38  are  able   to  block  p53  stabilisation   in  the  presence  of  mitotic  errors,  resulting   in  
continued  cell  proliferation  and  an  accumulation  of  cells  with  polyploidy  and  aneuploidy,  a  
hallmark  of  cell  transformation  (182).    
These   E6   proteins   primarily   bind   to   the   LXXLL  motif   on   the   transcription   co-­activator  
proteins   mastermind-­like   1   and   3   (MAML1   and   3)   of   the   Notch   signalling   pathway  
(183,184).  HPV8  E6  also   binds   to   the  mothers   against   decapentaplegic   homolog   2  
(SMAD2)/SMAD3  transcriptional  cofactors  of  the  TGF-­b  signalling  pathway  (184).  These  
interactions  result  in  the  inhibition  of  these  tumour  suppressor  pathways  and  the  induction  
of  papilloma  formation  in  infected  mice.     
The  b  HPV  E6  proteins  can  enhance  the  UVB  induced  carcinogenesis  by  promoting  
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p300  degradation,  thus  reducing  ataxia  telangiectasia  and  Rad3-­related  (ATR)  protein  
expression,  which  leads  to  increased  thymine  dimer  persistence  and  increased  UVB  
induced  double  stranded  DNA  breaks  (182,185).  This  degradation  of  p300  also  results  
in  the  reduction  of  Breast  Cancer  1  and  2  (BRCA1  and  2),  resulting  in  the  attenuation  of  
homology-­dependent  repair  of  these  double  stranded  DNA  breaks.     
  
In  summary,  the  ‘high  risk’  E6  proteins  from  the  a-­genus  HPV  types  are  essential  proteins  
that  are  able  to  drive  cell  proliferation,  whilst  inhibiting  detection  of  the  virus  by  the  immune  
system  and   inhibiting  apoptosis  of   infected  cell   induced  by  expression  of   the  HPV  E7  
protein.  However,  various  studies  have  demonstrated  that  the  functions  of  E6  identified  so  
far  cannot  account  for  all  of  the  phenotypes  induced  by  E6  and  thus  further  research  is  
required  to  identify  other  mechanism  of  E6  induced  cell  proliferation  and  transformation.  
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1.8  The  STAT  Family  
The  Signal  Transducer  and  Activator  of  Transcription  (STAT)  family  of  proteins  were  first  
recognised  as  ligand  induced  transcription  factors  in  IFN  treated  cells  (186).  Seven  family  
members   have   currently   been   identified;;   STAT1,   STAT2,   STAT3,   STAT4,   STAT5a,  
STAT5b   and   STAT6.   STAT1  and   STAT4  map   to   chromosome   2,   bands  q12   to   q33;;  
STAT3,  STAT5a  and  b  map  to  chromosome  12,  bands  q13  to  q14  and  STAT2  and  STAT6  
map  to  chromosome  17,  bands  q11-­1  to  q22  (187).     
The  STAT  proteins  range  in  size  from  750  amino  acids  to  850  amino  acids,  but  they  
all   share   a   common   domain   structure   (188).   The   N-­terminal   domain  mediates   the  
interaction   between  STAT   dimers,   leading   to   the   formation   of   STAT   tetramers   (189).  
Adjacent  to  the  N-­terminus  is  a  coiled  coil  domain  which  is  involved  in  the  interaction  with  
other  transcription  factors  and  regulatory  proteins(189).  STAT  proteins  contain  a  central  
DNA  binding  region  which  bins   the  consensus  sequence  TT(N4-­6)AA  (190).  The  SRC-­
homology-­2  (SH2)  domain  binds  to  the  phosphotyrosine  of  other  STAT  proteins  to  mediate  
dimer   formation.   The   transactivation   domain   is   involved   in   the   transcriptional  
activation  of  STAT   target  genes.  This  carboxy-­terminal  domain  contains  a  serine  
phosphorylation  site   that  enhances   transcriptional  activity   in  some  STAT  proteins  
(191).     
  
The  STAT  proteins  share  a  common  mechanism  of  activation  through  receptor  signalling,  
although  the  different  STATs  are  activated  by  different  receptors  (Fig  1.5).  STAT  activation  
was  originally  identified  as  being  downstream  of  cytokine  signalling,  specifically  IFN  and  
Interleukin-­6  (IL-­6)  signalling  (186).  Unlike  growth  factor  receptors,  cytokine  receptors  do  
not  possess  kinase  activity;;  therefore,  STAT  proteins  engage  with  non-­receptor  tyrosine  
kinases   (nRTKs)   bound   to   activated   receptors.   The   most   common   nRTKS   that   are  
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associated  with  STAT  activation  are  the  Janus  Kinase  (JAKs)  family  and  the  SRC  family  
kinases  (SFKs)   (192,193).  This   leads   to  phosphorylation  of   the  cytoplasmic   tail  of   the  
cytokine  receptors  by  the  nRTKs,  presenting  a  phosphotyrosine  site  for  STAT  monomers  
to  bind  through  their  SH2  domains  (194).  This  results  in  STAT  tyrosine  phosphorylation  




Figure  1.5.  STAT  activation  by  cytokine  signalling.  A)  Schematic  representation  of  
STAT  protein  activation  by  cytokine  signalling  pathways.  The  preference  for  certain  
STAT   proteins   for   certain   cytokine   signalling   is   demonstrated.   Adapted   from   Life  
Technologiesä.  
 
STAT  proteins  can  also  be  activated  by  growth  factor  signalling,  in  particular  EGFR  
and  PDGFR  signalling  (195,196).  In  this  case,  the  receptors  may  also  recruit  nRTKs  and  
co-­operate  with  them  in  the  phosphorylation  of  STATs.    
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1.8.1  STAT1  
The  STAT1  transcription   factor  exists   in   two   isoforms;;  a   longer  STAT1a  and  a  shorter  
STAT1b  (197).  The  shorter  STAT1  isoform,  therefore,  contains  a  shorter  transactivation  
domain  and  lacks  the  serine  phosphorylation  site.  The  major  role  of  STAT1  is  in  the  IFN-­
signalling  pathway  (198);;  however,  STAT1  can  also  be  activated  by  IL-­4,  IL-­6  and  IL-­27  
(199,200).  STAT1  exists  as  a  monomer  in  the  cytoplasm.  Upon  IFN  signalling,  STAT1  can  
homo-­dimerise   (mostly   in   response   to   IFNg)  or  hetero-­dimerise  with  STAT2   (mostly   in  
response  to  IFNa/b)  (201).  These  STAT1  homo-­dimers  then  translocate  to  the  nucleus  
where  they  bind  to  Interferon  Gamma  Activated  Sequence  (GAS)  promoter  elements  
and drive  the  expression  of  key  genes  involved  in  the  innate  immune  response,  such  as  
IRF1  (202).     
STAT1  has  many  pleiotropic  roles  other  than  its  canonical  function  in  innate  immunity;;  for  
example,  many  studies  have  demonstrated  opposing  role  in  cancer  development(203).  
As   a   tumour   suppressor,   STAT1   can   promote   the   expression   of   pro-­apoptotic   genes  
through  the  activation  of  p53  dependent  apoptosis  (204).  Additionally,  STAT1  promotes  
the   surface  expression  of   Fas/FasL   in   colorectal   carcinoma(205).  STAT1  also   directly  
controls   the   expression   of   the   MHC   class   I   components   LMP2   and   7,   to   promote  
immunosurveillance  in  cancer  cells  (202).     
However,  several  studies  have  also  demonstrated  a  pro-­oncogenic  role  for  STAT1.  The  
activation  of  STAT1  by  IFN  results  in  the  expression  of  pro-­inflammatory  cytokines  and  the  
induction   of   an   inflammatory   state   (206).   The   link   between   inflammation   and   cancer  
progression  has  been  clearly  demonstrated  and  STAT1  may  contribute  to  this  as  many  of  
these  processes  are  STAT1-­dependent  (203).  
  
Despite   the  conflicting  data  on   the   role  of  STAT1   in  cancer,  current  data   from  several  
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cancers   demonstrates   that   STAT1   activation   is   inhibited   or   STAT1   expression   is   lost  
(203,207).   STAT1   is   ubiquitinated   and   degraded   in   oesophageal   squamous   cell  
carcinoma   (ESCC)   due   to   constitutive   ERK   signalling   (208).   Furthermore,   the   STAT1  
promoter  is  often  methylated  in  HNSCC  (207).  The  upregulation  of  negative  regulators  of  
STAT1   is   also   increased   in   some   cancers;;  Src   homology   region  2   domain-­containing  
protein  2  (SHP2)  expression  is  increased  in  HNSCC  and  loss  of  SHP2  expression  results  
an   increase   in   cytotoxic   T   lymphocyte   recognition   (209,210).   Another   mechanism   of  
STAT1  inhibition  in  cancer  is  the  aberrant  activation  of  STAT3.  STAT1  DNA  binding  can  
be  directly  inhibited  by  active  STAT3  as  they  bind  to  similar  GAS  binding  sites.  Conversely,  
activated  STAT1  has  been  shown  to  increase  apoptosis  by  inhibiting  STAT3  function  in  
HNSCC  (211).  These  data  suggest  a  reciprocal   relationship  between  these  two  STAT  
proteins  that  may  have  consequences  in  cancer  biology.  
  
1.8.2  STAT2  
The  STAT2  transcription  factor  is  only  activated  by  type  1  IFN  isoforms  (IFN-­a,  -­b,  -­t  and  
-­w)  (212).  STAT2  hetero-­dimerises  with  STAT1  upon  activation  by  IFN  signalling  (197);;  
the   role   of   STAT1-­independent,   STAT2-­dependent   signalling   is   not   clear,   but   STAT1  
deficient  mice  showed  that  STAT2  still  supported  the  induction  of  ISG  expression  (213).  
STAT1/STAT2  hetero-­dimers  then  bind  to  IRF9,  forming  the  IFN  Stimulated  Gene  Factor  
3  (ISGF3)  complex  (214).  ISGF3  complexes  then  translocate  into  the  nucleus  where  they  
bind  to  the  promoter  of  ISGs  through  an  IFN  Sensitive  Response  Element  (ISRE),  with  
DNA   binding   mediated   by   STAT1   and   IRF9   (215).   STAT2   is   responsible   for   the  
recruitment  of  co-­activators,  such  as  p300  and  pp32,  through  its  TAD  (216,217).       
STAT2  is  essential  for  the  function  of  type  I  IFN  signalling:  STAT2  deficient  mice  had  
a   compromised   anti-­viral   response   and   were   vulnerable   to   viral   infection   (218).   A  
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recent   study   also   demonstrated   that   STAT2   deficiency   resulted   in   vaccine-­derived  
measles  dissemination  in  a  child  (219).     
The   role   of   STAT2   in   tumourigenesis   is   poorly   understood.   STAT2   deficient   mice  
expressing  an  IFN-­a  transgene  died  prematurely  with  neuroblastoma  development  and  
over   expressed   IFN-­g   (220).   Additionally,   STAT2   loss   in   an   azoxymethane   (AOM)   /  
dextran   sodium   sulphate   (DSS)   colorectal   carcinogenesis   mouse   model   resulted   in  
increased  survival  and  less  chronic  inflammation  (221).  This  was  likely  due  to  the  decrease  




Unlike  most  STAT  proteins,  which  are  ubiquitously  expressed,  STAT4  expression  appears  
to  be   limited   to   lymphoid,  myeloid  and  testis   tissue  (222).  The  most  well  characterised  
function  of  STAT4  proteins  are  as  key  regulators  of  T  cell  function  in  the  adaptive  immune  
response  (223)  STAT4  is  most  prominently  activated  by  IL-­12  signalling  but  can  also  be  
activated  by  IL-­23  and  type  I  interferons,  resulting  in  homo-­dimerisation  (222).  STAT4  is  
essential  for  IL-­12  function;;  STAT4  knock  out  mouse  fail  to  induce  IFN-­g  or  enhance  natural  
killer  (NK)  cell  cytolytic  function,  a  key  function  of  IL-­12  signalling  (224).  Additionally,  IL-­12  
is  essential  for  the  correct  development  of  Th1  cells  and  a  Th1  immune  response;;  STAT4  
is  also  essential   for   this   function  of   IL-­12   (223).  This   leads   to  an   increased  number  of  
parasitic  infections,  as  a  functional  Th1  response  is  essential  to  combat  these  infections  
(225).  STAT4  also  plays  a  role  in  the  production  of  IFN-­g   in  response  to  viral   infection,  
which  works  in  concert  with  the  generation  of  cytotoxic  T  cell  to  control  the  infection  (226).  
Due  to  the  defect  in  the  immune  response  upon  STAT4  loss,  many  autoimmune  diseases  
are  associated  with  STAT4.  Polymorphisms   in  STAT4  have  been  demonstrated   to  be  
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associated   with   the   development   of   both   rheumatoid   arthritis   and   systemic   lupus  
erythematosus  (227,228).  Recently,  STAT4  has  been  implicated  in  cancer  development  
(229,230).   In   epithelial   ovarian   cancer   (EOC),  STAT4   is   essential   for   the   induction   of  
metastasis  and  epithelial-­mesenchymal  transition  (EMT)  and  is  required  for  the  induction  
of  Wnt  signalling  (229).  
    
1.8.4  STAT5a  and  STAT5b  
STAT5   exists   as   two   separate   proteins,   STAT5a   and   STAT5b,   transcribed   from   two  
different  genes,  unlike  STAT1,  which  is  two  isoforms.  These  proteins  share  94%  homology  
but  are  transcribed  from  different  genes  (231).  STAT5b  is  a  smaller  protein,  with  20  fewer  
amino  acids  in  the  TAD.    The  STAT5  proteins  are  most  commonly  activated  through  JAK2  
phosphorylation   in   response   to   IL-­2,   IL-­3   and   Granulocyte   Macrophage   Colony-­
Stimulating   Factor   (GM-­CSF)   signalling   (232).   This   results   in   the   formation   of   STAT5  
homo-­dimers.  Occasionally,  STAT5:STAT3  heterodimers   form,  particularly   in  repose  to  
GM-­CSF   signalling,   and   these   are   required   for   the   binding   of   particular   consensus  
sequences  (233).     
  
The  mechanism  of  STAT5  transcriptional  activation  is  poorly  understood.  The  STAT5  TAD  
binds   to   several   co-­activators  such  as  p300   (234);;   however,  STAT5   can  also  bind   to  
transcriptional  co-­repressors  such  as  Nuclear  Receptor  Co-­repressor  2  (NCOR2)  (235).  
Like  STAT4  and  STAT6,  much  of   the   information  on   the  biological   functions  of  STAT5  
have  come  from  studies  in  immune  cells.  Mice  in  which  both  STAT5  genes  were  knocked  
out  produced  defects   in  both  T  and  B  cells   (236).  Furthermore,   the  T  cell  proliferative  
response  to  T  cell  receptor   (TCR)  activation  was   lost  and  responses   to  IL-­2  were  also  
abrogated  (237).  Additionally,  mice  that  expressed  constitutively  active  STAT5b  through  
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T  cell  and  B  cell  development  exhibited  increased  number  of  pro-­B  cells,  CD4+  regulatory  
T  cells  and  CD8+  memory  T  cells  (238).  Therefore,  expression  of  a  constitutively  active  
STAT5b  was  not  the  polar  opposite  of  the  STAT5a  and  b  knockout  mouse.  STAT5  also  
plays   a   key   role   in   Th2   development;;   over   expression   of   active   STAT5   skews   the  
differentiation  toward  Th2  development  (239).     
  
STAT5  also  plays  a  role  in  the  anti-­viral  response;;  mice  in  which  STAT5  cannot  form  higher  
order   tetramers  suggests   that   the   formation  of  these  tetramers   is  essential   to  mount  a  
robust  increase  in  the  proliferation  of  CD8+  T  cells  and  thus  clear  viral  infections(240,241).    
  
Constitutive   STAT5   activation   has   been   identified   in   several   cancers,   particularly   in  
haematopoietic   cancers(242).   A   constitutively   active   mutant   of   STAT5a   was   able   to  
efficiently   transform   haematopoietic   cell   lines   (243).   Further,   STAT5a   activation   in  
myeloma   and   lymphoma   is   required   for   the   oncogenicity   of   the   TEL/JAK2   fusion  
oncogene(244).   STAT5   mediates   the   transforming   ability   of   the   Bcr-­Abl   fusion   gene    
(245).  Additionally,  STAT5  may  play  a  role  in  the  tumourigenesis  of  solid  cancers,  such  as  
HNSCC   (246)   and   prostate   cancer   (247).   Recently,   EMT   has   been   shown   to   be   a  
determinant  of  EGFR  inhibitor  sensitivity  in  HNSCC.  STAT5  activation  correlates  with  the  
expression  of  certain  EMT  markers  in  these  cancers  and  subsequently  HNSCC  cell  with  
high  levels  of  STAT5  activity  are  also  less  sensitive  to  EGFR  inhibition  (248)  
  
1.8.5  STAT6  
Like  STAT4,  most   of   the  work   to   date   on  STAT6  has  derived   from   its   involvement   in  
immune  cell  responses,  having  been  first  identified  in  B  cells  (249).  STAT6  can  exist  as  
one   of   three   isoforms   –   STAT6a,   STAT6b   and   STAT6c.   STAT6a   and   b   have   been  
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demonstrated  to  have  similar  biological  properties;;  STAT6c  acts  as  a  dominant  negative  
for  of  STAT6  due  to  a  disrupted  SH2  domain  (250).        
Classic  STAT6  activation   is  mediated  by   IL-­4  and   IL-­13   signalling   (251).  Activation   of  
STAT6  results  in  homo-­dimerisation  and  nuclear  translocation.  Additionally,  STAT6  can  
be  activated  by  IL-­3;;  however,  this  only  occurs  in  IL-­3  dependent  cells  (252).  Furthermore,  
IL-­15,  known  for  its  ability  to  perform  some  IL-­2  related  functions  in  T  cells  and  NK  cells,  
can   induce   STAT6   tyrosine   phosphorylation   through   TYK2   activation,   although   less  
potently  than  IL-­4  (253).     
The  transactivation  function  of  STAT6  requires  its  ability  to  bind  to  several  co-­activators,  
including  p300,  C/EBPb  and  p100  (234,254,255).  The  main  role  of  STAT6  is  mediating  
the  biological   functions  of   IL-­4  and  IL-­13.   IL-­4   is   the  predominant  determinant  of  T  cell  
differentiation   to  Th2   cells;;   this   almost   exclusively   occurs   via   STAT6   (256).   STAT6   is  
additionally  a  key  regulator  of  MHC  class  II  induction  by  IL-­4  (257).     
More   recently,  STAT6  has  been  demonstrated   to   be  essential   for   the   anti-­viral   innate  
immune  response.  Virus   induced  STAT6  activation  occurs   through  the  adaptor  protein  
Stimulator  of   Interferon  Genes  (STING)  and  TANK-­binding  protein1  (TBK1)  upon  DNA  
virus  stimulation,  or  Mitochondrial  antiviral-­signalling  protein  (MAVS)  upon  RNA  virus  
stimulation;;  STAT6   knockout  mice  are  much  more   susceptible   to   viral   infection   (258)  
The  role  of  STAT6  in  cancer  development  is  currently  poorly  understood.  However,  studies  
have  shown  that  STAT6   is  over  expressed   in  both  prostate  cancer  (259)  as  well  as  a  
number  of  blood  cancers  (260,261).  
  
1.8.6  STAT  proteins  in  HPV  infection  and  associated  disease  
Several  of  the  STAT  family  members  are  modulated  by  HPV,  either  during  the  virus  life  
cycle  or  in  HPV  associated  disease.  STAT1,  as  an  essential  part  of  IFN  signalling  in  the  
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anti-­viral  response,  is  targeted  by  HPV  in  order  to  evade  the  immune  response  (262).  Early  
work  demonstrated  that  the  presence  of  the  HPV31  genome  in  keratinocytes  resulted  in  
the  downregulation  of  STAT1  protein  expression  and  IFNa  or  IFNg  failed  to  induce  STAT1  
expression  in  HPV31  containing  keratinocytes  (149).  Further  studies  demonstrated  that  
the  HPV16  E6  protein  downregulates  STAT1  protein  expression  and  its  binding  to  ISREs  
through  modulating  its  nuclear  translocation  (263).     
During  the  productive  viral  life  cycle,  HPV16  and  31  also  reduce  the  expression  of  STAT1,  
but  not  STAT2;;  this  is  due  to  transcriptional  down  regulation  of  STAT1  mRNA  expression  
(149).  Re-­introduction  of  STAT1   in  HPV  containing  keratinocytes   inhibits  viral  genome  
amplification  and  stable  expression  of  STAT1  reduces  episome  maintenance  (149).     
HPV18  E6  is  also  able  to  inhibit  the  activation  of  ISGF3  by  binding  to  the  nRTK  TYK2;;  the  
binding  of  HPV18  E6  to  TYK2  impairs  its  ability  to  bind  to  the  IFN-­a  receptor  1  (IFNAR1),  
resulting  in  the  reduction  of  STAT1  and  2  phosphorylation  and  activation  of  ISGF3  (176).  
Interestingly,  the  ‘low  risk’  HPV11  E6  does  not  share  this  function  and  the  effect  of  HPV18  
E6  is  specific  to  IFN-­a  as  signalling  after  treatment  with  IFN-­g  is  not  affected  (176).     
  
The  STAT5  proteins  have  been  extensively  studied  during  the  HPV  productive  life  cycle  
and  have  essential  roles  in  viral  genome  amplification  (150).  STAT5  was  first  identified  as  
being  necessary  for  the  induction  of  the  ATM  DNA  damage  pathway.  The  ATM  pathway  
was   previously   identified   as   being   essential   for   genome   amplification   (150);;   STAT5b  
phosphorylation  is  induced  by  the  HPV31  E7  protein  and  this  is  required  for  the  activation  
of  ATM  activity.  Importantly,  the  authors  showed  that  inhibition  of  STAT5  using  the  specific  
small  molecule   inhibitor  pimozide   resulted   in  a   reduction   in  viral  genome  amplification,  
suggesting  a  potential  therapeutic  target  for  viral  infection.  Further  work  demonstrated  that  
STAT5  was  also  required  for  activation  of  the  ATR  pathway  during  the  HPV  life  cycle;;  this  
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was  through  the  regulation  of  Topoisomerase  IIb-­binding  protein  1  (TopBP1)  transcription  
(264).  Recently,  the  transcription  factor  Krüppel-­like  factor  13  (KLF13)  was  demonstrated  
to  be  essential  for  the  phosphorylation  of  STAT5  and  activation  of  the  ATM  pathway  in  
HPV31  containing  keratinocytes  (265).  These  studies  demonstrate  the  essential  role  of  
STAT5  during  the  productive  HPV  life  cycle;;  however,  the  role  of  STAT5  in  HPV  mediated  
cancers   remains   poorly   understood.   The   chemokine  CCL17   has   been   identified   as   a  
regulator   of   cervical   cancer   cell   proliferation   and   this   is  partially   dependent  on  STAT5  
activity(266).   Furthermore,   treatment   of   cervical   cancer   cells   with   IL-­2   stimulates   their  
proliferation   and   this   may   be   attributed   to   increased   STAT5   phosphorylation   (267).  
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1.9  STAT3  
1.9.1  STAT3  structure  
STAT3  was   first   discovered   as   an   IL-­6   responsive   factor   with  DNA-­binding   activity   in  
hepatocytes  (268).  Structurally,  STAT3  is  similar  to  the  other  STAT  proteins  and  the  crystal  
structure  of  various  forms  of  STAT3  have  been  identified  (Fig  1.6)  (189,269,270).  STAT3  
exists  as  two  isoforms,  STAT3a  and  STAT3b,  that  occur  due  to  different  splicing  of  the  
stat3  gene  (271).  These  isoforms  differ  in  their  TAD,  with  STAT3b  containing  a  smaller  
TAD;;  the  functional  difference  between  these  isoforms  remains  controversial  and  remains  




















Figure   1.6.   Crystal   structure   and   domain   organisation   of   STAT3.      Cartoon  
representation  of  the  unphosphorylated  STAT3  crystal  structure  (PDB  ID;;  4ZIA  for  the  N-­
termini   and   4E68   for   the   remain   structure).   Domain   organisation   of   the   two   STAT3  
isoforms  (bottom).  Cyan  =  N-­terminal  domain;;  Green  =  Coiled-­coil  domain;;  Red  =  DNA-­







1.9.2  STAT3  activation  
Of  all  the  members  of  the  STAT  transcription  factor  family,  STAT3  has  the  strongest  link  
with  the  promotion  of  tumour  growth  and  is  classified  as  a  bona  fide  oncogene  (272).  It  is  
additionally   the  only  STAT  family  member  whose  genetic  deletion  results   in  embryonic  
lethality,  suggesting  it  has  other,  essential  roles  in  development  (273).      
Similar  to  the  other  STAT  family  members,  STAT3  exists  as  a  monomer  in  the  cytoplasm.  
The  most  well  studied  inducers  of  STAT3  activation  are  EGF,  through  the  EGFR,  and  the  
IL-­6   family   of   cytokines,   with   IL-­6   being   the  most   well   studied   to   date.   IL-­6  mediated  
activation   of   STAT3   occurs   through   the   IL-­6   receptor   (IL-­6R)   and   the   co-­receptor  
glycoprotein  130  (gp130)  (194).  This  homo  receptor  exists  as  a  part  of  a  hetero-­hexameric  
signalling  complex,  comprising  of  a  gp130  homodimer  plus  two  IL-­6R  homodimers  bound  
to  two  IL-­6  ligands.  The  formation  of  this  complex  result  in  the  activation  of  receptor  bound  
JAK   proteins,   which   subsequently   phosphorylate   gp130,   leading   to   the   recruitment   of  
STAT3   (246).  Other   IL-­6   family  members   include   leukaemia   inhibitory   factor   (LIF),  
oncostatin  M  (OSM)  and  IL-­11,  which  all  utilise  the  gp130  co-­receptor  for  receptor  
activation  (274).     
IL-­6   signalling   occurs   in   two   forms;;   classic   and   trans-­signalling.   In   classic   IL-­6  
signalling,  IL-­6  binds  to  the  membrane  bound  IL-­6R,  inducing  formation  of  the  hetero-­
hexameric   complex   and   subsequent   downstream   signalling   (194).   As   well   as   the  
activation   of   JAK/STAT3   signalling,   IL-­6   can   also   signal   through   the   PI3K/AKT   and  
RAS/RAF/MEK/ERK  signalling  pathways  (275).  IL-­6  trans  signalling  was  discovered  due  
to  the  detection  of  soluble  IL-­6R  (sIL-­6R)  in  patient  samples  (276).  Subsequent  studies  
identified   that   the   IL-­6R   can   be   cleaved   from   the  membrane   by   the   disintegrin   and  
metalloproteinase  domain-­containing  protein  10  (ADAM10)  or  ADAM17  proteases  
or   by   alternative   splicing   (277).  Binding  of   IL-­6   to   sIL-­6R  extracellularly   induces   the  
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dimerisation  of  gp130  monomers  and  the  activation  of  downstream  signalling.  Alternative  
splicing  can  also  result  in  the  expression  of  secreted  forms  of  gp130  (sgp130).  Sgp130  
can  bind  to  the  IL-­6/sIL-­6R  complex  and  inhibit  IL-­6  trans  signalling  (278).       
The  nRTK  JAK  proteins  are  key  components  of  STAT3  activation  through  IL-­6  signalling.  
There   are   four   isoforms  of   JAK  proteins:   JAK1,   JAK2,   JAK3  and  TYK2   (279).  These  
proteins  contain  a  JAK  homology  (JH)  1  domain,  which  is  enzymatically  functional,  and  a  
pseudokinase  domain,  JH2,  which  retains  JH1  in  an  inactive  state(194).  Upon  stimulation,  
formation  of  the  gp130/IL-­6/IL-­6R  complex  results  in  the  selective  activation  of  JAK1,  JAK2  
or  TYK2  via  binding  to  gp130.  This  binding  initiates  a  conformational  change  in  the  JAK  






















Figure   1.7.   The   IL-­6   signalling   pathway.   Schematic   diagram   of   IL-­6/IL-­6R/gp130  
complex   signalling.  Details   are   in   the  main   text.  Key   regulators   are   identified   and  are  








STAT3  is  the  prominent  mediator  of  IL-­6  signalling  in  normal  cell  processes  and  in  cancer  
formation.  Activation  of  IL-­6  signalling  results  in  STAT3  recruitment  via  its  SH2  domain  to  
phosphotyrosine  sites  on  gp130;;   this  brings  STAT3   in  close  proximity   to  JAK  proteins,  
resulting   in   STAT3   tyrosine   phosphorylation   at   Y705.   This   allows   the   head-­to-­tail  
dimerisation  of  STAT3  and  its  nuclear  translocation.  In  the  nucleus,  STAT3  binds  to  GAS  
promoter  elements  and  mediates  the  expression  of  genes  involving  key  regulators  of  cell  
proliferation   (cyclin   D1,   MYC),   cell   survival   (Survivn,   Bcl   xL),   angiogenesis   (vascular  
endothelial  growth  factor  (VEGF))  and  inflammation  (IL-­6,  COX-­2)  (280).     
  
1.9.3  STAT3  post-­translational  modifications  
The  tyrosine  phosphorylation  of  STAT3  was  thought   for  a   long   time  to  be  essential   for  
STAT3  nuclear  translocation;;  however,  many  studies  have  now  demonstrated  that  STAT3  
nuclear  translocation  is  independent  of  tyrosine  phosphorylation  and  is  instead  dependent  
on  importin  b1  and  a3  (281).  Indeed,  unphosphorylated  STAT3  has  been  demonstrated  
to   control   a   distinct   subset   of   genes   that   are  not   activated  by   phosphorylated  STAT3  
dimers  (282).    
Despite  this,  tyrosine  phosphorylated  STAT3  is  mostly  associated  with  STAT3  activation  
and  is  mostly  commonly  associated  with  malignancy  (283).  In  addition  to  the  JAK  proteins,  
several   other   protein   kinases   have   been   demonstrated   to   induce   STAT3   tyrosine  
phosphorylation   at   Y705   in   response   to   diverse   stimuli,   including   c-­Src   and   Bcr-­Abl  
(193,284).  Tyrosine  705  is  with  the  SH2  domain  of  the  STAT3  protein;;  STAT3  can  also  
be   phosphorylated   at   tyrosine   640   in   the   SH2   domain   by  TYK2.   The   function   of   this  
phosphorylation  site  is  poorly  understood  but  reports  suggest  it  may  be  involved  in  the  
negative  regulation  of  STAT3  transcriptional  activity  (285).       
As  another  layer  of  regulation,  STAT3  is  also  phosphorylated  at  serine  727.  The  function  
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of  this  phosphorylation  site  is  controversial  and  has  been  shown  to  induce  the  maximal  
transcriptional   activity   of   STAT3   (286)   and   to   inhibit   STAT3   tyrosine   phosphorylation  
(287).   Furthermore,   this   serine   residue   can   be   phosphorylated   by   a   number   of   host  
kinases,  including  MAP  kinase(287-­289),  PKC(290,291),  mTOR(292)    and  CDK5(293).  
Therefore,   it   is   likely   that   the   function  and  mechanism  of   this  phosphorylation   is  highly  
dependent  on  cell   type.  Additionally,  a  novel  dual  phosphorylation  event,  occurring  on  
residues  threonine  714  and  serine  727  and  induced  by  Glycogen  Synthase  Kinase  3a/b  
(GSK3a/b),   has   been   demonstrated   to   be   essential   for   STAT3-­dependent   gene  
expression  in  renal  cell  carcinoma  (294).  
Other  post-­translational  modifications  have  been  identified  that  regulate  STAT3  activation.  
STAT3  acetylation  is  essential  in  maintaining  the  stability  of  STAT3  dimers  in  response  to  
cytokine  treatment.  This  acetylation  occurs  at  Lysine  685  and  is  mediated  by  the  p300  
histone  acetyltransferase  (295).  STAT3  can  also  methylated  at  Lysine  49;;  this  methylation  
occurs  following  phosphorylation  of  tyrosine  705  and  is  mediated  by  Enhancer  of  zeste  
homolog   2   (EHZ2).   This   methylation   event   positively   regulates   STAT3   transcriptional  
activity  in  response  to  IL-­6  signalling  (296).       
STAT3  is  also  modulated  by  ubiquitination;;  Lysine  97  in  the  N-­terminal  domain  of  STAT3  
is  the  major  conjugation  site  of  mono-­ubiquitin  (297).  This  ubiquitination  event  regulates  
STAT3  interactions  with  BRD4  and  regulates  STAT3  mediated  transcription.  STAT3  can  
also   be   deubiquitinated   by   CYLD;;   this   results   in   the   inhibition   of   STAT3   nuclear  
translocation  (298).  Finally,  STAT3  can  be  SUMOylated  at  Lysine  451;;  de-­SUMOlyation  
of   this   residue  by   the  protease  SENP3   results   in  an   increase   in  STAT3   transcriptional  




1.9.4  STAT3  regulation    
As  STAT3  regulates  a  number  of  genes  that  are  important  in  proliferation,  survival  and  
inflammation,  STAT3  signalling  is  itself  negatively  regulated  by  many  cellular  proteins  to  
avoid   aberrant   signalling.   As   mentioned   above   (1.9.3),   several   post   translational  
modifications   are   able   to   inhibit   STAT3   transcriptional   active,   switching   off   STAT3  
signalling.  A  major  class  of  proteins  that  regulate  STAT3  activity  are  protein  phosphatases,  
including   the   SHP1   and   SHP2,   protein   phosphatase   receptor-­type   tyrosine-­protein  
phosphatase  C  (PTPRC),  PTPRD,  PTPRT,  and  dual  specificity  protein  phosphatase  
22   (DUSP22);;   these  proteins   induce   the   dephosphorylation   of  STAT3  or   upstream  
kinases   (300-­303).  The  Suppressor  of  Cytokine  Signalling  3   (SOCS3)  protein   impairs  
STAT3   activation   by   preventing   the   phosphorylation   of   STAT3   (304)   and   the   protein  
inhibitor  of  activated  STAT3  (PIAS3)  protein  prevents  the  STAT3  dimer  from  binding  DNA  
(305).   PDZ   and   LIM   domain   protein   2   (PDLIM2),   an   E3   ligase,   promotes   the  
polyubiquitination  and  degradation  of  STAT3  (305)  and  TRIM28  binds  the  coiled-­coil  and  
DNA  binding  domain  of  STAT3,  negatively  regulating  the  serine  phosphorylation  of  STAT3  
(306).  
  
STAT3  is  also  regulated  by  many  microRNAs  (miRNAs)  that  directly  target  stat3  mRNA,  
including  miR-­29b  and  miR-­124  (307,308).  Let-­7a  can  also  directly  target  stat3  miRNA    
and   indirectly   inhibits  STAT3  by  promoting  SOCS3  expression  (309,310).  The  miRNA  
miR-­34a  and  miR-­218  also  supresses  STAT3  signalling  by  targeting  il6  mRNA  (311,312).  
miRNAs  can  also  promote  STAT3  signalling  by  downregulating  the  expression  of  negative  
regulators  of  STAT3.  For  example,  miR-­18a  targets  the  E3  SUMO  ligase  PIAS3  (313),  
while  miR-­221  and  -­222  supress  expression  of  PDLIM2  (314).  
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1.9.5  Biological  functions  of  STAT3  
As  genetic  deletion  of  STAT3  results  in  embryonic  lethality  (273),  STAT3  plays  essential  
functions  in  normal  biological  functions.  The  development  of  STAT3-­deficient  mice  that  
have  tissue  specific  genetic  deletions  of  the  stat3  gene  has  revealed  some  of  the  essential  
functions  of  STAT3.  For  example,  in  keratinocytes,  loss  of  STAT3  results  in  a  migration  
defect,  resulting  in  a  defective  wound  healing  response  (315).    
The  major   functions  currently  attributed   to  STAT3  are   in   the  correct   functioning  of   the  
immune  system;;  however,  STAT3  has  been  demonstrated  to  both  enhance  and  inhibit  the  
immune  response  to  pathogens  (316).  In  T  cells,  STAT3  is  essential  for  IL-­6  dependent  
survival  and  proliferation  and  for  the  correct  expression  of  CD25,  a  component  of  the  IL-­2  
receptor  (IL-­2~R),  an  essential  mediator  of  T  cell  function  (317).  Furthermore,  STAT3  loss  
in  monocytes  and  neutrophils  results  in  an  enhanced  inflammatory  response,  suggesting  
STAT3  may  play  a  role  in  dampening  the  inflammatory  response  (317).     
In  addition  to  genetic  studies  in  mice,  several  naturally  occurring  mutations  of  STAT3  have  
identified   its   important   role   in   normal   cell   function   and   how   this   relates   to   disease.  
Autosomal  dominant  STAT3  inactivating  mutations  are  frequently  observed  in  the  human  
immunodeficiency   condition   Hyper   Immunoglobulin   E   syndrome   (HIES)   (318).   The  
mutation  observed  in  HIES  includes  disruptions  in  the  SH2  domain  and  the  TAD  (319).  
The  features  of  this  disease  are  recurring  bacterial  infections  of  the  skin  and  oral  fungal  
infections  (318).  This  is  likely  due  to  an  altered  cytokine  response  due  to  defective  STAT3  
signalling.  Further  evidence  for  the  role  of  STAT3  as  an  essential  mediator  of  the  immune  
response  came  from  studies  in  keratinocytes;;  these  cells  require  the  activity  of  cytokines  
from   STAT3   dependent   Th17   cells   and   pro-­inflammatory   cytokines   to   mount   an  
appropriate   immune   response   through   the   generation   of   antibacterial   mediators   and  
neutrophil  chemoattractants  (320).    
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In   line   with   the   role   of   STAT3   in   promoting   a   robust   immune   response,   STAT3  
hyperactivation   has   been   demonstrated   to   play   a   key   role   in   autoimmune   disease.  
Recently,  de  novo   gain   of   function  mutations,   located  within   the  DNA  binding  or  SH2  
domains,   were   identified   in   patients   with   early-­onset,   multi-­organ   autoimmunity   and  
lymphoproliferative   disease   (321).   These  mutations   result   in   constitutive   STAT3  DNA  
binding   without   STAT3   tyrosine   phosphorylation.   Patients   with   these   gain   of   function  
mutations  show  a  decreased  number  of  T  regulatory  cells,  suggesting  STAT3  is  important  
for  their  development.     
Another  key  function  of  STAT3  in  regulating  the  immune  response  is  in  the  control  of  the  
immunosuppressive   cytokine   IL-­10   (322).   In   HIES,   the   elevation   of   pro-­inflammatory  
cytokine  production  coincides  with   the   loss  of  anti-­inflammatory   IL-­10  expression,  both  
attributed  to  the  loss  of  function  mutations  in  STAT3  (319).     
  
1.9.6  STAT3  in  viral  infection  
As  STAT3  has  essential  roles  in  the  immune  response,  STAT3  also  plays  important  roles  
in  viral  infection.  Therefore,  many  viruses  have  developed  strategies  to  manipulate  STAT3.  
The  hepatitis  B  virus  (HBV)  promotes  the  formation  of  STAT3  dimers  to  bind  enhancer  
regions  in  the  viral  genome  and  drive  viral  replication  (323).  This  is  partially  mediated  by  
the  HBx  protein,  which  drives  JAK1  mediated  tyrosine  phosphorylation  of  STAT3  (324).  
HBx  also  inhibits  the  expression  of  the  miRNA  Let-­7a,  a  negative  regulator  of  stat3  mRNA  
expression  (325).  Furthermore,  HBV  epigenetically  silences  SOCS3  mRNA  expression  
through  upregulation  of  SNAIL1  expression  (326).     
     
Another   clinical   important   hepatitis   virus,   hepatitis  C   virus   (HCV),  manipulates  STAT3  
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signalling   in   several   was   to   its   own   benefit.   HCV   drive   STAT3   activity   by   the   direct  
interaction  between  the  HCV  core  protein  and  STAT3  (327).  HCV  also  stimulates  STAT3  
activity  through  co-­opting  JAK1  by  HCV  NS5A  activity  (328).  
Viruses  of  the  Herpesviridae  can  also  modulate  STAT3  activity.    Human  cytomegalovirus  
(HCMV)  induces  the  tyrosine  phosphorylation  of  STAT3  via  the  viral  US28  protein  and  the  
expression  of  viral  IL-­10  expression  (329,330).  Similarly,  Epstein  Barr  Virus  (EBV)  induces  
STAT3   dual   phosphorylation   via   the   latent   membrane   protein   1   (LMP1)   (331)   and  
increases  the  DNA  binding  and  transcriptional  activity  of  STAT3  via  Epstein  Barr  Nuclear  
Antigen   2   (EBNA2)   expression.   This   drives   expression   of   poly(rC)-­binding   protein2  
(PCBP2),  limiting  the  response  of  latent  cells  to  lytic  signals,  promoting  viral  persistence  
(332).  Kaposi  Sarcoma  Herpesvirus  (KSHV)  infection  also  drives  the  dual  phosphorylation  
of  STAT3  (333,334),  potentially  via  the  expression  of  a  viral  IL-­6  homologue  (335).  KSHV  
mediated  activation  of  STAT3  persists  due  to  sustained  serine  phosphorylation  induced  
by  the  kaposin  B  protein  via  the  negative  regulation  of  TRIM28  by  the  p38/MK2  pathway  
(334).  As  with  EBV,   the  activation  of  STAT3  by  KSHV   lead   to   the  persistence  of  viral  
latency  through  the  repression  of  the  viral  protein  R  Transactivator  (RTA).     
  
Many  of  these  viruses  utilise  the  ability  of  STAT3  to  dampen  the  effect  of  the  inflammatory  
response.  However,  suppression  of  STAT3  can  also  reduce  the  host’s  ability  to  respond  
to  inflammatory  cytokines  in  the  acute  phase.  This  counterintuitive  response  of  inhibiting  
STAT3,  therefore,  needs  to  be  analysed  in  a  virus-­dependent  manner.  In  contrast  to  the  
ability   of   HCMV   to   induce   STAT3   tyrosine   phosphorylation,   in   certain   circumstances,  
HCMV  can   inhibits  STAT3  activation  by  sequestering  unphosphorylated  STAT3   in   the  
nucleus  (336).  Additionally,  KSHV  can  reduce  STAT3  mRNA  levels  via  the  virally  encoded  
miRNAs   miR-­K6-­5   and   miR-­K8   (337).   This   results   in   the   down   regulation   of   ISGs,  
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including  ISG15,  IFITM1  and  OAS2.  Whether  or  not  the  ability  of  HCMV  and  KSHV  to  
induce  STAT3  activation  outweighs  the  negative  regulation  of  STAT3  by  these  viruses  is  
unknown.     
Influenza  A  virus  (IAV)  induces  STAT3  activation  during  early  infection,  but  this  decreases  
during  infection  in  correlation  to  the  pathogenicity  of  the  viral  strain  (338).  This  may  be  due  
to  the  ability  of  the  viral  protein  non-­structural  protein  1  (NS1)  to  induce  SOCS3  mRNA  
(339).  The  Mumps  virus  V  protein  induces  the  degradation  of  STAT3  by  promoting  the  
formation  of  STAT3-­K49  ubiquitin  complexes  (340).     
  
1.9.7  STAT3  in  cancer  biology  
STAT3  is  bona  fide  oncogene;;  overexpression  of  a  constitutively  active  STAT3  resulted  in  
the  induction  of  anchorage-­independent  growth  and  increased  tumourigenic  potential  of  
fibroblasts  (272).  STAT3  is  aberrantly  activated  in  an  estimated  70%  of  human  cancers  
(341).  This   includes  a  number  of  haemopoietic  cancers  (342,343),     multiple  myeloma  
(344),  and  cancers  of  the  breast,  brain,  colon,  prostate  and  pancreas  to  name  a  few  (345-­
347).  In  many  of  these  cancers,  STAT3  activity  and  phosphorylation  correlates  with  poor  
clinical  prognosis  (348,349).     
The  mechanism  of  STAT3  oncogenicity  is  an  intense  area  of  study  as  it  is  an  interesting  
therapeutic  target   in  several  cancers  (350);;   this   is  particularly   true   for  cancers   that  are  
resistant   to  conventional  chemo  or  radiotherapies,  or  more   targeted   therapies  such  as  
EGFR  inhibitors.  In  these  resistant  cancers,  STAT3  is  often  aberrantly  expressed,  and  thus  
the  combination  of  standard  cancer   therapies  with  STAT3   inhibitors  may  be  beneficial.
     
STAT3   contributes   to   the   expression  of   several   genes   that   regulate   key   processes   in  
cancer  cells,  including  cell  proliferation  and  metabolism,  cell  survival  and  cell  metastasis  
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(280).   STAT3   induces   the  expression  of  cyclin  D1,  an  oncogene  upregulated   in  most  
cancers  that  is  a  key  regulator  of  cell  cycle  progression  (351).  STAT3  also  regulates  the  
expression  of  Bcl  xL  and  survivin,  proteins  involved  in  pro-­survival  pathways,  often  over  
expressed  in  cancers.  Furthermore,  STAT3  regulates  the  expression  of  VEGF  and  several  
MMP  proteins,  key  regulators  of  angiogenesis  and  cell  migration  and  metastasis.     
STAT3  has  also  been  demonstrated  to  control  the  expression  of  IL-­6,  resulting  in  a  positive  
feed-­forward  loop,  maintaining  oncogenic  STAT3  signalling.  The  combined  upregulation  
of   both   IL-­6   and   VEGF   by   STAT3   also   results   in   a   potent   immunosuppressive  
environment,  which  may  facilitate  the  immune  evasion  of  tumour  cells  harbouring  STAT3  
activity  (352).    
STAT3  mutations  are  rare  in  cancer  and  are  mostly  commonly  found  in  haematological  
cancers   (353).  Most  common  are  mutations   in   the  SH2  domain  of  STAT3,   found   in  a  
number  of  patients  with  large  granular  lymphocytic  (LGL)  leukaemia  (354).  As  mutations  
in   STAT3   that   contribute   to   cancer   development   are   rare,   other  mechanisms   are   the  
predominant  causes  of  hyperactivation  of  STAT3  in  malignant  tissue.  A  common  cause  of  
STAT3  activation  in  cancer  is  the  increased  expression  and  autocrine/paracrine  signalling  
of  IL-­6.  This  induces  the  activation  of  the  IL-­6R  and  subsequent  JAK/STAT3  signalling.  
Serum  IL-­6  levels  are  increased  in  several  cancers,  including  HNSCC  (355),  ovarian  (356)  
and  renal  carcinoma  (357).  Aberrant  IL-­6  signalling,  mediated  through  STAT3,  is  involved  
in  many  of  the  hallmarks  of  cancer,  including  the  induction  of  EMT  in  breast  cancer  and  
HNSCC  (358,359).     
Despite  the  aberrant  activity  of  IL-­6/IL-­6R/gp130  in  many  cancers,  no  genomic  alterations  
in  this  pathway  have  been  found  in  cancer  genome  databases.  However,  gp130  activating  
mutations   are   found   in   some   cancers,   such   as   hepatocellular   adenomas   (360).  
Furthermore,  a  point  mutation  in  the  IL6  promoter  results  in  an  increased  expression  in  IL-­
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6  (361).     
Downstream  of  IL-­6/IL-­6R/gp130,  the  JAK  proteins  also  play  a  role  in  cancer  development,  
most  commonly  in  haematological  cancers.  A  common  JAK2  mutation,  JAK2V617F,  is  found  
in  around  95%  of  patients  with  the  myeloproliferative  disorder  polycythaemia  vera  (362);;  
this   mutation   results   in   a   constitutively   active   JAK2   protein   independent   of   cytokine  
signalling.  Additionally,  JAK2  mutations  occur  in  other  haematological  cancers  including  B  
cell  acute  lymphoblastic  leukaemia  (B-­ALL)  and  B  cell  lymphoma  (363,364).  
Additionally,  the  autocrine  activation  of  growth  factor  receptor  signalling  is  often  activated  
is   cancer;;   over   expression   of   EGFR   in   cancers   such   as   NSCLC,   can   result   in   the  
downstream  activation  of  STAT3  (365).  
STAT3  activation  in  cancer  also  occurs  due  to  the  inhibition  or  loss  of  negative  regulators  
of  STAT3  through  a  multitude  of  mechanisms.  Loss  of  SOCS3,  most  commonly  due  to  
transcriptional   regulation  by  promoter  methylation,  occurs   in  several  cancers,   including  
colon  and  pancreatic  (366,367).  Additionally,  SHP1  and  SHP2  can  be  inactivated  due  to  
loss  of  function  mutations  (368);;  mutations  in  PTPRT  and  PTPRD  occurs  at  around  5.6%  
and  3.7%,  respectively,  in  HNSCC  (300).     
  
1.9.8  STAT3  in  HPV  infection  and  associated  disease  
The  role  of  STAT3  during  the  productive  HPV  life  cycle  has  not  been  studied  to  date;;  
however,   the   involvement   of   STAT3   in   HPV   associated   disease   has   been  
demonstrated.  The  aberrant  phosphorylation  of  STAT3,  at  both   tyrosine  and  serine  
residues,  has  been  demonstrated  to  be  associated  with  both  HPV16  and  18+  cervical  
cancers  (369).  STAT3  phosphorylation  and  DNA  binding  activity  has  also  been  shown  to  
correlate   with   cervical   disease   progression,   from   pre-­cancerous   legions   to   invasive  
carcinoma.  Other  studies  have  shown  that  the  increase  in  STAT3  phosphorylation  may  
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be   due   to   ‘high   risk’   HPV   E6   expression   (370)   and   that   abolishing   STAT3  
phosphorylation,   by   using   inhibitors   of   upstream   effectors   such   as   JAK2,   inhibits  
HPV16  E6  and  E7  express  and  restores  p53  and  pRb  expression  (370).  Conversely,  
STAT3   has   been   demonstrated   to   be   down   regulated   in   papilloma   tissue   due   to  
increased   expression   of   phosphatase   and   tensin   homologue   (PTEN),   a   well  
characterised  tumour  suppressor  (371).      
  
Despite   the   fact   that   a   number   of   studies   have   suggested   that   STAT3   may   be  
deregulated  by  HPV  in  cancer  development,  there  is  a  currently  no  data  regarding  a  
role   for   STAT3   during   the  HPV   productive   life   cycle.   STAT3   expression   has   been  
shown  to  be  required   for   the  differentiation  of  a  normal  human  stratified  squamous  
epithelium,   which   is   deregulated   upon   HPV   infection,   and   expression   of   a  
constitutively   active   STAT3   expressed   at   physiological   levels   can   induce  
immortalisation  of  keratinocytes  in  a  knock-­in  mouse  model  (372).  However,  whether  
HPV  infection  can  alter  STAT3  signalling  to  drive  keratinocyte  proliferation  is  unknown.  
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1.10  Aims  of  the  Project  
Despite  the  availability  of  vaccines  that  target  the  small  number  of  HPV  types  most  
commonly  associated  with  cancer  development,  the  long  term  effectiveness  of  these  
remains  to  be  seen.  Additionally,  there  is  no  currently  available  directly  acting  antiviral  
for  HPV,  and  thus  a  better  understanding  of  the  complex  interactions  of  the  virus  with  
the   host   cell   is   required   for   the   development   of   anti-­virals   or   cancer   therapies.  
Furthermore,   a   greater   understanding  of   the  mechanisms  used  by  HPV   to   disable  
epithelial  homeostasis  may  provide  novel  insight  into  fundamental  cellular  processes.  
Recent  work  in  the  Macdonald  group  identified  a  link  between  the  presence  of  HPV18  
in  primary  keratinocytes  and  the  activation  of  STAT3  signalling.  Therefore,  the  aims  of  
this  PhD  project  are  to  investigate  the  role  of  STAT3  during  the  productive  virus  life  
cycle   and   to   assess   the   effect   of   STAT3   inhibition   in   HPV+   cervical   cancer.  
Specifically,  the  objectives  of  the  project  are:     
  
1.   Investigate  the  role  of  STAT3  signalling  during  the  HPV18  viral  life  cycle  using  
a  primary  keratinocyte  and  organotypic  raft  culture  model  system     
  
2.   Examine  the  upstream  signalling  pathway  leading  to  the  activation  of  STAT3  
by  HPV  in  HPV+  cervical  cancers    
  
3.   Investigate   the   importance   of   STAT3   in   key   cancer   phenotypes   such   as  
proliferation,  migration  and  epithelia-­mesenchymal   transition   (EMT)   in  HPV+  
cervical  cancers    
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Chapter  2.  Methods  and  Materials     
2.1  Bacterial  cell  culture     
2.1.1  Bacteria  growth  and  storage     
The  Escherichia  coli  strain  DH5α  (New  England  BioLabs  (NEB),  USA)  was  used  for  
the  amplification  of  plasmid  DNA  vectors.  E.  coli  were  grown  on  semisolid  medium  
(agar  in  Luri-­Bertani  (LB)  Medium)  and  in  liquid  shaking  cultures  (LB  medium:  10  g/L  
tryptone  soya  broth,  10  g/L  NaCl,  5  g/L  yeast  extract),  respectively,  overnight  (o/n)  at  
37°C.   Appropriate   antibiotics   were   added   for   selection   (50   μg/μL   Kanamycin,   100  
μg/μL  Ampicillin).  For  long-­term  storage,  cells  were  frozen  at  -­80°C  in  freezing  medium  
(50%  glycerol  in  liquid  o/n  culture).     
  
2.1.2   Transformation   of   chemically   competent   bacteria  with   plasmid  
DNA  
For  the  transformation  of  DH5α  cells,  plasmid  DNA  (1  μL)  was  added  to  50  
μL  of  chemically-­competent  DH5α  (2.1.2)  cells  and  incubated  on  ice  for  20  
mins.  Cells  then  underwent  heat  shock  treatment  at  42°C  for  45  sec.  Cultures  were  
incubated  on  ice  for  5  min  followed  by  the  addition  of  949  μL  of  LB  medium  and  an  1  
h  incubation  at  37°C  shaking  at  180  rpm.  The  cultures  were  streaked  out  onto  selective  
semisolid  medium  (2.1.1).  For  a   list  of  plasmids  used   in   this   thesis,  see  Table  1   in  
Appendix.     
  
2.1.3  Preparation  of  plasmid  DNA       
To  purify  plasmid  DNA  on  a  small  scale,  20  ml  of  selective  LB  medium  were  inoculated  
with  a  single  colony  previously  grown  on  semisolid  medium.  The  culture  was  shaken  
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o/n  at  37°C.  Cells  were  harvested  by  centrifugation  of  20  mL  of  culture  for  30  min  at  
4000  x  g.  The  plasmid  DNA  was  purified  using  the  sodium  dodecyl  sulphate  (SDS)-­
alkaline   denaturation   method   employed   by   the   Wizard®   Plus   SV   Minipreps   DNA  
Purification   System   (Promega,   UK).   Purification   was   conducted   according   to   the  
manufacturer’s  protocol.  DNA  was  eluted  from  the  Wizard®  SV  Minicolumns  with  100  
μL  ddH20.     
  
To  purify  plasmid  DNA  on  a  larger  scale,  a  starter  culture  was  prepared  by  inoculating  
20  mL  of  selective  LB  medium  with  a  single  colony  grown  on  semisolid  medium.  The  
culture  was  shaken  for  8  h  at  37°C  and  added  to  80  mL  of  LB  medium.  This  large-­
scale  culture  was  shaken  o/n  at  37°C.  Cells  were  harvested  by  centrifugation  at  4000  
x   g   for   30   min   at   4°C.   The   plasmid   DNA   was   purified   using   the   Plasmid   Maxikit  
(Qiagen,   Germany)   according   to   the   manufacturer’s   protocol.   Plasmid   DNA   was  
resuspended  in  200  μL  –  600  μL  ddH2O.    
  
The   concentration   of   the   plasmid   DNA   was   determined   using   a   Nanodrop  
spectrophotometer  (Thermo  Fisher  Scientific,  USA).     
  
2.2  Protein  Biochemistry     
2.2.1  Bicinchoninic  acid  assay  for  protein  concentration  determination  
Protein   concentrations   of   mammalian   cell   lysates   were   determined   with   a  
bicinchoninic  acid  (BCA)  protein  assay  kit  (Thermo  Fisher  Scientific,  USA)  according  
to   the  manufacturer’s  protocol   for  microplates.  After  10  min   incubation  at  RT,   the  
absorbance   at   562   nm   was   determined   on   a   PowerWave   XS2   Microplate  
Spectrophotometer   (BioTek,   UK).   A   standard   curve   was   generated   using   the  
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accompanying  software  (Gen5  1.07.5,  BioTek,  UK)  to  determine  the  samples’  total  
protein  concentration  considering  the  dilution  factor.  
2.2.2  SDS  polyacrylamide  gel  electrophoresis  (SDS-­PAGE)     
Proteins   were   separated   according   to   molecular   weight   using   a   minigel   system  
(BioRAD,   USA).   8%,   12.5%   and   15%   SDS-­polyacrylamide   gels   were   prepared  
according  to  protein  resolution  required.  Protein  samples  with  lithium  dodecyl  sulphate  
(LDS)   sample   buffer   (Invitrogen,   USA)   and   0.1%   2-­mercaptoethanol,   were   loaded  
alongside   4  μL   SeeBlue   prestained   protein  marker   (Invitrogen,   USA)   or   ColorPlus  
Prestained  Protein  Marker  (NEB,  USA).  Electrophoresis  was  carried  out  at  120-­180  V  
in  1  x  SDS  running  buffer  (34.7  mM  SDS,  250  mM  Tris  Base,  1.92  M  Glycine)  until  the  
desired  protein  resolution  was  achieved.    
  
2.2.3  Western  blot  analysis     
Separated   proteins   were   transferred   from   the   SDS-­polyacrylamide   gels   to  
HybondTM-­C  Extra  mixed  ester  nitrocellulose  membranes  (Amersham  BioSciences,  
UK)  using  a  Bio-­Rad  Trans-­blotâ  Turboä  transfer  system  (Bio-­Rad).  Nitrocellulose  
membranes   were   then   blocked   in   blocking   solution   (5%   w/v   dried   skimmed   milk  
powder  in  TBS-­T  (TBS:  25  mM  Tris/Cl,  pH  7.5;;  138  mM  NaCl  and  0.1%  Tween-­20))  
for  1  hr  at  RT.  Primary  antibody  diluted  in  blocking  solution  to  the  appropriate  dilution  
(Table  3   in  Appendix)  was  added  to   the  membrane  and   incubated  o/n  at  4˚C  on  a  
shaking   platform.  Membranes  were   then  washed   4   x   5  min   in   TBS-­T   at   RT.   The  
secondary   antibody,   which   is   conjugated   to   horseradish   peroxidase   (Table   3   in  
Appendix),  was  diluted  in  blocking  solution  (1:5000)  and  incubated  for  1  hr  at  RT.  The  
membranes  were  washed  4  x  5  min  in  TBS-­T  at  RT.  To  detect  the  chemiluminescent  
 77 
signal,  membranes  were  briefly  incubated  in  Pierceä  ECL  western  blotting  solution  
(Pierce).  Membranes  were  then  placed  in  a  protective  sleeve  with  film  (CL-­Xposureä  
Film,  Thermo)  placed  on  top  and  developed  for  an  appropriate  length  of  time.  The  film  
was  automatically  using  a  Xograph  Compact  4  machine.  
2.2.4  Densitometry  analysis  of  Western  blots    
Western  blot  films  (2.3.3)  were  digitalised  by  scanning.  Protein  levels  were  quantified  
using   ImageJ  (National   Institutes  of  Health,  USA).  For   this,   the  protein  bands  were  
selected  with  a  square.  The  same  square  surface  was  selected  for  every  protein  band.  
Band  intensity  was  determined  with  the  ‘measure’  function.  Areas  of  the  film  with  no  
protein  bands  were  measured  and  deducted  as  background.  The  resulting  data  was  
entered  into  Excel  (Microsoft,  USA)  and  analysed  using  a  Two-­tailed  Student  T-­Test.
     
2.3  Mammalian  cell  culture     
2.3.1  Cell  lines  and  their  maintenance     
Mammalian  cell  lines  (Table  4  in  Appendix)  were  maintained  in  Dulbecco’s  modified  
Eagle  medium   (DMEM;;  Lonza,  Switzerland)   supplemented  with   10%   foetal   bovine  
serum  (FBS;;  GIBCO,  UK),  1%  Non-­essential  amino  acids  (GIBCO,  UK)  and  50  U/ml  
penicillin   and   streptomycin   (Lonza,   Switzerland),   respectively.   All   cell   lines   were  
typically  kept  in  75  cm3  flasks  (Sarstedt,  Germany)  and  grown  in  a  humidified  incubator  
(Sanyo,  USA)  at  37°C  and  5%  CO2.  All  cell  culture  work  was  conducted  in  an  Airstream  
Class  II  Biological  Safety  Cabinet  (ESCO,  UK).       
  
2.3.2  Passaging  of  cell  lines    
Cells  were  passaged  upon  reaching  80%  -­  90%  confluence.  For  passaging,  medium  
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was  aspirated,   and   cells  were  washed  once  with   sterile   phosphate   buffered   saline  
(PBS).  To  detach  cells  from  the  culture  flask,  1  x  trypsin  was  added  and  incubated  at  
37°C,   5%   CO2   until   cells   were   detached.   Trypsin   was   inactivated   by   addition   of  
complete  DMEM.  Cells  were  then  re-­seeded  in  T75  flask  at  a  1:8  ratio,  cell  suspension:  
fresh  DMEM,  or  seeded  into  the  appropriate  dishes  at  the  required  density  for  each  
experiment.  
2.3.3  Transient  transfections  with  polyethylenimine     
For  transfection  of  HEK293TT  cells,  cells  were  seeded  into  6  well  or  12  well  cell  
culture   plates   (Corning,   USA)   at   a   density   of   1   x   106   or   0.5   x   106   cells/mL,  
respectively,   and   incubated   overnight   at   the   aforementioned   conditions.   The  
required  amount  of  plasmid  DNA  was  added  to  200  μL  of  1  x  Opti-­MEM  Reduced  
Serum   Medium   (Opti-­MEM;;   GIBCO,   UK).   After   5   min   incubation   at   RT,   the  
chemical   transfection   reagent   polyethylenimine   (PEI;;   23966,   Polyscience   Inc.)  
was  added  at  a  ratio  of  4:1  PEI:DNA.  The  PEI:DNA  mix  was  incubated  for  a  further  
20  min  at  RT.  For  co-­transfections  of  two  plasmids,  equal  amounts  of  each  plasmid  
were   added.   Complete   DMEM   in   culture   dishes   was   replaced   with   Opti-­MEM   I  
Reduced  Serum  Medium  and  the  DNA-­PEI  mixture  was  added  dropwise.  Cells  were  
incubated  for  overnight  as  described.  The  mixtures  were  removed  and  fresh  DMEM  
was  added  to  each  well  of  the  culture  plate  and  cells  were  incubated  as  described  for  
the  appropriate  length  of  time.     
  
2.3.4  Transient  transfections  with  Lipofectamine  2000     
For   transfection  of  primary  keratinocytes,  HeLa,  CaSKi  and  C33A  cells,  cells  were  
seeded  into  6  well  or  12  well  cell  culture  plates  (Corning,  USA)  at  a  density  of  1  x  
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106   or   0.5   x   106   cells/mL,   respectively,   and   incubated   overnight   at   the  
aforementioned  conditions.  The   required  amount  of  plasmid  DNA  was  added   to  
200  μL  of  1  x  Opti-­MEM  (GIBCO,  UK)).  In  a  separate  eppendorf,  the  appropriate  
amount  of  Lipofectamine®  2000  to  make  a  2.5:1  Lipofectamine®  2000:DNA  was  
added  to  200  μL  of  1  x  Opti-­MEM  (GIBCO,  UK).  After  5  min  incubation  at  RT,  the  
Lipofectamine®  2000  mix  was  added  to  the  DNA  mix  and  this  was  incubated  for  a  
further  20  at  RT.  For  co-­transfections  of  two  plasmids,  equal  amounts  of  each  plasmid  
were   added.   Complete   DMEM   in   culture   dishes   was   replaced   with   Opti-­MEM   I  
Reduced   Serum  Medium   and   the   Lipofectamine®   2000:DNA   mixture   was   added  
dropwise.   Cells   were   incubated   overnight.   The   mixtures   were   removed   and   fresh  
DMEM  was  added  to  each  well  of  the  culture  plate  and  cells  were  incubated  for  the  
appropriate  length  of  time.     
  
2.3.5  Transfection  of  siRNA  with  Lipofectamine  2000     
For  transfection  of  siRNA,  the  required  cells  were  plated  into  6-­well  dishes  at  a  density  
of  1  x  106  cells/mL.  The  siRNA  at  the  appropriate  concentration  was  added  to  200  μL  
of   1   x   Opti-­MEM   (GIBCO,   UK).   In   a   separate   eppendorf   tube,   the   appropriate  
amount  of  Lipofectamine®  2000  was  added  to  200  μL  of  1  x  Opti-­MEM  (GIBCO,  
UK).  After  5  mins,  the  Lipofectamine®  2000  mix  was  added  to  the  siRNA  mix  and  
this  was  incubated  for  20  mins  at  room  temp.  Complete  DMEM  in  culture  dishes  was  
replaced   with   Opti-­MEM   and   the   siRNA  mixture   was   added   dropwise.   Cells   were  
incubated  for  overnight.  The  mixtures  were  removed  and  fresh  DMEM  was  added  to  
each  well  of  the  culture  plate  and  cells  were  incubated  for  the  appropriate  length  of  
time.     
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2.3.6  Harvesting  of  cells  and  lysis    
For  preparation  of  cell  lysate,  media  was  aspirated  from  cells  in  culture  plates  and  
washed  once  in  PBS.  Leeds  lysis  buffer  (10  mM  Tris/Cl,  pH7.5;;  150  mM  NaCl,  0.5  
mM   EDTA,   0.5%   NP40,   1   x   Protease   inhibitor   cocktail,   EDTA-­free   (Roche,  
Switzerland))  was  added  to  each  well  and  cells  were  scrapped  into  the  lysis  buffer.  
Cell  lysate  was  transferred  to  an  eppendorf  tube  and  incubated  on  ice  for  20  mins.  
Lysate  was  then  centrifuged  at  17,000  x  g  at  4°C  for  10  mins.     
  
2.3.7  Normal  human  keratinocytes  (NHKs)     
Primary   NHKs   isolated   from   neonate   foreskin   tissues   (ethical   approval   no.  
06/Q1702/45)  were  obtained   from  Dr  Sally  Roberts,  University  of  Birmingham,  UK.  
The  transfection  of  NHK  with  the  wild  type  HPV  genome  was  performed  in  S.  Roberts’  
laboratory   as   described   previously   (129).   Briefly,   plasmids   containing   the   HPV18  
genome   were   digested   with   EcoRI   to   release   the   genome,   which   was   then   re-­
circularised  with  T4  DNA   ligase.  The  genomes  were  co-­transfected  with  a  plasmid  
encoding  resistance  to  neomycin  into  low  passage  NHK.  After  24  hours,  the  cells  were  
harvested  and  seeded  onto  a  layer  of  γ-­irradiated  J2-­3T3  fibroblasts  and  selected  with  
G418  in  complete  E  media  containing  foetal  calf  serum  (FCS,  Lonza)  and  epidermal  
growth   factor   (EGF,   BD   BioSciences)   for   8   days.   Cell   colonies   were   pooled   and  
expanded  on  γ-­irradiated  J2-­3T3  fibroblasts.  After  selection,  NHKs  stably  expressed  
episomal  wild  type  HPV18  genomes.     
  
2.3.8  Maintaining  and  passaging  untransfected  NHKs     
NHKs  were  maintained  in  serum  free  medium  (SFM;;  GIBCO,  UK)  supplemented  with  
25   µg/mL   bovine   pituitary   extract   (GIBCO,   UK)   and   0.2   ng/mL   recombinant   EGF  
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(GIBCO,  UK).  The  medium  was  replaced  with  every  2  days.  Cells  were  only  grown  to  
a  confluency  of  ≤  80%  in  10  cm  dishes.  The  incubation  conditions  were  the  same  as  
described  for  established  cell  lines  (2.3.1).     
To  passage,  the  medium  was  aspirated,  and  cell  were  washed  once  with  PBS.  After  
the  PBS  was  removed,  trypsin  was  added  and  left  to  incubate  for  5  min  -­  10  min  until  
cells  detached.  Trypsin  was  inhibited  by  the  addition  of  SFM  supplemented  with  1%  
Trypsin  inhibitor  (GIBCO,  UK).  NHKs  were  then  re-­seeded  a  density  of  2  x  105  cells  
per  dish  in  serum  free  media.     
  
2.3.9  Maintaining  and  passaging  NHKs  with  HPV18  genomes     
The  HPV18  containing  NHK  cell  lines  of  both  donors  were  maintained  in  10  cm  dishes  
with   3T3   J2   fibroblasts   as   feeder   cells   in   E-­medium   supplemented   with   2   mM   L-­
glutamine   (Lonza,   Switzerland)   and   5   ng/ml   EGF   (BD   Biosciences,   UK).  
3T3  J2  fibroblasts  were  pre-­treated  with  8  μg/mL  mitomycin-­C  (Roche,  Switzerland)  in  
DMEM  for  4  h  and  2  x  106  cells  were  seeded  in  E-­medium  in  10  cm  dishes  24  h  prior  
to  addition  of  transfected  NHKs.  NHKs  containing  the  HPV18  WT  were  passaged  as  
described  (2.5.1)  and  seeded  into  the  dishes  containing  the  mitomycin-­C  treated  3T3  
J2  fibroblasts.     
  
One  litre  of  E-­medium  was  prepared  as  follows:  600  ml  of  DMEM  Hepes  (Sigma,  USA)  
were   mixed   with   320   ml   Hams-­F-­12   (GIBCO,   UK),   20   mL   Penicillin/Streptomycin  
(GIBCO,  UK),  5%  FBS,  10  µg  Cholera  Toxin  (Sigma,  USA),  1  x  hydrocortisone  (Sigma,  
USA)  and  1  x  cocktail.  100  mL  of  100  x  cocktail  was  prepared  by  mixing  10  mL  of  0.18  
M  Adenine  (Sigma,  USA),  10  ml  of  5  mg/mL  Insulin  (Invitrogen,  USA),  10  mL  5  mg/ml  
transferrin  (Sigma,  USA),  10  mL  2  x  10-­8  M  3,3`,5-­Triiodo-­L-­thyronine  (T3)  (Sigma,  
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USA)  in  PBS.  The  E-­medium  was  sterile-­filtered  prior  to  use.    
  
2.3.10  Monolayer  differentiation  assays    
For  calcium  differentiation  of  NHKs  and  HPV18  containing  NHKs,  cells  were  grown  in  
6  well  plates  until  80%  confluent.  The  medium  was  then  removed  and  replaced  with  
SFM  without  supplements  (SFM,  Invitrogen)  containing  1.8  mM  calcium  chloride.  Cells  
were  maintained  in  this  media  for  48-­72  hours  before  lysis  (2.3.6)  and  analysis.    
For  methylcellulose  differentiation  of  NHKs  and  HPV18  containing  NHKs,  cells  were  
grown   in   6   well   plates   until   80%   confluency.   Cells   were   then   detached   and  
resuspended  in  E-­media  containing  1.5%  methylcellulose  and  cultured  for  between  
24  and  120  hours  before  lysis  (2.3.6)  and  analysis.  
2.3.11  Organotypic  raft  cultures     
NHKs  or  HPV18  containing  NHKs  were  grown  on  a  matrix  of  8  mg/ml  rat  tail  collagen  
(BD  Biosciences,  UK)  and  2  x  106  3T3  J2  fibroblasts  in  E-­medium  supplemented  with  
2  mM  L-­glutamine  and  5  ng/mL  EGF.  After  4  days,  the  matrix  and  keratinocytes  were  
transferred  onto  a  sterile  wire  mesh  at  an  air-­liquid  interface  created  by  addition  of  
E-­medium  without  EGF.  The  organotypic  raft  cultures  were  grown  for  10  -­  14  days  
at  37°C  and  5%  CO2  with  media  changes  every  two  day.  Rafts  were  fixed  by  flooding  
in  4%  paraformaldehyde  (PFA;;  4%  PFA  in  PBS,  pH  7.4).  Rafts  were  embedded  in  
paraffin   and   sectioned   into   5   µm  slices   by   Propath,  UK.  Haematoxylin   and  eosin  
(H&E)  staining  of  the  sections  was  also  carried  out  by  Propath,  UK.  Raft  cultures  of  
NHK  and  WT  HPV18  containing  NHKs  were  prepared  and  H&E  samples  imaged  by  
Dr  Christopher  Wasson,  University  of  Leeds,  UK.  Raft  cultures  of  HPV18  E6ΔPDZ  
containing   NHKs  were   prepared   and  H&E   samples   imaged   by  Dr   Sally   Roberts,  
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University  of  Birmingham,  UK.     
  
2.3.12  Immunohistochemistry  of  organotypic  rafts    
For   the   analysis   of   the   paraffin   embedded   organotypic   raft   cultures   slices   or  
pathological  sections  (kindly  provided  by  Prof  Sheila  Graham,  University  of  Glasgow,  
UK),  sections  were  analysed  by  immunohistochemistry  (IHC).  Paraffin  was  removed  
by  submersing  in  Histo-­Clearâ  (GENEFLOW  LTD,  UK)  for  3  x  5  min.  Rehydration  of  
samples  occurred  by  incubation  for  1  min  in  100%  ethanol,  followed  by  1  min  in  90%  
ethanol  and  1  min  in  70%  ethanol,  followed  by  5  min  incubation  in  ddH2O.  Antigen  
retrieval  was  achieved  by  boiling  in  sodium  citrate  buffer  for  15  min  (10  mM  Tri-­sodium  
citrate,  pH  6;;  0.05%  Tween-­20).  Samples  were  washed  in  ddH2O  followed  by  blocking  
in  10%  normal  goat  serum  (NGS)  in  PBS  for  1h  at  RT.  The  primary  antibody  (Table  3  
in  Appendix)  was  incubated  for  1h  at  RT  in  1%  NGS  buffer.  Slides  were  washed  5  x  
in  PBS  prior   to   incubation  with  AlexaFluor   labelled  secondary  antibody  (Table  3   in  
Appendix)  for  1h  in  1%  NGS  buffer.  Slides  were  washed  5  x  in  PBS  and  the  samples  
were   mounted   using   ProLong   Gold   Antifade   Reagent   with   4',6-­diamidino-­2-­
phenylindole   (DAPI)   (Molecular  Probes,  UK).  Dr  Chris  Wasson  performed   IHC   for  
NHK   and  WT   HPV18   containing   NHKs   and   Dr   Sally   Roberts   performed   IHC   for  
HPV18  E6ΔPDZ  containing  NHKs.     
  
2.4  Viral  Gene  Transduction     
2.4.1  Production  of  lentiviruses  for  gene  transduction     
For   the  preparation  of   lentiviruses   for  gene  transduction,  HEK293TT  cells   (Table  4   in  
Appendix)  were  seeded  into  10  cm  cell  culture  plates  (Corning,  USA)  at  a  density  
of  1  x  107  cells/mL  and  incubated  overnight  at  the  aforementioned  conditions.  The  
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required  amount  of  plasmid  DNA  for  the  gene  of  interest  (GOI)  was  added  to  500  
μL  of  1  x  Opti-­MEM  (GIBCO,  UK).   In  addition   the  packaging  vectors  pUMVC3-­
gag-­pol   and   the   envelope   vector   pCMV-­VSV-­G   were   added   so   that   the   final  
plasmid  ratio  was  GOI:GAG/POL:VSV  was  2.4:1:1.  In  a  separate  eppendorf  tube,  
the  appropriate  amount  of  Lipofectamine®  2000   to  make  a  2:1  Lipofectamine®  
2000:DNA   was   added   to   500   μL   of   1   x   Opti-­MEM   (GIBCO,   UK).   After   5   min  
incubation  at  RT  the  Lipofectamine®  2000  mix  was  added  to  the  DNA  mix  and  this  
was  incubated  for  a  further  20  mins  at  RT.  The  Lipofectamine®  2000:DNA  mixture  
was  added  dropwise  to  the  cells.  After  48  hours,  the  cell  supernatant  was  harvested  
and  was  at  centrifuged  at  3000  x  g  at  4°C  for  10  mins   to  remove  cell  debris.  The  
cell  supernatant  was   then  concentrated  10-­fold   in  a  10k  molecular  weight  cutoff  
(MWCO)  concentrator  (Spin-­XR  UF20,  10k  MSCO,  20mL;;  431488,  Corningâ).    
2.4.2  Virus  transduction       
For  the  transduction  of  lentiviruses,  target  cells  were  seeded  at  1  x  106  cells/mL  in  6  
well   plates   and   incubated   overnight   at   the   aforementioned   conditions.   Before  
addition  of  concentrated  virus,  culture  medium  was  removed  and  the  cells  were  
washed  once  with  PBS.  The  concentrated  virus  was  then  added  for  3  hours  (NHKs  
and  HPV  containing  NHKs)  or  overnight  (HeLa  and  CaSKi).  The  virus  was  then  
removed,   cells   were  washed   once   in   PBS   and   the   cells  were   incubated   for   the  
appropriate  length  of  time.     
  
2.5  Small  Molecule  Inhibitors    
The  STAT3  inhibitor  S3I-­201  was  purchased  from  AdooQ  BioSciences  and  used  at  a  
final  concentration  of  10  μM.  This  cell  permeable  compound  binds  to  the  STAT3  SH2  
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domain  to  prevent  phosphorylation  and  activation.  Cryptotanshinone  was  purchased  
from   LKT   Laboratories   to   inhibit   STAT3   dimerisation   and   activation.   The   STAT5  
inhibitor  Pimozide  was  purchased  from  Calbiochem  and  used  at  a  final  concentration  
of  10  μM.  UO126  is  a  selective  MEK1/2  inhibitor,  and  is  used  to  inhibit  activation  of  
ERK1/2   and   was   used   at   a   final   concentration   of   20   μM   and   purchased   from  
Calbiochem.   VX-­702   was   purchased   from   Tocris   and   used   to   inhibit   p38   kinase  
activity  and  was  used  at  a  final  concentration  in  cells  of  10  μM.  The  JNK1/2  inhibitor  
JNK-­IN-­8   was   purchased   from   Cambridge   BioSciences   and   used   at   a   final  
concentration  of  3  μM  in  cells.  SB-­747651  was  used  to  inhibit  MSK1/2  and  used  at  a  
final   concentration   of   5   μM   in   cells.   The   JAK1/2   inhibitor   Ruxolitinib,   and   JAK2  
inhibitor  Fedratinib  were  kindly  provided  by  Dr  Edwin  Chen,  University  of  Leeds.  IKK-­
16  is  a  selective  inhibitor  of  the  IkB  kinase  IKKa  and  IKKb  and  was  purchased  from  
Calbiochem.   All   compounds   were   used   at   concentrations   required   to   minimise  
potential  off-­target  activity.    
2.6  Quantitative  Real-­time  PCR     
2.6.1  RNA  extraction   
For  extraction  of  total  RNA  from  cells,  TRK  lysis  buffer  was  added  to  cells  and  the  
lysate  was  processed  with  the  E.Z.N.A.  Total  RNA  Kit  I  (Omega  Bio-­  Tek)  according  
to   the   manufacture’s   protocol.   RNA   yield   was   determined   using   a   Nanodrop  
spectrophotometer  (Thermo  Fisher  Scientific,  USA).     
  
2.6.2  Reverse  transcription     
One   μg   of   total   RNA   was   DNase   treated   following   the   RQ1   RNase-­Free   DNase  
protocol  (Promega)  and  then  reverse  transcribed  with  a  mixture  of  random  primers  
 86 
and   oligo(dT)   primers   using   the   qScript   cDNA   SuperMix   (Quanta   Biosciences)  
according  to  instructions.       
  
2.6.3  Quantitative  Real-­time  PCR     
The   quantitative   real-­time   PCR   (qPCR)   reaction   was   conducted   using   the  
QuantiFast®  SYBR®  Green  PCR  kit  (Qiagen,  Germany)  and  a  Corbett  Rotor-­Gene  
6000  (Qiagen,  Germany).  Briefly,  2.5  µl  of  RT-­reaction  mix  (2.10.2)  (equals  62.5  ng  
of  cDNA)  and  1  µM  of  each  forward  and  reverse  primer  (Table  2.4)  were  added  to  
the  2  x  QuantiFast  SYBR  Green  PCR  Master  Mix.  The  PCR  reaction  was  conducted  
as   follows:   initial   activation   step   for   10   min   at   95°C   and   a   two-­step   cycle   of  
denaturation  (10  sec  at  95°C)  and  combined  annealing  and  extension  (15  sec  at  
60°C)  which  was  repeated  40  times.  The  data  obtained  was  analysed  according  to  
the  ΔΔCt  method  using  the  Rotor-­Gene  6000  software.  Specific  primers  were  used  
for  each  gene  analysed  (Table  6  in  Appendix).  U6  served  as  normaliser  gene.  
2.7  Immunofluorescent  Microscope     
2.7.1  Cell  growth  on  coverslips     
Immunofluorescence   staining   was   conducted   in   12-­well   dishes   (130185,   Thermo).  
Cells   were   seeded   into   wells   containing   circular   cover   slips   (400-­08-­26;;   glass  
coverslips,  Dia.  19.  Academy  Science,  UK)  at  a  density  of  5  x  104  cells/mL.  Cells  were  
taken   forward   for   staining   (2.6.2,   2.6.3)   when   approximately   80%   confluent.  
  
2.7.2  Fixation  and  permeabilisation  of  cells     
At   the  appropriate   time,  culture  medium  was   removed  and   the  cells  on  coverslips  
were   washed   once   with   PBS.   Cells   were   then   fixed   by   incubation   in   4%  
 87 
paraformaldehyde  (PFA)  in  PBS  at  RT  for  10  min.  Cells  were  washed  again  in  PBS  
and   permeabilised   in  Triton   X-­100   (0.1%  Triton   X-­100   in   PBS)   for   15  min   at   RT.  
  
2.7.3  Immuno-­labelling     
After  permeabilisation,  coverslips  were  incubated  in  blocking  buffer  (4%  BSA  in  PBS)  
for  1  hour  at  RT.  After  a  washing  step  in  PBS,  the  primary  antibody  (Table  3)  was  
diluted   in   antibody   solution   (4%   BSA   in   PBS)   and   incubated   at   4°C   overnight.  
Following  by  4  washing  steps  with  PBS,  the  secondary  antibody  (Table  3)  was  diluted  
in  antibody  solution  and  incubated  for  2h  at  RT.  The  coverslips  were  then  washed  4  
times  in  PBS  and  the  coverslips  were  mounted  onto  glass  slides  (0.8  -­  1.0  mm  thick:  
VWR,  USA)  using   the  mounting  agent  ProLong  Gold  Antifade  Reagent  with  DAPI  
(Molecular  Probes,  UK).  Edges  of  coverslips  were  sealed  with  nail  varnish  and  slides  
were  stored  at  4°C  until  viewing.  
2.7.4  Microscopy     
Samples  were  imaged  with  a  Zeiss  laser  scanning  confocal  microscope  (LSM700  
inverted;;   Zeiss,   Germany)   under   an   oil-­immersion   63   x   objective   lens.  
Representative   images   were   processed   using   the   Zen   2011   software   (Zeiss,  
Germany).  
  
2.8  Cell  cycle  analysis  by  flow  cytometry       
After  incubation  of  cells  as  required  per  experiment,  cells  were  harvested  and  fixed  in  
70%  ethanol  at  -­20°C  overnight.  The  ethanol  was  removed,  and  cells  were  washed  
twice  in  with  PBS  containing  0.5%  BSA.  Cells  were  stained  with  PBS  containing  0.5%  
BSA,  50  μg/mL  propidium  iodide  (Sigma)  and  5  μg/mL  RNase  (Sigma)  and  incubated  
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in  this  solution  for  30  minutes  at  room  temperature.  Samples  were  processed  on  an  
LSRFortessaTM   cell   analyzer   (BD)   and   the   PI   histograms   analysed   on   modifit  
software.     
  
2.9  Conditioned  Media     
For  the  collection  of  HeLa  and  CaSKi  conditioned  media,  5  x  106  cells/mL  were  seeded  
in  10  cm  dishes.  When  the  cells   reached  90%  confluency,   the  cell   supernatant  was  
harvested  and  was  centrifuged  at  3000  x  g  at  4°C  for  10  mins  to  remove  cell  debris.  
The   cell   supernatant   was   then   concentrated   10-­fold   in   a   10k  molecular   weight  
cutoff   (MWCO)   concentrator   (Spin-­XR   UF20,   10k   MSCO,   20mL;;   431488,  
Corningâ).    
  
For  conditioned  media  experiments,  C33A  cells  were  seeded  at  a  density  of  1   x   106  
cells/mL  were  serum  starved  in  DMEM  without  FBS  addition  for  24  hours.  After  serum  
starvation,  concentrated  media  from  HeLa  or  CaSKi  cells  was  added  for  the  indicated  
time  points   for   each  experiment.   For   neutralization   assays,   IL-­6   neutralising   antibody  
(ab6672;;  Abcam)  or  gp130  neutralising  antibody  (28105;;  R&D  system,  USA)  was  added  
4  hours  before  cell  lysis,  with  conditioned  media  added  2  hours  before  cell  lysis.  
  
2.10  Cytokine  and  neutralization  assays     
For  cytokine  treatments,  recombinant  human  Interleukin-­6  (rhIL-­6)  was  purchased  from  
R&D  Systems  and  re-­suspended   in  PBS.  For   treatments,  HeLa,  C33A  or  CaSKi  cells  
were   seeded   in   6   or   12   well   plates   at   a   density   of   1   x   105   or   5   x   104   cells/mL,  
respectively.  The  cells  were  then  serum  starved  in  DMEM  without  FBS  addition  for  24  
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hrs.  After  serum  starvation,  IL-­6  was  added  at  20  ng/mL  for  the  indicated  time  points  for  
each  experiment,  or  for  the  doses  indicated.  
  
For   pre-­treatments  with   small  molecule   inhibitors,   the   required   inhibitor   was   added   4  
hours  before  cell   lysis,  with  rhIL-­6  added  30  mins  before  cell   lysis.     For  neutralization  
assays,   IL-­6   neutralising   antibody   (ab6672;;   Abcam)   or   gp130   neutralising   antibody  
(28105;;  R&D  system,  USA)  was  added  4  hours  before  cell  lysis.  
  
2.11  ELISA      
Human   interleukin-­6   (IL-­6)   levels   were   detected   in   the   cell   supernatants   using   the  
DuoSet®  ELISA  kit  according  to  the  manufacturer’s  instructions  (R&D  Systems).  
  
2.12  Luciferase  reporter  assays     
C33A  cells  were  seeded   in  12  well  plates  at  a  density  of  1   x  105  cells/mL  and  were  
transfected  by  using  polyethyleneimine  (PEI)  with  expression  plasmids  in  combination  
with  a  reporter  plasmid  expressing  firefly  luciferase  under  the  control  of  the  β-­casein  
or   PomC   promoter,   which   contain   tandem   repeats   of   a   STAT-­response   element  
(373,374)A  constitutively  expressing  Renilla   luciferase  plasmid  was  used  to  assess  
transfection  efficiency.  Transfected  cells  were  then  lysed  and  assayed  for  luciferase  
activities  using  Dual-­Luciferase  Stop  and  Glo  reagent  (Promega)  and  a  luminometer  
(EG&G   Berthold).   Fold   promoter   activity   was   calculated   by   dividing   the   relative  





2.13  Proliferation  assays  
2.13.1  Cell  growth  assay     
For  the  measurement  of  cell  proliferation,  cells  were  seeded  in  6  well  plates  at  a  density  
of  1  x  106  cells/mL  and  were  treated  as  required  per  experiment.  At  the  experiment  end  
point,  cells  were  trypsinised  and  50,000  cells  were  re-­plated  in  a  6  well  plate.  Cells  were  
then  harvested  daily  and  counted  manual  using  a  haemocytometer.  
  
2.13.2  Colony  formation  assay     
For  the  measurement  of  anchorage  dependent  cell  proliferation,  cells  were  seeded  in  6  
well  plates  at  a  density  of  1  x  106  cells/mL  and  were  treated  as  required  per  experiment.  
At  the  experiment  end  point,  cells  were  trypsinised  and  500  cells  were  re-­plated  in  a  6  
well  plate.  Cells  were  analysed  daily  by  microscopy  until  visible  colonies  were  noted  (14  
-­  21  days).  At  this  point,  culture  medium  was  removed  and  colonies  were  stained  in  crystal  
violet  staining  solution  (1%  crystal  violet  (CHE1680;;  Science  Laboratory  Support  SLS,  
UK),  25%  methanol)  for  15  mins  at  RT.  Colonies  were  then  thoroughly  washed  in  water  
and  photographed.  Colonies  were  counted  manually.     
  
2.13.3  Soft  Agar  assay    
For  the  measurement  of  anchorage  independent  cell  proliferation,  cells  were  seeded  in  6  
well  plates  at  a  density  of  1  x  106  cells/mL  and  were  treated  as  required  per  experiment.  
In  parallel,  60  mm  dishes  were  coated  with  a   layer  of  1%  agarose  (ThermoFischer  
Scientific,  USA)  in  2X  DMEM  (ThermoFischer  Scientific,  USA)  supplemented  with  20  
%   FBS.   At   the   experiment   end  point,   cells  were   trypsinised  and  1000   cells/mL  were  
added  to  0.7  %  agarose  in  2X  DMEM  (ThermoFischer  Scientific,  USA)  supplemented  
with  20  %  FBS.  Once  set,  DMEM  supplemented  with  10  %  FBS  and  50  U/mL  penicillin  
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was  added.  The  plates  were  then  incubated  for  14  -­  21  days.  Colonies  were  counted  
manually.    
  
2.14  Migration  assays  
2.14.1  Wound  healing  assay    
Cells  were  seeded  in  6  well  plates  at  a  density  of  1  x  106  cells/mL  cells.  Cells  were  grown  
to  full  confluency  and  then  serum  starved  for  24  hours.    Cells  were  then  wounded  with  
a  P200  pipette  tip.  Images  were  taken  immediately  after  initiation  of  the  wound  and  at  
24   hours   post  wounding.  For   siRNA   treatment,   cells  were   transfected  with  STAT3  
specific  siRNA  and   incubated   in  serum   free  media.  After  16  hours,   the  media  was  
replaced  with  normal  DMEM  with  10%  FBS.  48  hours  post   transfection,  cells  were  
wounded  using  a  P200  pipette  tip.  Images  were  then  taken  as  for  inhibitor  treatment.  
All  images  were  analysed  using  Image  J  (NIH).  
  
2.14.2  Transwellâ  migration  and  Invasion  assays       
Cells  were  seeded  in  6  well  plates  at  a  density  of  1  x  106  cells/mL  and  were  treated  as  
required   per   experiment.   Cells   were   then   serum   starved   for   26   hours   in   serum   free  
medium.  Cells  were   then   trypsinised  and  5  x   104  cells  were   replated  onto   the   upper  
chamber  of  a  Transwellâ filter  with  8  μm  pores  (Falconâ,  Corning,  USA)  coated  with  
(invasion)   or   without   (migration)   200   μg/mL   Matrigelâ Matrix   (Corning).   DMEM  
containing  10%  FBS  was  used  as  the  chemoattractant.  After  24  hours,  non-­migrated  
cells  on  the  upper  side  of  the  filter  were  removed  with  a  cotton  swab,  and  cells  on  the  
underside  of  the  filter  were  stained  with  1%  crystal  violet  in  25%  methanol.  For  each  
experiment,  the  number  of  cells  in  five  random  fields  on  the  underside  of  the  filter  was  
counted,  and  three  independent  filters  were  analysed.  
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2.15  Apoptosis  assays    
2.15.1  Annexin  V  assay     
Annexin  V  apoptosis  assay  (TACSâ  Annexin  V  kit;;  4830-­250-­K)  was  performed  as  
indicated  on   the   product   datasheet.  Briefly,   cells  were   seeded   in  6  well  plates  at  a  
density  of  1  x  106  cells/mL  and  were  treated  as  required  per  experiment.  Cells  were  then  
trypsinised  and  cell  were  collected  by  centrifugation  at  700  x  g  for  5  mins.  Cells  were  then  
washed   in   cold   PBS   and   re-­centrifuged.   1x106   cells   were   then   incubated   in   100   μL  
Annexin  V  reagent  (10  μL  10X  binding  buffer,  10  μL  propidium  iodide,  1  μL  Annexin  V-­
FITC  (diluted  1   in  500),  880  μL  ddH2O)   for  15  mins,  RT   in   the  dark.  400  μL  of  1X  
binding   buffer   was   then   added   before   analysis   by   flow   cytometry.   Samples   were  
processed  on  an  LSRFortessaTM  cell  analyzer  (BD)  and  the  PI  histograms  analysed  
on  modifit  software.  
  
2.15.2  DNA  Condensation  assay     
DNA  condensation  was  analysed  using  the  Vybrant®  DyeCycle™  Violet/SYTOX®  
AADvanced™  Apoptosis   Kit   (TermoFischer;;  A35135)   and  was  performed  as  
indicated  on   the   product   datasheet.  Briefly,   cells  were   seeded   in  6  well  plates  at  a  
density  of  1  x  106  cells/mL  and  were  treated  as  required  per  experiment.  Cells  were  then  
trypsinised  and  cell  were  collected  by  centrifugation  at  700  x  g  for  5  mins.  1x106  cells  were  
then  washed  in  cold  Hank’s  Balanced  Salt  Solution  (HBSS)  and  re-­centrifuged.  Cells  were  
then  resuspended  in  1  mL  HBSS  and  1  μL  of  1  μM  Vybrant®  DyeCycle™   Samples  
were  then  incubated  on  ice  in  the  dark  for  30  min  and  immediately  analysed  by  flow  
cytometry.  Samples  were  processed  on  an  LSRFortessaTM  cell  analyzer  (BD)  and  the  
PI  histograms  analysed  on  modifit  software.     
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Chapter   3.   The   role   of   STAT3   during   the   differentiation-­
dependent  HPV18  life  cycle  
  
3.1  Introduction     
As  an  obligate   intracellular  parasite,  HPV  replication   is  critically  dependent  on  host  
factors,  which  are  mainly  controlled  by  the  activities  of  the  virus  encoded  E5,  E6  and  
E7   proteins   (375).   HPV   E5   can   reregulated   EGFR   signalling,   promoting   the  
proliferative  abilities  of  infected  keratinocytes  (129,376).  HPV  E7  proteins  promote  S  
phase  re-­entry  in  the  differentiated  keratinocytes  via  an  ability  to  bind  and  inactivate  
the  pocket  family  proteins  pRb,  p107  and  p130  (137,377).  HPV  E6  recruits  the  cellular  
ubiquitin  ligase  E6-­associated  protein  (E6AP)  into  a  protein  complex  with  the  tumour  
suppressor  protein  p53,  resulting  in  the  degradation  of  p53  (158).  In  addition,  high-­risk  
E6   proteins   bind   and  modulate   a   select   group   of   PDZ   domain   containing   proteins  
(169,170).  Despite  our  increased  understanding  of  the  role  of  E5,  E6  and  E7  during  
the   HPV   life   cycle,   there   is   still   a   clear   need   to   better   understand   HPV-­host   cell  
interactions  in  order  to  develop  novel  strategies  to  treat  HPV  infections.  
As   a  member   of   the   signal   transducer   and  activator   (STAT)   family   of   transcription  
factors,  STAT3  is  activated  by  cytokine  and  growth  factor  signalling,  which  typically  
involves  phosphorylation  of  a  tyrosine  (Y705)  residue  (280).  Tyrosine  phosphorylated  
STAT3  molecules   form  activated  dimers  and  translocate   to   the  nucleus  where  they  
initiate  a  programme  of  gene  expression  controlling  fundamental  biological  processes  
including   proliferation,   immune   regulation   and   differentiation   (283).   STAT3   is   also  
subject  to  stimulus-­  and  tissue-­dependent  phosphorylation  of  a  serine  (S727)  residue  
in   its   transactivation   domain   (191).   The   function   of   this   additional   phosphorylation  
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event  remains  controversial,  as  the  modification  has  been  reported  to  both  enhance  
and  suppress  STAT3  transcriptional  activity  (286).    
In  stratified  epithelia,  STAT3  functions  to  drive  proliferation  and  is  required  to  maintain  
cells  in  an  undifferentiated  state  by  impairing  differentiation  (372).  Over  expression  of  
constitutively   active  STAT3   in   the  epithelia   of  mice   results   in  hyperplasia,   reduced  
keratinocyte  differentiation  and  an  increase  in  inflammatory  cytokine  secretion  (372).  
Despite   the   fact   that   STAT3   activation   is   critical   for   keratinocyte   proliferation   and  
disrupting  keratinocyte  differentiation,  it   is  not  known  whether  STAT3  contributes  to  
the  productive  infectious  HPV  life  cycle.  This  is  surprising  given  the  important  role  of  
STAT3  in  maintaining  an  undifferentiated  phenotype  in  keratinocytes.     
  
The  aim  of  this  chapter  is  to  assess  the  activation  status  of  STAT3  in  HPV-­containing  
keratinocytes  compared  with  normal  keratinocytes  and  to  identify  the  role  of  STAT3  
during  the  productive  HPV  life  cycle.    
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3.2  Results    
3.2.1   HPV18   enhances   STAT3   phosphorylation   in   primary   human  
keratinocytes  
To  investigate  the  role  of  STAT3  in  the  HPV18  life  cycle,  stable  cell  lines  harbouring  
HPV18  episomes  were  generated  from  two  primary  foreskin  keratinocyte  donors.  To  
exclude  donor  effects,  all   experiments  were  performed  using  both   donor   lines   and  
representative  data  are  presented.  Levels  of  STAT3  phosphorylation  were  measured  
in  normal  human  keratinocytes  (NHK)  and  HPV18-­containing  cells  by  western  blotting.  
In   undifferentiated   cells,   phosphorylation   of   the   tyrosine   (Y705)   and   serine   (S727)  
residues  was  significantly  enhanced  in  HPV18-­containing  keratinocytes  compared  to  
NHK  donor  controls  (Fig  3.1A,  compare  lanes  1  and  4,  Fig  3.1B,  showing  combined  
data  from  two  donors;;  N  =  8  p<0.05).  To  ascertain  whether  STAT3  phosphorylation  
was  modulated  during   keratinocyte   differentiation,  monolayer   cultures   of   NHK   and  
HPV18-­containing  cells  were  cultured  in  high  calcium  media  for  72  hours.  Keratinocyte  
differentiation  was  confirmed  by  increased  involucrin  expression  (Fig  3.1A).  In  HPV  
containing  keratinocytes,  enhanced  STAT3  phosphorylation  was  maintained  at  upon  
differentiation  (Fig  3.1A,  compare  lanes  2  and  5,  3  and  6).  In  contrast,  HPV18  had  no  
effect  upon  the  total  levels  of  STAT3  protein  in  the  primary  keratinocytes  (Fig  3.1A).    
Next,  an  organotypic  raft  culture  system,  in  which  NHK  and  HPV18-­containing  cells  
were  stratified  for  14  days,  was  used  to  confirm  our  findings;;  this  method  recapitulates  
all   stages   of   the   HPV   life   cycle   (378).   Raft   sections   were   stained   with   antibodies  
detecting   the   total   and   phosphorylated   forms   of   STAT3   (representative   sections  
shown  in  Fig  3.1C  and  1D).  Staining  of  total  STAT3  protein  was  comparable  between  
the   donor-­matched   NHK   and   HPV18-­containing   rafts.   Efforts   to   detect   tyrosine  
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phosphorylated   STAT3   by   immunofluorescence   proved   unsuccessful.   However,  
serine  phosphorylated  STAT3  was  evident  in  both  the  basal  and  suprabasal  layers  of  
the  NHK  and  HPV18  containing  rafts.  However,  the  level  of  the  S727  phosphorylated  
form  of  STAT3  was  elevated  in  the  presence  of  HPV18  (Fig  3.1C  and  3.1D),   in  line  
with   our   monolayer   culture   data.   Our   data   clearly   demonstrate   that   primary  
keratinocytes  harbouring  HPV18  genomes  exhibit  increased  STAT3  phosphorylation.  
     
 97 
  
Figure   3.1.   HPV18   induces   the   activation   of   STAT3   in   primary   human  
keratinocytes.   A)   Representative   western   blots   of   normal   human   keratinocytes  
(NHK)  and  HPV18  containing  keratinocytes  subjected  to  high  calcium  differentiation  
and   analysed   for   Tyrosine   705   and   Serine   727   STAT3   phosphorylation   and   total  
STAT3.  Involucrin  expression  is  a  marker  of  differentiation  and  E7  demonstrates  the  
presence   of   HPV18.  GAPDH   serves   as   a   loading   control.  B)  Quantification   of   the  
protein   band   intensities   in   A)   standardised   to   GAPDH   levels.   Bars   represent   the  
means  ±  standard  deviation  from  4  independent  biological  repeats  using  2  donor  cell  
lines.  *P<0.05  (Student’s  t-­test).  Representative  sections  of  organotypic  raft  cultures  
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from  C)  NHK  and  D)  HPV18  containing  keratinocytes  stained  with  antibodies  specific  
for  pS727  STAT3  and  total  STAT3  (green)  and  counterstained  with  DAPI  to  highlight  
the  nuclei  (blue  in  the  merged  panels).  Images  were  acquired  using  identical  exposure  
times.  Scale  bar,  40  µm.  White  dotted  lines  indicate  the  basal  cell  layer.    
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3.2.2  HPV18  E6  is  necessary  and  sufficient  for  the  dual  phosphorylation  
and  activation  of  STAT3     
The   HPV   oncoproteins   (E5,   E6   and   E7)   are   critical   in   modulating   the   host   cell  
environment   in  order   to  favour  viral  replication.  Thus,  one  of   the  HPV  oncoproteins  
may  be  responsible  for  the  promotion  of  the  STAT3  phosphorylation  observed  in  the  
HPV18  life  cycle  model.  For  this,  we  expressed  GFP-­tagged  HPV18  oncoproteins  in  
C33A  cells  (an  HPV-­negative  cervical  carcinoma  cell  line)  and  measured  the  levels  of  
STAT3   phosphorylation   by  western   blot   analysis   (Fig   3.2A).   Interestingly,   all   three  
oncoproteins  increased  Y705  STAT3  phosphorylation  compared  to  cells  expressing  
GFP  alone  (compare  lanes  1  with  2,  3  and  4);;  E5  by  average  of  3  fold  (p<0.05),  E6  by  
an  average  of  4.1  fold  (p<0.05)  and  E7  by  an  average  of  3.6  fold  (p<0.05).  In  contrast,  
however,   only   HPV18   E6   expression   increased   S727   STAT3   phosphorylation  
significantly,  by  an  average  of  5.6  fold  (p<0.01)  (Fig  3.2A,  lane  3).  In  agreement  with  
our  observations  from  primary  keratinocytes,  the  presence  of  the  HPV  oncoproteins  
did  not  alter  the  level  of  total  STAT3  protein.  
Next,  it  was  important  to  investigate  whether  the  viral  oncoproteins  are  responsible  for  
the  increased  STAT3  phosphorylation  observed  in  HPV18-­containing  keratinocytes.  
For  this,  E6  expression  was  silenced  in  the  HPV18-­containing  keratinocytes  using  a  
pool  of  E6-­specific  siRNA  and  the  levels  of  phosphorylated  STAT3  compared  to  those  
in  cells  transfected  with  a  scrambled  control  siRNA  (Fig  3.2B).  Treatment  with  the  E6-­
siRNA  resulted  in  a  loss  of  E6  protein  expression  coupled  to  an  increase  in  levels  of  
the   E6   target   p53   (Fig   3.2B).   Importantly,   the   loss   of   E6   also   correlated   with   a  
significant  reduction  in  both  Y705  and  S727  STAT3  phosphorylation  (p<0.001).  The  
depletion  of  HPV  E6  also  resulted  in  decreased  E7  expression  (average  of  55%)  (Fig  
3.2B).  To   rule  out  any  contributory   role   for   this  oncoprotein,   the  effects  of  HPV  E7  
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expression   on   STAT3   phosphorylation   was   also   assessed.   Treatment   of   HPV18  
containing   cells   with   E7-­specific   siRNA   reduced   E7   protein   expression   by  
approximately   60%   without   impacting   on   either   E6   expression   or   STAT3  
phosphorylation  (Fig  3.2C).  To  test  the  contribution  of  the  E5  oncoprotein,  a  recently  
generated  primary  keratinocyte  line  from  our  lab  containing  an  E5  knockout  HPV18  
genome  was  used   {Wasson:2017ju}.   In   this  system,   the   loss   of  E5  did   not   reduce  
STAT3   phosphorylation   in   either   monolayer   cultures   differentiated   in   high   calcium  
media  or  organotypic  raft  cultures  (Fig  3.2D  and  E)  In  summary,  these  data  indicate  
that  E6  is  the  protein  predominantly  responsible  for  increasing  STAT3  phosphorylation  
in  HPV18-­containing  keratinocytes.     
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Figure  3.2.     HPV  E6   is  necessary  and  sufficient   for   the  dual  phosphorylation  
STAT3.  A)  Representative  western  blot  of  C33A  cells   transfected  with  GFP  tagged  
HPV18  oncoproteins  E5,  E6  or  E7  and  analyzed  for  STAT3  activation  using  specific  
antibodies   detecting   phosphorylated   and   total   STAT3.   Expression   of   HPV  
oncoproteins   was   confirmed   using   a   GFP   antibody.   GAPDH   served   as   a   loading  
control.  A)  Representative  western  blot  of  HPV18  containing  keratinocytes  transfected  
with   a   two   HPV18   E6   specific   siRNA   and   analysed   for   phosphorylated   and   total  
STAT3,   HPV18   E6   and   E7   and   p53.   GAPDH   expression   was   used   as   a   loading  
control.   B)   Representative   western   blots   of   HPV18   containing   keratinocytes  
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transfected  with  HPV18  E7  specific  siRNA  and  analysed  for  phosphorylated  and  total  
STAT3,  HPV18  E6  and  E7.  GAPDH  expression  was  used  as  a   loading  control.  C)  
Representative  western  blots  of  HPV18-­containing  keratinocytes  and  HPV18  E5KO  
containing   keratinocytes   subjected   to   high   calcium   differentiation   and   analysed   for  
phosphorylated   and   total   STAT3.   GAPDH   serves   as   a   loading   control.   D)  
Representative  sections  of  organotypic  raft  cultures  from  HPV18  wild  type  and  HPV18  
E5KO-­containing  keratinocytes  stained  with  antibodies  specific  for  pS727  STAT3  and  
counterstained  with  DAPI  to  highlight  the  nuclei  (blue  in  the  merged  panels).  Images  
were  acquired  using  identical  exposure  times.  Scale  bar,  20  μm.  White  dotted  lines  
indicate  the  basal  cell  layer.    
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To   address   whether   increased   STAT3   phosphorylation   correlated   with   enhanced  
STAT3   transactivation,   the   activity   of   two   STAT3-­dependent   luciferase   reporter  
plasmids   was   measured.   C33A   cells   were   co-­transfected   with   isolated   HPV18  
oncoproteins  and  reporter  plasmids  driving  firefly  luciferase  from  the  β-­casein  (373)  
and  pro-­opiomelanocortin  (PomC)  (374)  promoters.  Expression  of  HPV18  E5  and  E7  
did   not   significantly   increase   STAT3-­dependent   luciferase   expression.   Conversely,  
expression  of  HPV18  E6  led  to  an  average  8-­fold  increase  in  β-­casein  promoter-­driven  
luciferase   (p<0.01)   and  a   5.5-­fold   increase   in  PomC-­driven   luciferase   (p<0.01)   (Fig  
3.3A).  Whilst  these  reporter  constructs  have  been  widely  used  to  monitor  the  activation  
of   STAT3,   they   can   also   be   responsive   to   other   members   of   the   STAT   family   of  
transcription   factors   {Kitamura:2006hl,  Macdonald:2004gn}.   In   this   regard,  a   recent  
study  identified  that  HPV31  activates  STAT5,  which  is  necessary  for  HPV31  genome  
amplification  {Hong:2013fh}.  To  exclude  the  possibility  that  the  increase  in  luciferase  
expression   was   a   result   of   STAT5   activation,   we   used   small   molecule   inhibitor  
molecules   to   specifically   block   the   activation   of   STAT3   and   STAT5   (Fig   3B).  
Transfected  C33A  cells  were  treated  with  the  STAT5  inhibitor  pimozide  (150)  or  two  
chemically  distinct  STAT3  inhibitors,  cryptotanshinone  and  S3I-­201.  Cells  treated  with  
pimozide  showed  no  reduction  in  luciferase  expression,  whereas  treatment  with  the  
two  STAT3   inhibitors   resulted   in  a  significant   (p<0.01)   reduction   in  β-­casein-­driven  
luciferase  expression  (Fig  3.3B).  
Next,  the  impact  of  HPV  E6  on  the  expression  of  endogenous  STAT3-­dependent  gene  
products   was   assessed.   Expression   of   HPV18   E6   in   C33A   cells   led   to   increased  
expression  of  cyclin  D1  and  Bcl-­XL,   two  well  characterised  STAT3-­dependent  gene  
products  (Fig  3.3C).  To  confirm  that  the  induction  of  cyclin  D1  and  Bcl-­xL  was  STAT3-­
dependent,   E6   expressing   cells   were   treated   with   cryptotanshinone   and   S3I-­201.  
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Treatment  with  either  inhibitor  reduced  STAT3  phosphorylation  at  both  tyrosine  and  
serine  residues  and  also  reduced  cyclin  D1  and  Bcl-­xL  expression   to  control   levels  
(Fig   3.3C).   To   understand   if   this   was   at   the   level   of   gene   transcription,   qRT-­PCR  
analysis   was   performed.   The   data   showed   E6-­dependent   increases   in   cyclin  
D1(ccnd1)  and  Bcl-­XL  (bcl2l1)  mRNA  transcripts,  and  these  increases  were  sensitive  
to  treatment  with  STAT3  inhibitors  (ccnd1  plus  crypto  p<0.01  and  bcl2l1  plus  crypto  
p<0.05)  (Fig  3.3D  and  E).  Additional  STAT3-­dependent  genes,  including  HIF1α  and  
Survivin  (birc5),  were  up-­regulated  by  E6  in  a  STAT3-­dependent  manner  (hif1α  plus  
crypto  p<0.05  and  birc5  plus  crypto  p<0.001)  (Fig  3.3F  and  G).  Taken  together,  these  
data  suggest  HPV  E6  increases  the  transcription  of  STAT3-­dependent  genes.     
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Figure   3.3.      HPV   E6   promotes   STAT3   activation   and   STAT3-­dependent   gene  
expression.   A)   Representative   luciferase   reporter   assays   from   C33A   cells   co-­
transfected  with  GFP  tagged  HPV18  oncoproteins  E5,  E6  or  E7  and  either  a  b-­casein  
promoter   reporter   plasmid   (left)   or   a   PomC   reporter   plasmid   (right),   which   contain  
STAT3  binding  sites,  and  promoter  activity  measured  using  a  dual-­luciferase  system.  
Data  are  presented  as  relative  to  the  GFP  transfected  control  cells.  Bars  represent  the  
means   ±   standard   deviation   from   at   least   three   independent   biological   repeats.  
*P<0.05,  NS  =  not  significant  (Student’s  t-­test).    B)  Representative  luciferase  reporter  
assay  from  C33A  cells  co-­transfected  with  GFP-­E6  and  a  b-­casein  promoter  reporter  
plasmid   treated   with   the   STAT3   inhibitors   cryptotanshinone   and   S3I-­201,   and   the  
STAT5   inhibitor   pimozide.  Promoter   activity  was  measured  using  a   dual-­luciferase  
system.  Data  are  presented  as  relative  to  the  GFP  transfected  control.  Bars  represent  
the  means  ±  standard  deviation   from  at   least   three   independent  biological   repeats.  
*P<0.05,  **P<0.01  (Student’s   t-­test).     C)  Representative  western  blot  of  C33A  cells  
transfected  with  GFP  or  GFP-­18E6,  untreated  or  treated  with  the  STAT3  inhibitors  as  
above  and  analysed  for  the  expression  of  the  STAT3  dependent  genes  cyclin  D1  and  
Bcl-­xL.   GAPDH   expression   was   used   as   a   loading   control.   Data   shown   are  
representative  of  at   least  three  biological  repeats.  D-­G)  C33A  cells  were  transiently  
transfected   with   GFP   or   GFP-­18E6   and   left   untreated   or   treated   with   the   STAT3  
inhibitors  as  above  and  RNA  was  extracted   for  qRT-­PCR  analysis  of   the   indicated  
STAT3   dependent   genes.   Samples   were   normalized   against   U6   mRNA   levels.  
Representative  data  are  relative  to  the  GFP  transfected  control.  Bars  are  the  means  
±   standard   deviation   from   at   least   three   biological   repeats.   *P<0.05,   **P<0.01,  
***P<0.001  (Student’s  t-­test).  
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3.2.3   STAT3   is   phosphorylated   in   cells   expressing   E6   mutants  
defective  for  E6AP  binding,  p53  degradation  and  PDZ  domain-­binding  
HPV  E6  proteins  lack  intrinsic  enzymatic  activities;;  therefore,  to  manipulate  the  host  
cell  environment,  high-­risk  E6  proteins  have  evolved   the  ability   to   interact  with  key  
cellular   partners   including   E6AP,   p53   and   a   number   of   PDZ-­domain   containing  
proteins   to  modulate   cellular   functions   (154,158,169).   To   test   if   these  well-­studied  
partners  of  E6  are  required   for  E6-­dependent  STAT3  phosphorylation,   the   levels  of  
STAT3  phosphorylation  were  measured  in  cells  transfected  with  wild  type  and  mutant  
HPV18  E6  proteins  deficient  in  their  ability  to  bind  p53,  E6AP  or  PDZ  domains.  Valine  
substitution  of  phenylalanine  at  amino  acid  position  four  (F4V)  generates  an  E6  protein  
incapable  of  destabilizing  p53  (379).  Whilst  deficient  for  inhibiting  p53  destabilization,  
the  E6  F4V  mutant  enhanced  STAT3  phosphorylation  to  levels  comparable  with  wild  
type  E6  (Fig  3.4A;;  compare   lanes  2  and  4).  Expression  of  an  E6  mutant  unable   to  
interact  with  E6AP  (L52A)  (380),  an  interaction  required  for  p53  degradation,  impaired  
p53   degradation   as   expected,   but   retained   the   ability   to   enhance   STAT3  
phosphorylation  (Fig  3.4A;;  lane  5).  Finally,  the  requirement  for  HPV  E6  interaction  with  
PDZ  proteins  in  E6  mediated  STAT3  phosphorylation  was  assessed  by  engineering  a  
HPV18  E6  ΔPDZ,  which  lacks  the  C-­terminal  four  amino  acid  PDZ-­binding  motif  and  
cannot  bind  to  PDZ  domains  (381).  When  expressed  in  C33A  cells,  this  mutant  protein  
induced  STAT3  phosphorylation  to  wild  type  E6  levels  (Fig  3.4A;;  compare  lanes  2  and  
3).  Additionally,  organotypic  raft  cultures  were  generated  from  NHK  harbouring  wild  
type  and  ΔPDZ  HPV18  genomes  (381).  STAT3  S727  phosphorylation  was  observed  
throughout   the   basal   and   suprabasal   layers   of   the   HPV18   wild   type   and   ΔPDZ  
containing   rafts   (Fig   3.4B),   together   suggesting   that   E6   promotes   STAT3  




Figure  3.4.  STAT3   is  phosphorylated   in  cells  expressing  E6  defective   for  p53  
degradation  and  PDZ  domain  binding.  A)  Representative  western  blot  of  C33A  cells  
transfected  with  GFP  or  GFP  tagged  HPV18  E6  wild  type,  E6  DPDZ,  E6  F4V  or  L52A  
and  analyzed  using  antibodies  detecting  phosphorylated  and  total  STAT3  and  p53.  
GAPDH  expression  was  used  as  a  loading  control  and  GFP  confirmed  expression  of  
the   E6   proteins.   Data   presented   are   representative   of   at   least   three   independent  
experiments.    B)  Organotypic  raft  sections  were  stained  with  an  antibody  specifically  
detecting  STAT3  pS727  (green)  and  counterstained  with  DAPI  to  highlight  the  nuclei  
(blue  –  in  merged  panels).  Images  were  acquired  with  identical  exposure  times.  The  





3.2.4   Janus   kinases   (JAK)   are   responsible   for   STAT3   Y705  
phosphorylation  in  HPV18  containing  keratinocytes  
Janus   family   receptor-­associated   tyrosine   kinases   are   the   most   common   kinases  
responsible  for  mediating  STAT3  Y705  phosphorylation,  which  is  deemed  necessary  
for  STAT3  activation  (283).  Previously,  it  has  been  shown  that  the  non-­specific  JAK  
inhibitor  AG490  prevented  STAT3  tyrosine  phosphorylation  in  HPV16-­positive  cervical  
cancer   cells   (370).   To   discover   if   JAKs   played   a   role   in   HPV   mediated   STAT3  
phosphorylation  during  the  viral   life  cycle,  activation  of  JAK2  was  assessed  in  HPV  
containing   keratinocytes.   Levels   of   phosphorylated   JAK2   were   higher   in   HPV18-­
containing   keratinocytes   compared   to  NHK  controls,   and   this   phosphorylation  was  
retained  during  differentiation  (Fig  3.5A).  Next,  levels  of  JAK2  phosphorylation  were  
assessed   in   cells   overexpressing   GFP   HPV18   E6.  Western   blot   analysis   showed  
increased   JAK2   tyrosine   phosphorylation   in   C33A   cells   expressing   GFP-­18E6  
compared  to  GFP  control  (Fig  3.5B;;  compare  lanes  1  and  2).  Finally,  in  order  to  identify  
if  JAK  kinase  activity  was  required  for  HPV-­mediated  STAT3  phosphorylation,  HPV18-­
containing   keratinocytes   were   treated   with   the   clinically   available   JAK1/2   inhibitor  
Ruxolitinib  (382),  or  the  JAK2  inhibitor  Fedratinib  (383).  Treatment  with  either  inhibitor  
led   to   a  marked   reduction   in   STAT3  Y705  phosphorylation  without   affecting   S727  
phosphorylation  (Fig  3.5C;;  compare   lane  1   to  2  and  3).  These  results   indicate   that  
JAK2  is  the  major  mediator  of  the  STAT3  Y705  phosphorylation  observed  in  HPV18-­




Figure  3.5.    JAK2  is  responsible  for  tyrosine  phosphorylation  of  STAT3  in  HPV18  
containing   keratinocytes.   A)   Representative   western   blot   of   normal   human  
keratinocytes  (NHK)  and  HPV18  containing  keratinocytes  subjected  to  high  calcium  
differentiation  and  analysed  for  phosphorylated  and  total  JAK2.  GAPDH  serves  as  a  
loading  control.  B)  Representative  western  blot  of  C33A  cells  transfected  with  GFP  or  
GFP-­18E6  analysed  for  phosphorylated  and  total  JAK2.  GAPDH  expression  was  used  
as   a   loading   control   and   GFP   confirmed   expression   of   the   E6   proteins.   C)  
Representative  western   blot   of  HPV18   containing   keratinocytes   incubated  with   the  
JAK1/2   inhibitor   Ruxolitinib   or   JAK2   inhibitor   Fedratinib   analysed   with   antibodies  
detecting  phosphorylated  and  total  STAT3.  GAPDH  served  as  a  loading  control.  Data  
shown  are  representative  of  at  least  three  independent  biological  repeats.    
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3.2.5   Functionally   redundant   MAPK   proteins   mediate   STAT3   S727  
phosphorylation  in  HPV18-­containing  keratinocytes  
In  addition  to  the  well-­studied  tyrosine  phosphorylation  of  STAT3,  the  protein  can  also  
be  phosphorylated  at  a  serine  residue  in  its  transactivation  domain.  The  precise  role  
of   this   additional   phosphorylation   event   is   contentious;;   however,   it   has   been  
postulated  to  be  required  for  the  maximal  transcriptional  activity  of  STAT3.  A  number  
of  candidate  STAT3  S727  kinases  have  emerged  including;;  CDK5  (293),  mTOR  (292)  
and  several  PKC  isoforms  (290,291).  However,  the  strongest  evidence  indicates  that  
MAPK  members  mediate  the  serine  phosphorylation  of  STAT3,  since  it  is  embedded  
within   a   strong   MAPK   consensus   sequence   (725PMSP728)   (191).   To   identify   the  
kinase(s)  responsible  for  STAT3  serine  phosphorylation,  the  activation  status  of  each  
of  the  canonical  MAPK  members  was  first  assessed  in  differentiating  keratinocytes.  In  
these   studies,   levels   of   total   ERK1/2   were   increased   in   HPV18-­containing  
keratinocytes  compared  to  NHK  controls  (Fig  3.6A;;  compare  lanes  1–3  and  4–6).  As  
expected,  both  basal  and  differentiation-­induced  ERK1/2  phosphorylation  was  greater  
in  HPV  positive  cells  (Fig  3.6;;  compare  lanes  1  and  4,  and  lanes  3  and  6).  Whereas  
total  p38  protein  expression  did  not  alter  in  the  presence  of  HPV18,  the  levels  of  p38  
phosphorylation   were   greater   in   both   undifferentiated   and   differentiated   HPV18-­
containing  keratinocytes  (Fig  3.6A;;  compare  lanes  1  and  4,  3  and  6).  In  contrast  with  
ERK1/2   and  p38,   less   is   known  of   JNK1/2   regulation   by  HPV18;;   however,   studies  
demonstrate  that  JNK1/2  signalling  can  prevent  keratinocyte  differentiation  (384).  In  
keeping   with   this   role,   levels   of   JNK1/2   phosphorylation   were   highest   in  
undifferentiated   NHKs,and   decreased   rapidly   upon   differentiation   in   high   calcium  
media  (Fig  3.6A;;  compare   lanes  1  and  3).  JNK1/2  phosphorylation  also  declined   in  
differentiating  HPV18  positive  keratinocytes,  but  overall  levels  were  noticeably  higher  
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than   in   NHK   (compare   lanes   1   and   4,   lanes   3   and   6).   Together,   these   data  
demonstrate   the  presence  of  active  MAPK  members   in  HPV18  genome-­containing  
cells.  To  confirm  that  MAPK  activation  was  dependent  on  the  actions  of  E6,  transient  
transfection   experiments   were   performed,   and   these   demonstrated   that   the  
phosphorylation  of  all  three  MAPK  members  was  increased  in  C33A  cells  expressing  
GFP-­18E6  compared  to  a  GFP  control  (Fig  3.6B).     
To  test  the  roles  of  endogenous  MAPK  in  the  phosphorylation  of  STAT3,  the  levels  of  
STAT3   S727   phosphorylation   in   undifferentiated   HPV18-­containing   cells   was  
assessed  after   treatment  with   the  p38   inhibitor  VX-­702   (385),   the  MEK1/2   inhibitor  
UO126  (386)  and  the  JNK1/2  inhibitor  JNK-­IN-­8  (387),  alone  or  in  combinations  (Fig  
3.6C  and  D).  The  STAT3   inhibitor  cryptotanshinone  served  as  a  positive  control   in  
these   experiments   and   the   Mitogen   and   Stress   activated   protein   Kinase   (MSK)  
inhibitor  SB-­747651  acted  as  a  negative  control  (388).  As  shown  in  Fig  6C,  STAT3  
S727   and   Y705   phosphorylation   were   significantly   (p<0.001)   impaired   by  
cryptotanshinone   (lane  2)  but  unaffected  by   the  MSK   inhibitor  SB-­747651   (lane  3).  
STAT3  Y705  phosphorylation  remained  intact  in  cells  treated  with  the  MAPK  inhibitors,  
indicating  that  tyrosine  phosphorylation  of  STAT3  is  not  dependent  on  active  MAPK  in  
keratinocytes,   in   line   with   our   previous   data.   In   contrast,   whilst   STAT3   S727  
phosphorylation  was   largely  unaffected   in  cells   treated  with  VX-­702  (p38   inhibitor),  
JNK-­IN-­8,   and   only   partially   suppressed   by   the  MEK1/2   inhibitor   UO126   (lanes   5  
(p<0.05)  and  7  (p<0.01)),  the  combination  of  UO126,  VX-­702  and  JNK-­IN-­8,  blocking  
all  three  MAPK  members,  was  required  to  significantly  (p<0.001)  reduce  STAT3  S727  
phosphorylation  (lane  8)  (Fig  3.6D).  Western  blot  analysis  of  the  phosphorylated  forms  
of  the  MAPK  substrates  MAPKAP-­K2  (p38),  MSK  (ERK1/2)  and  c-­Jun  (JNK1/2)  were  
used  to  demonstrate  the  efficacy  of  inhibitor  treatment.  Together,  these  data  indicate  
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that   several   MAPK   family   members   can   phosphorylate   STAT3   S727   in   HPV18-­
positive  keratinocytes.     
  
  
Figure  3.6.    MAP  kinases  are  responsible  for  serine  phosphorylation  of  STAT3  
in   HPV18   containing   keratinocytes.   A)   Representative   western   blot   of   normal  
human  keratinocytes   (NHK)  and  HPV18  containing  keratinocytes  subjected   to  high  
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calcium  differentiation   and  analysed   for   total   and  phosphorylated   forms  of  ERK1/2  
(Thr202/Tyr204),  p38  (Thr180/Tyr182)  and  JNK  (Thr183/Tyr185).  GAPDH  served  as  
a   loading   control.   Data   shown   are   representative   of   at   least   three   independent  
biological  repeats.  B)  Representative  western  blot  of  C33A  cells  transfected  with  GFP  
or  GFP  tagged  HPV18  E6  analysed  for  the  total  and  phosphorylated  forms  of  ERK1/2  
(Thr202/Tyr204),  p38  (Thr180/Tyr182)  and  JNK  (Thr183/Tyr185).  GAPDH  served  as  
a  loading  control.  C)  Representative  western  blots  of  HPV18  containing  keratinocytes  
treated  with  specific  inhibitors  of  STAT3  (Crypto),  MSK1  (SB-­747651A;;  SB),  p38  (VX-­
745;;  VX)),   JNK   (JNK-­IN-­8),  Mek1/2  (UO126)  or   in  combination  as  described   in   the  
methods  and  materials  and  examined  with  antibodies  specific  for  phosphorylated  and  
total  STAT3.  The  phosphorylation  status  of  substrate  proteins  pMSK1  (T581),  p-­cJun  
(S63),  pMAPKAPK2  (T334),  and  ERK1/2  (T202/Y204)  demonstrated  inhibitor  efficacy  
and  specificity.  D)  Quantification  of  the  protein  band  intensities  of  (C)  standardised  to  
GAPDH   and   shown   relative   to   the   DMSO   control.   Bars   represent   the   means   ±  
standard   deviation   from   at   least   three   independent   biological   repeats.   *P<0.05,  
**P<0.01,  ***P<0.001  (Student’s  t-­test).  
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3.2.6   Active   STAT3   is   required   for   viral   gene   expression   in  
undifferentiated  primary  keratinocytes  
The  data  thus  far  suggests  that  STAT3  is  activated  in  HPV18-­containing  keratinocytes;;  
it  was  then  important  to  investigate  if  STAT3  was  necessary  for  the  virus  life  cycle.  For  
this,  STAT3  was  depleted  from  HPV18-­containing  keratinocytes  using  a  panel  of  four  
commercially-­validated   siRNAs.   Each   siRNA   produced   a   reproducible   depletion   of  
STAT3  by  an  average  of  38%  compared  to  a  scrambled  control  (Fig  3.7A).  Despite  
the  relatively  modest  depletion  of  STAT3,  expression  of  the  HPV18  E6  and  E7  proteins  
was  significantly  reduced  compared  to  the  scrambled  control  (Fig  3.7A).  To  assess  if  
the  inhibition  of  HPV18  oncoprotein  expression  occurred  at  the  transcriptional  level,  
HPV18  containing  keratinocytes  were  transfected  with  a  pool  of  STAT3  siRNA,  and  
mRNA  expression  was  assessed  by  qRT-­PCR  for   the   levels  of  STAT3,  E6  and  E7  
transcripts.  STAT3  depletion  (p<0.05)  caused  a  significant  decrease  in  early  oncogene  
expression  (E6  p<0.05,  E7  p<0.05),   indicating   that  STAT3  has  a  role   in  HPV  gene  
expression  in  undifferentiated  cells  (Fig  3.7B).       
  
In  combination  with  our  knock  down  strategy,  small  molecule  inhibitors  were  used  to  
specifically  block  STAT3  phosphorylation  and  activation.  HPV  protein  expression   in  
undifferentiated   HPV18-­containing   keratinocytes   treated   with   increasing  
concentrations  of  the  STAT3  inhibitor  cryptotanshinone  was  then  analysed  by  western  
blot.  As  shown  in  Fig  3.7C,  inhibitor  treatment  reduced  STAT3  phosphorylation  at  both  
sites  in  a  dose-­dependent  manner,  whilst  having  no  impact  upon  keratinocyte  viability  
during   the   experiment   (Fig   3.7D).  Concentrations   of   cryptotanshinone   that   blocked  
STAT3  phosphorylation  also  decreased  HPV  E6  and  E7  protein  expression  (Fig  3.7C)  
and  transcript  levels  (p<0.05)  (Fig  3.7E).  
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Next,  the  importance  of  the  individual  phosphorylation  sites  was  investigated,  as  there  
is  debate  about  the  role  of  serine  phosphorylated  STAT3  (280,286).  For  this,  dominant  
negative  forms  of  STAT3  were  used  in  which  Y705  was  replaced  with  a  phenylalanine  
or   S727   substituted   with   an   alanine,   generating   mutants   with   a   single   un-­
phosphorylatable   site   (389,390).   The   STAT3   mutants   were   expressed   in   HPV18-­
containing  keratinocytes  and  the  effect  of  STAT3  phosphorylation  was  assessed  by  
western   blot.   Importantly,   expression   of   the   Y705F   mutant   abolished   tyrosine  
phosphorylation   without   affecting   serine   phosphorylation;;   similarly,   expression   of  
S727A   abolished   serine   phosphorylation  without   affecting   tyrosine   phosphorylation  
(Fig  3.7F  compare  lanes  3  and  4).  Notably,  expression  of  either  of  the  phosphorylation  
site  mutants   led   to  a  substantial  reduction   in  HPV18  E6  and  E7  protein  expression  
(Fig  3.7F).  Taken  together,  these  data  demonstrate  that  dual  STAT3  phosphorylation  
is  essential  for  HPV  oncogene  expression  in  undifferentiated  keratinocytes.     
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Figure   3.7.   STAT3   is   required   for   viral   gene   expression   in   undifferentiated  
keratinocytes.   A)   Left:   Representative   western   blot   of   HPV18   containing  
keratinocytes   transfected  with  a  panel  of  4  STAT3  specific  siRNA  and  a  scrambled  
control  and  analysed  for  total  STAT3  antibody  and  HPV18  E6  and  E7.  GAPDH  served  
as   loading   control.   Right:   Quantification   of   the   STAT3   protein   band   intensities  
standardised   to  GAPDH   levels.   Data   are   expressed   as   fold   reduced   compared   to  
scramble  siRNA  treated  cells.  Bars  represent   the  means  ±  standard  deviation  of  at  
least  three  biological  repeats.  **p  <0.01  (Student’s  t-­test).    B)  RNA  was  extracted  from  
HPV18  containing  keratinocytes  after  transfection  with  a  pool  of  four  STAT3  specific  
siRNA  and  qRT-­PCR  analysis  was  performed   for  expression  of   the  stat3  and  HPV  
early   genes.   Samples   were   normalized   against   U6   mRNA   levels   and   data   are  
presented   relative   to   the   scrambled   control.   Bars   represent   means   ±   standard  
deviation   of   at   least   three   biological   repeats.   *P<0.05   (Student’s   t-­test).   C)  
Representative   western   blot   from   HPV18   containing   keratinocytes   treated   with  
increasing   doses   of   the   STAT3   inhibitor   cryptotanshinone   and   analysed   with  
antibodies   specific   for   phosphorylated   and   total   STAT3,   and   HPV18   E6   and   E7.  
GAPDH  served  as  a  loading  control.  Data  are  representative  of  at  least  three  biological  
repeats.  D)  MTT  assay  was  performed  in  HPV18  containing  keratinocytes  treated  with  
increasing  doses  of  the  STAT3  inhibitor  cryptotanshinone.  E)  RNA  was  extracted  from  
HPV18  containing  keratinocytes  treated  with  10  µM  cryptotanshinone  and  qRT-­PCR  
analysis  performed  for   levels  of  HPV  E6  and  E7  mRNA.  Samples  were  normalized  
against   the   U6   mRNA   levels   and   expressed   relative   to   the   DMSO   control.   Bars  
represent  means  ±  standard  deviation  of  at   least   three  biological   repeats.   *P<0.05  
(Student’s   t-­test).   F)   Representative   western   blot   from   HPV18   containing  
keratinocytes   transduced   with   a   lentivirus   encoding   a   dominant   negative   Y705F  
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phospho-­site   mutant   or   transiently   transfected   with   a   dominant   negative   STAT3  
S727A  mutant  and  analysed  for  phosphorylated  and  total  STAT3  and  HPV18  E6  and  
E7.   An   antibody   detecting   the   FLAG   epitope   confirmed   expression   of   the   Y705F  
STAT3   mutant   and   GAPDH   served   as   a   loading   control.   Data   shown   are  
representative  of  at  least  three  biological  repeats.    
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3.2.7  Suppression  of  STAT3  impairs  cell  cycle  progression  and  results  
in   loss   of   HPV18   genome   maintenance   in   undifferentiated  
keratinocytes  
As  STAT3  is  an  important  mediator  of  cell  proliferation,  the  impact  of  STAT3  inhibition  
on   the   proliferation   of   HPV   containing   keratinocytes   was   assessed.   Western   blot  
analyses  were  performed  to  determine  the  expression  of  the  STAT3-­dependent  gene  
product   and   key   cell   cycle   regulator   cyclin   D1,   in   undifferentiated   HPV-­positive  
keratinocytes   after   24   hours   of   cryptotanshinone   treatment.   Treatment   with  
cryptotanshinone  decreased  the  expression  of  cyclin  D1  in  a  dose-­dependent  manner  
(Figure  3.8A).  Lower  levels  of  cyclin  D1  protein  expression  correlated  with  significantly  
(p<0.01)  lower  levels  of  cyclin  D1  mRNA  in  these  cells  as  confirmed  by  qRT-­PCR  (Fig  
3.8B).  In  addition  to  our  inhibitor  data,  depletion  of  total  STAT3  protein  by  siRNA  (Fig  
3.8C)  or  expression  of  dominant  negative  forms  of  STAT3  (Fig  3.8D)  also  resulted  in  
reduced   cyclin   D1   expression   in   HPV   containing   keratinocytes.   STAT3   also  
contributes  to  cell  cycle  progression  through  regulation  of  the  cyclin  dependent  kinase  
(CDK)   inhibitor   p21WAF1/CIP1.   Inhibition   of   STAT3   activity,   or   loss   of   STAT3   protein  
expression,  led  to  an  up-­regulation  of  p21WAF1/CIP1  expression  at  both  the  protein  and  
transcript  level  (Fig  3.8A–D).       
As  cell  cycle  progression  depends  on  the  temporal  expression  of  cyclins,  the  effect  of  
STAT3  inhibition  or  loss  of  STAT3  expression  on  the  cell  cycle  was  analysed  by  flow  
cytometry.  When  HPV18-­containing  keratinocytes  were  treated  with  cryptotanshione,  
there  was  an  accompanying  increase  of  cells  in  S  phase  (p<0.05),  with  a  decrease  of  
cells   in   the   G2/M   phases   (p<0.001)   (Fig   3.8E).   This   is   in   contrast   to   normal  
keratinocytes,  in  which  cryptotanshinone  treatment  had  no  significant  impact  on  the  
cell  cycle  profile  (Fig  3.8F).  Similar  results  were  achieved  after  depletion  of  STAT3  by  
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siRNA  (p<0.001)  (Fig  8G),  together  suggesting  that  STAT3  is  essential  for  cell  cycle  
progression  and  the  proliferative  ability  of  HPV  containing  keratinocytes.     
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Figure   3.8.      Suppression   of   STAT3   impairs   cell   cycle   progression   and   HPV  
genome   maintenance   in   undifferentiated   keratinocytes.   A)   Representative  
western  blot   from  HPV18-­containing  keratinocytes   treated  with   increasing  doses  of  
the  STAT3  inhibitor  cryptotanshinone  and  analysed  for  cyclin  D1  and  p21  expression.  
GAPDH  served  as   loading   control.  B)  RNA  was  extracted   from  HPV18   containing  
keratinocytes  incubated  with  10  µM  cryptotanshinone  and  analysed  by  qRT-­PCR  for  
levels  of  ccnd1  and  p21  mRNA.  Samples  were  normalised  against  U6  mRNA  levels  
and   presented   relative   to   the   DMSO   control.   Bars   represent   means   ±   standard  
deviation   of   at   least   three   biological   repeats.   **P<0.01   (Student’s   t-­test).   C)  
Representative  western   blot   of  HPV18   -­containing   keratinocytes   transfected  with   a  
panel  of  4  STAT3  specific  siRNA  and  a  scrambled  control  and  analysed  by  western  
blotting  using  antibodies  specific   for  cyclin  D1  and  p21.  GAPDH  served  as   loading  
control.   D)   Representative   western   blot   from   HPV18   containing   keratinocytes  
transduced  with  a  lentivirus  encoding  a  dominant  negative  Y705F  phospho-­site  mutant  
or   transiently   transfected   with   a   dominant   negative   STAT3   S727A   mutant   and  
analysed  by  blotting  with  antibodies  specific  for  cyclin  D1  and  p21.  GAPDH  served  as  
loading   control.   Data   are   representative   of   at   least   three   biological   independent  
repeats.  Representative  flow  cytometric  analysis  of  the  cell  cycle  in  HPV18  containing  
keratinocytes   treated   with   10   µM   cryptotanshione   (E),   NHKs   treated   with   10   µM  
cryptotanshinone   (F)   or   a   pool   of   four   STAT3   specific   siRNAs   (G).   All   data   are  
expressed  as  percentage  of  cells  at  each  stage  of  the  cell  cycle.  Bars  represent  means  
±   standard   deviation   of   at   least   three   biological   repeats.   *P<0.05,   ***P<0.001  




3.2.8   STAT3   is   necessary   for   delayed   differentiation   and   increased  
keratinocyte  proliferation  in  stratified  epithelia  
Given   that   levels   of   STAT3   phosphorylation   were   maintained   upon   keratinocyte  
differentiation,   STAT3   may   also   be   important   during   the   differentiation-­dependent  
stages  of  the  HPV18  life  cycle.  HPV18-­containing  keratinocytes  were  co-­cultured  for  
48   hours   in   media   containing   high   calcium   to   induce   differentiation   and  
cryptotanshinone   to   block   STAT3   activation.   Phosphorylation   of   STAT3   and   the  
expression  of  HPV  E6  and  E7  were  reduced  but  maintained  upon  differentiation   in  
control   cells;;   however,   they   were   suppressed   by   cryptotanshinone   treatment   (Fig  
3.9A;;  compare  lanes  2  and  3).  High  expression  levels  of  cyclin  proteins  are  required  
for  HPV-­containing  cells  to  remain  active  in  the  cell  cycle  upon  differentiation  to  allow  
for  virus  genome  amplification.  In  accordance  with  this,  upon  differentiation  high  levels  
of  cyclin  D1  were  maintained,  and  expression  of  the  CDK  inhibitor  p21WAF1/CIP1  was  
not  elevated  (Fig  3.9A;;  compare  lanes  1  and  2).  STAT3  inhibition  led  to  a  reduction  in  
cyclin   D1   levels   in   differentiated   cells   (Fig   3.9A;;   compare   lanes   2   and   3),   and   an  
increase  in  p21WAF1/CIP1  expression  (Fig  3.9A;;  compare  lanes  2  and  3).    
The  switch  between  keratinocyte  proliferation  and  differentiation   is   tightly  controlled  
and   STAT3   has   been   identified   as   a   regulator   of   this   process(391).   As   STAT3  
inhibition   reduced   the   proliferative   ability   of   HPV18-­containing   keratinocytes,   the  
impact  of  STAT3  inhibition  on  keratinocyte  differentiation  was  analysed.  In  untreated  
HPV18-­containing   keratinocytes,   levels   of   the   differentiation-­specific   proteins  
involucrin  and  filaggrin  did  not  increase  significantly  upon  incubation  in  high  calcium  
media   (Fig   3.9A;;   compare   lanes   1   and   2),   consistent   with   the   ability   of   HPV   to  
suppress  keratinocyte  differentiation.  In  contrast,  cells  treated  with  cryptotanshinone  
displayed  enhanced  expression  of  these  differentiation-­dependent  proteins  (Fig  3.9A;;  
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compare   lanes   2   and   3).   These   experiments   indicate   that   STAT3   regulates  
keratinocyte   differentiation   and   cell   proliferation   in   differentiating   HPV-­positive  
keratinocytes.    
The  monolayer  differentiation  assay  suggested  that  the  ability  of  HPV  to  promote  cell  
cycle   re-­entry   and   delay   differentiation   was   dependent   on   active   STAT3.   To  
understand   this   in   the   context   of   the   full   HPV   life   cycle,   we   transduced   HPV18-­
containing  keratinocytes  with  a   lentivirus  expressing   the  dominant  negative  STAT3  
Y705F   or   an   empty   vector   control   (pFugW).   The   Y705F  mutant   was   utilised   as   it  
appeared  marginally  more  effective  at  impairing  HPV  gene  expression  compared  to  
the   S727A  mutant   (Fig   3.7D   and   7E).   After   transduction,   cells   were   seeded   onto  
collagen   plugs   and   grown   as   organotypic   raft   cultures,   and   sections   stained   with  
haematoxylin  and  eosin  (Fig  3.9B).  In  comparison  to  NHK  epithelium,  the  presence  of  
HPV18  genomes  was  associated  with  a   thickening  of   the  supra  and  parabasal  cell  
layers  as  previously  show  (381).    Over-­expression  of  the  dominant  negative  STAT3  
had  no  overall  effect  on  raft  morphology  of  NHK  or  HPV  containing  keratinocytes  (Fig  
3.9B);;  however,  the  thickness  of  the  HPV  containing  keratinocytes  was  consistently  
and  drastically  reduced,  with  an  appearance  more  closely  resembling  an  NHK  raft.  
Viral  amplification  occurs  in  suprabasal  cell  that  have  an  elongated  G2  phase  of  the  
cell   cycle.   In  G2,  cyclin  B  accumulates   in   the  cytoplasm;;   therefore,  cells   that  have  
cytoplasmic  cyclin  B  are  likely  to  be  cells  where  viral  genome  amplification  is  occurring  
(392).  The  raft  cultures  were  therefore  stained  for  the  expression  of  cyclin  B;;  in  NHK  
rafts,  cyclin  B1  was  only  observed  in  the  basal  layers  of  the  raft  and  this  was  unaffected  
by  transduction  with  the  Y705F  STAT3  mutant  (Fig  3.9C).  In  contrast,  we  observed  a  
significant  (p<0.001)  decrease  in  the  population  of  cyclin  B1  positive  suprabasal  cells  
following   staining   of   the   Y705F   transduced   HPV18   rafts,   relative   to   empty   vector  
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transduced   HPV18   rafts   (Fig   3.9E   and   H).   These   data   demonstrate   that   STAT3  
inhibition   leads   to  a   failure   of   cells   to  maintain   cell   cycle   activity   in   the   suprabasal  
layers  of  the  epithelia.  
To  investigate  the  impact  of  STAT3  inhibition  on  keratinocyte  differentiation,  rafts  were  
stained  for  expression  of  the  differentiation  marker  involucrin,  an  intermediate  stage  
differentiation   marker   found   in   the   suprabasal   layer   of   the   epithelia.   In   control  
transduced  HPV18   rafts,   involucrin  expression   is  confined   to   the  upper  suprabasal  
layers  (Fig  3.9F).  In  contrast,  abundant  involucrin  staining  was  noted  throughout  the  
spinuous   layers   of   the   epithelium   in   rafts   transduced   with   the   dominant   negative  
Y705F   phosphorylation   mutant.   Finally,   the   effect   of   STAT3   activity   on   late   viral  
function   was   assessed.   Sections   were   also   stained   for   the   viral   protein   E1^E4,   a  
marker  of  productive  infection  (70,378).  E1^E4  staining  was  observed  in  the  mid  and  
upper   suprabasal   layers   of   HPV18   control   rafts   but   was   significantly   (p<0.001)  
reduced  in  rafts  expressing  STAT3  Y705F  (Fig  3.9G  and  H).  Taken  together,  these  
data   indicate   that   active   STAT3   is   not   required   for   the   formation   of   a   stratified  
epithelium  in  NHK  but  is  necessary  for  increased  suprabasal  cellular  proliferation  and  
cell   cycle   progression   in   cells   harbouring   HPV18   genomes.   STAT3   function   also  
contributes   to   the  delay   in  differentiation  and  expression  virus  proteins  observed   in  




Figure   3.9.      STAT3   is   necessary   for   delayed   differentiation   and   increased  
keratinocyte   proliferation   in   a   stratified   epithelium   containing   HPV.   A)  
Representative  western  blots  of  phosphorylated  and  total  STAT3,  HPV18  E6  and  E7,  
cyclin   D1,   p21,   involucrin   and   filaggrin   in   differentiated   HPV18   containing  
keratinocytes   in   the   presence   or   absence   of   10   µM   cryptotanshione.   Data   shown  
represent  at  least  three  biological  repeats.  B)  Representative  organotypic  raft  cultures  
of   NHK   and  HPV18   containing   keratinocytes   transduced  with   empty   lentivirus   and  
lentivirus  expressing  a  dominant  negative  phosphorylation  null  Y705F  mutant  STAT3  
fixed  at  day  14  and  stained  with  haematoxylin  and  eosin  (H&E)  to  assess  morphology.  
C-­D)   Representative   organotypic   raft   cultures   of   NHKs   transduced   with   empty  
lentivirus  and  lentivirus  expressing  a  dominant  negative  phosphorylation  null  Y705F  
mutant  STAT3  fixed  at  day  14  and  stained  C)  cyclin  B1  and  D)  involucrin.  Nuclei  are  
visualised  with  DAPI  (blue)  and  white  dotted  lines  indicate  the  basal  cell  layer.  
  E-­G)  Representative   organotypic   raft   cultures   of   HPV18   containing   keratinocytes  
transduced   with   empty   lentivirus   and   lentivirus   expressing   a   dominant   negative  
phosphorylation   null   Y705F  mutant   STAT3   fixed   at   day   14.   Sections   from  HPV18  
containing   keratinocyte   rafts   were   stained  with   antibodies   against  E)   cyclin   B1,  F)  
involucrin  and  G)  E1^E4.  Nuclei  are  visualised  with  DAPI  (blue)  and  white  dotted  lines  
indicate  the  basal  cell  layer.  H)  The  number  of  cells  positive  for  cyclin  B1  and  E1^E4  
in   the   empty   vector   and  Y705F  STAT3   transduced  HPV18   containing   keratinocyte  
sections  was   counted   in   5   fields   of   vision   from   sections   of   three   independent   raft  
cultures  from  two  donor  lines.  Bars  represent  means  ±  standard  deviation.  ***P<0.001  





3.2.9  STAT3  expression  and  phosphorylation  positively  correlate  with  
disease  state  in  cervical  biopsies    
Having   demonstrated   that   STAT3   phosphorylation   was   increased   in   primary  
keratinocytes  containing  HPV18,  the  role  of  STAT3  phosphorylation  in  cervical  cancer  
initiation   and   progression   was   assessed.   Initially,   the   W12  in   vitro  cervical   cancer  
progression  model  system  was  utilised  (393).  The  W12  system  was  developed  from  a  
polyclonal  culture  of  cervical  squamous  cells  infected  with  HPV16,  derived  from  a  low-­
grade   squamous   intraepithelial   lesion   (LSIL).   At   early   passages,   these   cells  
recapitulate  an  LSIL  in  organotypic  raft  cultures.  However,  following  long-­term  culture  
these   cells   mirror   the   events   associated   with   cervical   cancer   progression,   with  
phenotypic  progression  to  high-­grade  intraepithelial  lesions  (HSIL)  and  squamous  cell  
carcinoma.  Organotypic  raft  cultures  were  generated  from  NHK  cells  and  a  W12  clone  
representing   a   HSIL   phenotype   and   stained   for   serine   phosphorylated   STAT3.   In  
contrast  to  the  NHKs,  high  levels  of  S727  phosphorylation  was  observed  in  the  nuclei  
of  cells  throughout  the  basal  and  suprabasal  layers  of  the  HSIL  raft  (Fig  3.10A).  These  
data   confirm   that   STAT3   S727   phosphorylation   is   greater   in   a   high-­grade   lesion  
compared   to   normal   keratinocytes.   They  also   confirm   that   increased   STAT3  S727  
phosphorylation  is  observed  in  the  context  of  a  high-­risk  HPV16  infection.     
Next,  cervical  liquid-­based  cytology  samples  from  a  cohort  of  HPV16  positive  patients  
representing  the  progression  of  disease  development  (CIN1-­CIN3)  and  HPV  negative  
normal  cervical  tissues  were  collected  from  the  Scottish  HPV  archive  and  examined  
for  phosphorylated  and  total  STAT3  by  western  blot.  In  normal  cervical  tissue,  STAT3  
expression  and  phosphorylation  was   low   (Fig  3.10B).  However,  STAT3  expression  
and  phosphorylation  at  both   tyrosine  and  serine   residues   increased   in   the  disease  
samples   and   this   correlated   with   cervical   disease   severity   (Fig   3.10C-­E).   Finally,  
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immunofluorescence   analysis   was   used   to   examine   the   levels   of   STAT3   S727  
phosphorylation  in  human  cervical  sections  classified  as  LSIL  (CIN1),  LSIL  with  foci  of  
HSIL  (CIN1/CIN2)  and  HSIL  (CIN3).  An  analysis  of  the  staining  pattern  showed  a  clear  
difference   between   the   three   groups   (Fig   3.10F),   with   abundant   STAT3   S727  
phosphorylation   in   the   high-­grade   neoplasia   compared   with   lower   grade   lesions.  
Together,  these  findings  demonstrate  that  STAT3  phosphorylation  is  increased  in  HPV  
positive  keratinocytes  including  those  of  a  natural  HPV  infection  and  these  correlate  
with  cervical  disease  progression.    
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Figure   3.10.      STAT3   expression   and   phosphorylation   is   increased   in   HPV-­
associated   cervical  diseases  A)  Representative   immunofluorescence   analysis  of  
sections   from  organotypic   raft   cultures  of  NHK  and  a  W12  cell   line  presenting  with  
HSIL  morphology  detecting  pS727  STAT3  levels  (green).  Nuclei  were  visualized  with  
DAPI  (blue)  and  the  white  dotted  line  indicates  the  basal  layer.  Images  were  acquired  
with  identical  exposure  times.    B)  Representative  western  blots  from  cytology  samples  
of   CIN   lesions   of   increasing   grade   analysed   with   antibodies   specific   for  
phosphorylated  (Y705  and  S727)  and  total  STAT3  levels.  GAPDH  served  as  a  loading  
control.  C-­E)  Scatter  dot  plot  of  densitometry  analysis  of  a  panel  of  cytology  samples.  
20  samples  from  each  clinical  grade  (neg,  CIN  I-­III)  were  analysed  by  western  blot  and  
densitometry   analysis  was  performed  using   ImageJ.  Phosphorylated  STAT3   levels  
were   first  normalised  against   total  STAT3   levels  before  normalising  against  protein  
levels   using  GAPDH   as   a   loading   control.  F)  Representative   immunofluorescence  
analysis   of   tissue   sections   from  cervical   lesions   of   increasing  CIN  grade.  Sections  
were  stained  for  pS727  STAT3  levels  (green)  and  nuclei  were  visualized  with  DAPI  
(blue).  Images  were  acquired  with  identical  exposure  times.  Scale  bar,  20  µm.  Bars  
represent  the  means  ±  standard  deviation  from  at  least  three  independent  biological  
repeats.  *P<0.05,  **P<0.01,  ***P<0.001  (Student’s  t-­test).  
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3.3  Discussion  
This  study  identifies  the  STAT3  transcription  factor  as  a  critical  regulator  of  the  HPV18  
life   cycle.   Using   calcium   differentiation   in   monolayer,   and   organotypic   raft   culture  
models   of   primary   human   keratinocytes   harbouring   HPV18   episomes,   this   study  
demonstrates   that   STAT3   is   necessary   for   cell   cycle   progression   and   HPV   gene  
expression  in  both  undifferentiated  cells  and  in  stratified  epithelium.  In  undifferentiated  
cells,  inhibition  of  STAT3  activity,  either  by  small  molecule  inhibitors  or  expression  of  
dominant   negative   STAT3   phosphorylation   mutants,   led   to   a   reduction   in   HPV  
oncogene   expression.   Using   ChIP-­Seq,   previous   studied   have   demonstrated   that  
STAT3  binds   to   the  viral  URR   in  HPV18-­positive  HeLa  cervical  cancer  cells   (370).  
Further  studied  will  be  required  to  identify  if  STAT3  controls  viral  transcription  directly  
by  binding  to  the  viral  URR,  or  indirectly  by  controlling  the  expression  of  host  factors  
such  as  cyclin  D1.  This  is  one  possible  mechanism  that  HPV  mediated  up-­regulation  
of   STAT3   activity   may   drive   viral   transcription   –   by   generating   a   cellular   milieu  
favourable   for   virus   transcription.   In   this   regard,   STAT3   is   a   driver   of   cell   cycle  
progression   and   keratinocyte   proliferation.   Our   results   show   that   HPV-­containing  
keratinocytes   express   cyclin   D1   and   this   is   largely   STAT3-­dependent   as   STAT3  
inhibitor  treatment,  or  depletion  by  siRNA,  resulted  in  a  loss  of  cyclin  D1  expression  
and  an  increase  in  expression  of  the  cell  cycle  arrest  protein  p21WAF1/CIP1.  Furthermore,  
these  changes  correlated  with  induction  of  S  phase  arrest  of  the  cell  cycle.  This  likely  
results  from  the  reduced  expression  of  cyclin  D1,  which  in  actively-­cycling  cells  must  
be  increased  in  expression  in  order  for  cells  to  transition  into  G2.  A  similar  S-­phase  
arrest   is   observed   in   Epstein   Barr   virus   infected   lymphoblastoid   cell   lines   (LCLs),  
where   STAT3   is   required   to   relax   the   intra-­S   phase   checkpoint   (394).   Intriguingly,  
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STAT3  inhibition  had  no  discernable  impact  on  the  cell  cycle  profile  of  normal  human  
keratinocytes,  indicating  that  STAT3  is  non-­essential  in  HPV  negative  cells.  
As  STAT3  inhibition  leads  to  an  S  phase  accumulation  in  the  cell  cycle  and  a  decrease  
in  cells  in  G2,  it  is  likely  that  STAT3  has  a  role  in  viral  replication  in  HPV18-­containing  
keratinocytes.  Viral  genome  amplification  occurs  in  the  G2  phase  of  the  cell  cycle  in  
the  suprabasal   layers  of  the  epithelia  (79);;   in   these  cells,  G2  phase   is   identified  by  
cytoplasmic  cyclin  B  expression.  As  cyclin  B  expression  is  decreased  in  HPV18  raft  
expressing  dominant  negative  STAT3  Y705F,  it  is  likely  that  these  cells  have  lost  the  
ability  to  support  viral  genome  amplification.  Additionally,  the  viral  protein  E1^E4  is  a  
mark  of  productive  infection;;  as  dominant  negative  STAT3  Y705F  leads  to  a  reduction  
in   E1^E4   expression,   viral   genome   amplification   is   likely   to   be   impaired.   Although  
these  data  collectively  suggest   that  viral   replication   is   likely   to  be  disrupted,   further  
work   will   assess   the   impact   of   STAT3   inhibition   on   viral   episome  maintenance   in  
undifferentiated   keratinocytes   and   on   viral   genome   amplification   in   differentiating  
keratinocytes.  Again,  it  should  also  be  assessed  whether  or  not  this  effect  is  direct  –  
due  to  binding  of  STAT3  to  the  viral  URR  –  or  indirect,  due  to  change  the  cellular  milieu  
to  favour  viral  replication.     
  
Our   studies   show   that   HPV   infection   leads   to   enhanced   STAT3   Y705   and   S727  
phosphorylation  that  are  maintained  at  high  levels  during  keratinocyte  differentiation.  
Interestingly,  all   three  HPV  oncoproteins  could   induce  STAT3  phosphorylation   to  a  
degree,  but  only  E6  was  sufficient  to  induce  the  dual  phosphorylation  and  activation  
of  STAT3.  This   is  consistent  with  previous  observations  showing   increased  STAT3  
Y705  phosphorylation  in  HPV-­positive  cancer  cell  lines  and  leading  to  increased  levels  
of  STAT3-­dependent  gene  products   {Shukla:2010kg,  Shukla:2013hs}.  A  number  of  
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cellular  pathways  converge  to  phosphorylate  and  activate  STAT3  {Johnson:2018gu}.  
The   role   of   serine   STAT3   phosphorylation   has   been   contentious;;   it   has   been  
demonstrated   to  be   important  for  maximal   transcriptional  activity   (286)    or  to   inhibit  
tyrosine  phosphorylated  STAT3  (191).  Using  dominant  negative  STAT3  mutants  that  
blocked  phosphorylation  at  the  specific  tyrosine  or  serine  residues,  the  results  clearly  
demonstrate  that  in  HPV  containing  keratinocytes,  mono-­phosphorylation  of  either  site  
is  insufficient  to  activate  the  STAT3-­dependent  genes  analysed  in  this  study.  The  data  
also  demonstrate  that  phosphorylation  of  both  sites  in  STAT3  is  required  for  viral  gene  
expression,  suggesting  that  dual  phosphorylated  STAT3  is  critical  during  the  HPV  life  
cycle.   Moreover,   our   work   does   not   support   previous   findings   that   S727  
phosphorylation  is  detrimental  to  Y705  phosphorylation.    
In  addition  to  analysing  the  requirement  for  both  STAT3  phosphorylation  sites  for  the  
HPV  life  cycle,  this  study  also  identified  the  kinases  involved  in  that  phosphorylation  
in  HPV18-­containing  keratinocytes.  Using  clinically  available  small  molecule  inhibitors,  
Y705  phosphorylation  was  demonstrated  to  be  critically  dependent  on  JAK2  activity  in  
HPV   containing   keratinocytes.   Whilst   JAK   kinases   are   the   best   characterised  
mediators   of   Y705   phosphorylation   in   other   cellular   systems,   to   the   best   of   our  
knowledge  no  study  has  shown  that  E6   increases   their  activity.  Since   they   function  
downstream  of  growth  factor  and  gp130  cytokine  receptor  pathways,  it  is  possible  that  
E6   up-­regulates   an   upstream   component   which   subsequently   activates   JAK2   to  
phosphorylate   STAT3   Y705.   In   this   regard,   E6   activates   the   EGF   receptor   and  
increases   IL-­6  and  oncostatin-­M  expression,  which  mediate   their  effects  via  gp130  
receptors  (164,395,396).     
  
The  mechanisms  that  mediate  S727  phosphorylation  are  less  clear  due  to  a  wider  field  
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of  potential  candidate  kinases.  As  a  first  step  we  focused  on  MAPK  proteins,  given  the  
presence  of  a  strong  MAPK  consensus  motif  adjacent  to  S727.  Phosphorylation  and  
activation  of  all  three  canonical  MAPK  proteins  (ERK1/2,  p38  and  JNK1/2)  was  found  
to   be  dysregulated   in  HPV  containing   keratinocytes   (397).  This   study   showed   that  
inhibition   of   all   three  MAPK  members   was   necessary   to   fully   impair   STAT3   S727  
phosphorylation,  suggesting  functional  redundancy  between  the  kinases.  To  begin  to  
deduce  the  mechanism  by  which  E6  up-­regulates  STAT3  phosphorylation,  we  initially  
focused   on   the   key   functions   of   E6,   which   are   p53   degradation   and   PDZ   domain  
binding.  Surprisingly,  whilst  E6AP-­mediated  p53  degradation  and  PDZ  domain  binding  
are  well-­characterised  attributes  of  high-­risk  E6  proteins,  neither  of   these   functions  
was   required   for   the   increase   in   STAT3   phosphorylation.   Further   studies   will   be  
needed   to   investigate  whether  STAT3  phosphorylation   and  activation   is   conserves  
amongst  HPV  E6  proteins,  or  whether  it  is  specific  for  the  high-­risk  types  and  which  
domains  in  E6  are  required  for  this  function.     
  
Together,   this   study   has   identified   that   the   transcription   factor   STAT3   is  
phosphorylated  on  both  Y705  and  S727  during  the  HPV  differentiation-­dependent  life  
cycle.   It  has  also  shown  that  HPV  E6  protein  mediates  the  dual  phosphorylation  of  
STAT3  via  JAK2  and  MAP  kinase  activation.  Finally,  STAT3  activation  is  essential  for  
viral   gene   expression   and   for   cell   cycle   progression   and   proliferation   in   HPV   raft  
culture.  Further  studies  will   identify  how  STAT3  is  activated  by  HPV  E6  (Chapter  4)  
and   the   role   of   STAT3   in   HPV   mediated   cervical   disease   and   cervical   cancer  
progression  (Chapter  5).  
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Chapter  4.  Mechanistic  investigation  of  STAT3  activation  in  
cervical  cancer  
4.1     Introduction  
Human  papillomaviruses  (HPV)  are  the   leading  etiological  cause  of  cervical  cancer  
and  a  number  of  other  cancers,  including  Head  and  Neck  cancer  and  other  anogenital  
cancers.    High  risk  HPVs  (hrHPV),  including  HPV16  and  18,  are  responsible  for  >99%  
of  cervical  cancers  and  there  is  currently  an  epidemic  of  HPV  positive  oropharyngeal  
carcinomas  (398,399).  HPV  encodes  three  oncoproteins,  E5,  E6  and  E7,  which  have  
previously   been   shown   to   modulate   signalling   pathways   related   to   cellular  
transformation,   including  EGFR   (164),  Wnt   (400,401)   and  Hippo   signalling   (402).  
The  E5  oncoprotein  has  been  shown  to  modulate  EGFR  signalling  (116,129)  and  
its  viroporin  activity  may  be  required  for  induction  of  mitogenic  signalling  (121).  HPV  
E6  induces  the  proteosomal  degradation  of  the  tumour  suppressor  p53  and  increases  
the   activity   of   telomerase,   leading   to   the   prevention   of   apoptosis   and   the  
immortalisation  of  infected  cells,  respectively  (158,167,380).  Additionally,  the  E7  
oncoprotein  activates  the  DNA  damage  response,  driving  viral  replication  and  genomic  
instability,  and  promotes  the  progression  of  cells  through  the  S  phase  of  the  cell  cycle  
(403,404).  
Signal  transducer  and  activator  of  transcription  (STAT)  3  is  a  transcription  factor  and  
an   important   regulator   of   proliferation,   differentiation   and   cell   survival(283,405).  
STAT3  activation  is  mediated  by  extracellular  stimuli  and  requires  the  phosphorylation  
of   tyrosine  705   (Y705)  and  serine  727   (S727),   resulting   in   its  nuclear   translocation  
(406).  A  number  of  cytokines  and  growth  factors  can  induce  STAT3  signalling.  The  
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cytokine   IL-­6   is   key  mediator   of   STAT3   activation   through   its   receptors   IL-­6R   and  
gp130  (407),  leading  to  a  signalling  cascade  resulting  in  STAT3  phosphorylation  and  
nuclear  translocation  (187).    
Importantly,  STAT3  has  been  shown  to  be  a  bona  fide  oncogene,  implicated  in  several  
cancers  (283).    
Most   oncogenic   viruses   activate   STAT3   to   drive   cellular   proliferation,   and  
tumourigenesis  (327,333,408,409).  A  common  mechanism  used  by  other  oncogenic  
viruses  to  activate  STAT3  is  to  increase  expression  of  the  pro-­inflammatory  cytokine  
IL-­6,  a  key  regulator  of  STAT3  activation  (410).  This  can  be  achieved  via  activation  of  
the  transcription  factor  NF-­κB.  In  the  canonical  NF-­κB  pathway,  a  signalling  cascade  
results  in  the  phosphorylation  of  IκBα,  a  negative  regulator  of  the  NF-­κB  pathway,  by  
IκB  kinases  (IKKs)  (411).  This  leads  to  the  proteosomal  degradation  of  IκBα  and  the  
nuclear  translocation  of  the  NFκB  p65  and  p50  sub-­units  (Fig  4.1).  
Kaposi’s  Sarcoma  associated  Herpesvirus  (KSHV)  down  regulates  IκBα  via  the  viral  
miRNA  miR-­K12-­1,  leading  to  enhanced  IL-­6  expression  and  STAT3  activation  [23].  
Both  Hepatitis  C  virus  (HCV)  core  protein  and  Human  Cytomegalovirus  (HCMV)  US28  
protein   induce   STAT3   phosphorylation   and   nuclear   translocation   in   an   autocrine  
manner  via  up  regulation  of  IL-­6    (327,329,330,412).  
Previous  studies  have  provided  conflicting  data  on  HPV  mediated  activation  of  NF-­κB;;  
HPV  E6  has  been  shown  to   induce  expression  of  NF-­κB  dependent  genes  and  the  
anti-­apoptotic  gene  cIAP2  (413,414),  whilst  another  study  showed  it  can  activate  NF-­
κB  under  hypoxic  conditions  (173).  
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Figure  4.1.  The  canonical  and  alternative  NF-­κB  signalling  patwhways.  A)  The  
activation  of  the  canonical  NF-­κB  pathway.  Diverse  stimuli  induce  the  activation  of  the  
IκB  kinase  (IKK)  complex  (1).  This  results  in  the  phosphorylation  and  activation  of  IκB  
proteins,  in  particular  IκBa  at  serine  32/62  (2).  This  induces  the  polyubiquitination  of  
IκBa   and   its   subsequent   degradation   by   the   proteasome   (3).   Following   IκBa  
degradation,   the  p65/p50  complex   is   released  and   translocations   to   the  nucleus   to  
drive  gene  transcription  (4).  This  pathway  is  inhibited  by  small  molecule  inhibitors  of  
the   IKK   proteins,   or   a   mutant   IκBa   which   cannot   be   phosphorylated   at   S32/26  
(S32/36A).   B)   The   activation   of   the   NF-­κB   alternative   pathway.   Activation   of   this  
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pathway  occurs  through  stimuli  distinct  to  that  of  the  canonical  pathway  and  results  in  
the  specific  activation  of  IKKa,  mostly  through  the  kinase  NF-­κB  inducing  kinase  (NIK)  
(a,   b).   IKKa   then   phosphorylates   NF-­κB2/p100   (c)   inducing   its   partial   proteolysis,  
converting  it  to  p52  (d).  This  allows  p52  to  preferentially  bind  to  the  NF-­κB  protein  RelB  
and  translocate  to  the  nucleus  to  drive  a  gene  transcription  profile  different  to  canonical  
NF-­κB  signalling.  Image  modified  from(415).     
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In  contrast,  others  have  demonstrated  that  HPV  E7  attenuates  NF-­κB  activity,  whilst  
the  impact  of  E6  on  NF-­κB  is  cell  type  dependent  {Vandermark:2012kf}.  Ultimately,  a  
definitive  role  for  the  NF-­κB  pathway  in  HPV  mediated  malignancies  and  in  the  HPV  
lifecycle  is  still  lacking.  
The  data   in   the  previous  chapter   identified  a  critical   role   for  STAT3   in   the  HPV  life  
cycle;;  however,  the  role  STAT3  plays  in  cervical  cancer  is  currently  poorly  understood.  
Additionally,   the   mechanism   of   STAT3   phosphorylation   utilised   by   HPV   E6   is  
unknown;;  therefore,  in  this  chapter,  the  mechanism  of  STAT3  activation  by  HPV  E6  in  
cervical  cancer  cells  is  investigated.  
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4.2  Results    
4.2.1  STAT3  protein  expression  and  phosphorylation  is  higher  in  HPV+  
cervical  cancer  cells  compared  with  HPV-­  cancer  cells.    
To  begin  to  decipher  the  mechanism  by  which  HPV  augments  STAT  phosphorylation,  
the  level  of  STAT3  phosphorylation  was  analysed  in  a  panel  of  six  cervical  cancer  cell  
lines.  These  included  two  HPV  negative  (HPV-­)  lines  (C33A  and  DoTc2  4510),  two  
HPV16   positive   (HPV16+;;   SiHa   and   CaSKi)   and   two   HPV18   positive   (HPV18+;;  
SW756  and  HeLa)   lines.  Both  HPV16+  and  HPV18+  cancer  cells  displayed  higher  
levels  of  STAT3  phosphorylation  at  both  (Y705  and  S727)  sites  compared  to  the  HPV-­  
cell   lines   (significant   in   CaSKi   and   HeLa,   p<0.05).   Additionally,   the   levels   of   total  
STAT3  were  also  increased  in  the  HPV+  cervical  cancer  cells  compared  with  HPV-­  
cervical  cancer  cells  (Fig  4.2A  and  B).  Together,  these  data  demonstrate  that  STAT3  
expression  and  phosphorylation  is  increased  in  HPV+  cervical  cancer  cells.     
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Figure   4.2.   STAT3   phosphorylation   is   higher   in   HPV+   verses   HPV-­   cervical  
cancer  cells.  A)  Representative  western  blot  of  from  six  cervical  cancer  cell  lines  –  
two   HPV-­   (C33A   and   Dotc2   4510),   two   HPV16+   (SiHa   and   CaSKi)   and   HPV18+  
(SW756  and  HeLa)  –  for  the  expression  of  phosphorylated  (Y705  and  S727)  and  total  
STAT3.  GAPDH  served  as  a  loading  control.  Data  are  representative  of  at  least  three  
biological  independent  repeats.  B)  Quantification  of  the  protein  band  intensities  in  A)  
standardised  to  GAPDH  levels.  Bars  represent  the  means  ±  standard  deviation  from  
at   least   three   independent   biological   repeats.   *P<0.05,   **P<0.01,   ***P<0.001  
(Student’s  t-­test).  
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4.2.2   A   factor   in   the   media   from   HPV+   cancer   cells   induces   STAT3  
phosphorylation  in  C33A  cells.    
STAT3   is   primarily   activated   by   a   number   of   growth   factors   and   cytokines  
{Johnson:2018gu}.   To   identify   if   HPV   stimulates   the   secretion   of   factors   that   can  
induce   STAT3   phosphorylation,   we   incubated   C33A   cells   (HPV-­)   with   conditioned  
media  from  HeLa  cells  (HPV18+)  (Fig  4.3A).  Incubation  with  the  conditioned  media  
induced  phosphorylation  of  STAT3  on  both  Y705  and  S727  residues  in  C33A  cells,  
reaching  a  peak  between  30  minutes  and  1  hour.  Similar  results  were  observed  when  
conditioned  media  from  CaSKi  cells  (HPV16+)  was  used  (Fig  4.3B).  Additionally,  the  
conditioned   media   from   either   HeLa   or   CaSKi   cells   caused   STAT3   nuclear  
translocation  in  C33A  cells  (Fig  4.3C  and  D).  These  data  indicate  that  a  secreted  factor  
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Figure  4.3.  A  secreted  factor  from  HPV+  cervical  cancer  cells  can  induce  STAT3  
phosphorylation   in   HPV-­   cervical   cancer   cells.   A-­B)   C33A   cells   were   serum  
starved  for  24  hours  and  conditioned  media  from  A)  HeLa  or  B)  CaSKi  cells  was  added  
for  the  indicated  time  points.  Represented  western  blot  shows  cell   lysates  analysed  
for  the  expression  of  phosphorylated  and  total  STAT3.  GAPDH  served  as  a  loading  
control.  Data  are  representative  of  at  least  three  biological  independent  repeats.  C-­D)  
C33A  cells  were  serum  starved  for  24  hours  and   incubated  with  conditioned  media  
from   C)   HeLa   or   D)   CaSKi   cells   for   2   hours.   Cells   were   analysed   by  
immunofluorescence  staining  for  total  STAT3  (green)  and  counterstained  with  DAPI  
to  highlight  the  nuclei  (blue  in  the  merged  panels).  Scale  bar,  20  µm.  
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4.2.3  IL-­6  secretion  is  increased  in  HPV+  cervical  cancer  cells  
To   identify   the   soluble   factor   responsible   for   inducing   STAT3   phosphorylation,   we  
focused  on  members  of   the   IL-­6   family  of  pro-­inflammatory  cytokines,  as   these  are  
well  studied  mediators  of  STAT3  activation  {Kitamura:2017cr}.  Firstly,  the  expression  
levels  of  key  members  of  the  family  were  analysed.  In  both  HeLa  and  CaSKi  cells,  IL6,  
IL10,  LIF   (Leukemia   inhibitory   factor)  and  OSM   (Oncostatin  M)  mRNA   levels  were  
significantly  higher  than  in  C33A  cells  (Fig  4.4A);;  however,  IL-­6  showed  the  greatest  
increase.  To  confirm  this  result,  we  looked  at  IL-­6  mRNA  expression  in  all  six  cervical  
cancer  cells.  In  both  HPV16+  and  HPV18+  cervical  cancer  cells,  a  significantly  higher  
level  of   IL-­6  mRNA  expression  was  observed  compared  with  HPV-­  cervical  cancer  
cells   (Fig   4.4B).   Importantly,   this   result   correlated   to   IL-­6   protein   expression  when  
analysed  by  western  blot  (Fig  4.4C).  Finally,  to  confirm  that  the  IL-­6  protein  detected  
was   capable   of   being   secreted,   an   IL-­6   specific   ELISA   was   performed.   IL-­6   was  
undetectable  in  the  culture  medium  of  HPV-­  cells;;  in  contrast  a  significant  quantity  of  
IL-­6  could  be  detected  the  culture  medium  of  both  HPV16+  and  HPV18+  cells.  These  
data   suggest   that   IL-­6   is   a   likely   candidate   for   the   secreted   factor   responsible   for  
activation  of  STAT3  in  HPV+  cervical  cancer  cells.  
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Figure  4.4.  Interleukin-­6  (IL-­6)  is  up  regulated  in  HPV+  cervical  cancer  cells.  A)  
The  expression  level  of  cytokines  from  the  IL-­6  family  were  analysed  in  HPV-­,  HPV16+  
and  HPV18+  cervical  cancer  cells  by  qRT-­PCR.  Samples  were  normalized  against  U6  
mRNA  levels.  Representative  data  are  presented  relative  to  the  HPV-­  cervical  cancer  
cells.  Bars  are  the  means  ±  standard  deviation  from  at  least  three  biological  repeats.  
*P<0.05,  **P<0.01,  ***P<0.001  (Student’s  t-­test).  B)  The  expression  of  IL-­6  from  six  
cervical  cancer  cell  lines  –  two  HPV-­  (C33A  and  Dotc2  4510),  two  HPV16+  (SiHa  and  
CaSKi)  and  HPV18+  (SW756  and  HeLa)  –  was  analysed  by  qRT-­PCR.  Samples  were  
normalized  against  U6  mRNA  levels.  Representative  data  are  presented  relative   to  
the  HPV-­  cervical  cancer  cells.  Bars  are  the  means  ±  standard  deviation  from  at  least  
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three   biological   repeats.   *P<0.05,   **P<0.01,   ***P<0.001   (Student’s   t-­test).   C)  
Representative  western  blot  of  from  six  cervical  cancer  cell  lines  –  two  HPV-­  (C33A  
and  Dotc2  4510),  two  HPV16+  (SiHa  and  CaSKi)  and  HPV18+  (SW756  and  HeLa)  –  
for  the  expression  of  IL-­6.  GAPDH  served  as  a  loading  control.  Data  are  representative  
of  at   least  three  biological   independent  repeats.  D)  ELISA  analysis  from  the  culture  
medium  from  six  cervical  cancer  cell  lines  –  two  HPV-­  (C33A  and  Dotc2  4510),  two  
HPV16+   (SiHa   and   CaSKi)   and   HPV18+   (SW756   and   HeLa)   –   for   secreted   IL-­6  
protein.  Error  bars  represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  three  
biological   repeats.   ND   =   not   determined   (below   the   detection   threshold).   *P<0.05,  
**P<0.01,  ***P<0.001  (Student’s  t-­test).  
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4.2.4   IL-­6   induces   STAT3   phosphorylation   and   activation   in   cervical  
cancer  cell  lines  
Next,  the  role  of  IL-­6  in  the  activation  of  STAT3  in  cervical  cell  lines  was  interrogated.  
HeLa,  CaSKi  and  C33A  cells  were  serum  starved  for  24  hours  and  then  treated  with  
increasing  doses  of  recombinant  IL-­6  protein  (Fig  4.5A,  D  and  G).  IL-­6  induced  robust  
STAT3   phosphorylation   at   both   Y705   and   S727   residues,   without   affecting   total  
STAT3  levels,  in  both  HPV+  and  HPV-­  cell  lines.  Additionally,  time  of  addition  studies  
showed  that  IL-­6  mediated  STAT3  phosphorylation  peaked  around  30  minutes  after  
IL-­6   addition   (Figure   4.5B,   E   and  H).   Furthermore,   IL-­6   treatment   induced   STAT3  
nuclear  translocation  in  all  three  cell  lines  (Fig  4.5C,  F  and  I).  Taken  together,  these  
data   indicate   that   IL-­6   is   able   to   induce   STAT3   phosphorylation   and   nuclear  
translocation  in  cervical  cancer  cells.  
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Figure   4.5.   Exogenous   IL-­6   induces   STAT3   phosphorylation   and   nuclear  
translocation   in   cervical   cancer   cells.  Representative  western   blot   of  HeLa   (A),  
CaSKi  (D)  and  C33A  (G)  cells  treated  with  increasing  doses  of  recombinant  human  
IL-­6.   Cell   lysates   were   analysed   for   phosphorylated   and   total   STAT3   expression.  
GAPDH  served  as  a  loading  control.  Data  are  representative  of  at  least  three  biological  
independent  repeats.  Representative  western  blot  of  HeLa  (B),  CaSKi  (E)  and  C33A  
(H)  cells  treated  with  20  ng/mL  recombinant  human  IL-­6  for  the  indicated  time  points.  
Cell  lysates  were  analysed  for  phosphorylated  and  total  STAT3  expression.  GAPDH  
served   as   a   loading   control.   Data   are   representative   of   at   least   three   biological  
independent  repeats.  HeLa  (C),  CaSKi  (F)  and  C33A  (I)  cells  treated  with  20  ng/mL  
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recombinant   human   IL-­6   for   30   mins   were   fixed   and   were   analysed   by  
immunofluorescence  staining  for  total  STAT3  (green)  and  counterstained  with  DAPI  
to   highlight   the   nuclei   (blue   in   the  merged  panels).  SF   indicates   cells   incubated   in  
serume  free  media  with  C33A  conditioned  media  added  as  a  control.  Scale  bar,  20  
µm.  
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4.2.5  STAT3  phosphorylation  requires  IL-­6/gp130  signalling  in  cervical  
cancer  cells  
IL-­6  signalling  is  initiated  by  an  interaction  between  IL-­6  and  the  IL-­6  receptor  (IL-­6R)  
and  the  glycoprotein  130  (gp130)  co-­receptor  (407).  In  order  to  confirm  that  IL-­6  was  
required   for  STAT3  phosphorylation   in  cervical  cancer  cells,  neutralizing  antibodies  
against  IL-­6  and  the  IL-­6  co-­receptor  gp130  were  utilised.  C33A  cells  were  incubated  
with   either   antibody   for   4   hours   before   being   treated  with   recombinant   IL-­6   for   30  
minutes.   As   shown   in   Figure   4.6A,   phosphorylation   of   both   sites   on   STAT3   was  
induced  by  recombinant  IL-­6.  Pre-­incubation  with  neutralizing  antibodies  against  either  
IL-­6  or  gp130  led  to  a  loss  of  Y705  and  S727  phosphorylated  STAT3  (Fig  4.6A).  To  
confirm   that   IL-­6   was   the   mediator   secreted   by   HPV+   cells   to   induce   STAT3  
phosphorylation,  we  pre-­incubated  C33A  cells  with  the  gp130  neutralising  antibodies  
before  treating  them  with  conditioned  media  from  HeLa  and  CaSKi  cells.  Separately,  
we  added  the  neutralising  IL-­6  antibody  with  the  conditioned  media  before  addition  to  
cells.  As  before,  conditioned  media  from  HPV+  cells  induced  STAT3  phosphorylation  
in  HPV-­  cells;;  however,  pre-­incubation  of  C33A  cells  gp130  neutralising  antibody,  or  
the  addition  of  the  conditioned  media  containing  the  neutralising  IL-­6  antibody,  blocked  
the  ability  of  HPV+  conditioned  media   to   induce  STAT3  phosphorylation  (Fig  4.6B)  
and  nuclear   translocation   (Fig   4.6C).   This   suggests   that   IL-­6   secretion   from  HPV+  
cervical   cancer   cells   is   able   to   induce   the   paracrine   activation   of   STAT3   in   HPV-­  
cervical  cancer  cells.     
  
Finally,  to  confirm  that  IL-­6/gp130  signalling  was  required  for  the  autocrine  activation  
of  STAT3  in  HPV+  cervical  cancer  cells,  HeLa  cells  were  pre-­incubated  with  IL-­6  and  
g130   neutralizing   antibodies.   Incubation   with   either   neutralising   antibody   led   to   a  
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reduction  in  STAT3  phosphorylation  on  both  sites  accompanied  by  a  block  in  STAT3  
nuclear  translocation,  suggesting  that  IL-­6  is  required  for  the  autocrine  activation  of  
STAT3  (Fig  4.6D  and  E).  Taken  together,  HPV  induces  autocrine  and  paracrine  IL-­
6/STAT3  signalling  in  cervical  cancer.     
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Figure  4.6.     STAT3  phosphorylation   requires   IL-­6/gp130  signalling   in   cervical  
cancer  cells.  A)  Representative  western  blot  of  C33A  cells   treated  with  20  ng/mL  
recombinant  human  IL-­6  for  30  mins.  Cells  were  pre-­treated  with  IgG,  anti-­IL6  or  anti-­
gp130   antibody   for   4   hours   before   IL-­6   addition.   Cell   lysates   were   analysed   for  
phosphorylated   and   total   STAT3   expression.  GAPDH   served   as   a   loading   control.  
Data   are   representative   of   at   least   three   biological   independent   repeats.   B)  
Representative  western  blot  of  C33A  cells  treated  with  conditioned  medium  (CM)  from  
HeLa  and  CaSKi  cells  for  2  hours.  Cells  were  pre-­treated  with  IgG,  anti-­IL6  or  anti-­
gp130   antibody   for   4   hours   before   CM   addition.   Cell   lysates   were   analysed   for  
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phosphorylated   and   total   STAT3   expression.  GAPDH   served   as   a   loading   control.  
Data  are  representative  of  at  least  three  biological  independent  repeats.  C)  C33A  cells  
treated  with  conditioned  medium  (CM)  from  HeLa  and  CaSKi  cells  for  2  hours.  Cells  
were   pre-­treated   with   IgG,   anti-­IL6   or   anti-­gp130   antibody   for   4   hours   before   CM  
addition.  Cells  were  then  analysed  by  immunofluorescence  staining  for  total  STAT3  
(green)   and   counterstained   with   DAPI   to   highlight   the   nuclei   (blue   in   the  merged  
panels).  Scale  bar,  20  µm.  D)  HeLa  cells  were  treated  with  IgG,  anti-­IL6  or  anti-­gp130  
for   4   hours.   Cell   lysates   were   analysed   for   phosphorylated   and   total   STAT3  
expression.  GAPDH  served  as  a  loading  control.  Data  are  representative  of  at  least  
three  biological  independent  repeats.  E)  HeLa  cells  were  treated  with  IgG,  anti-­IL6  or  
anti-­gp130  for  4  hours.  Cells  were  then  analysed  by  immunofluorescence  staining  for  
total  STAT3  (green)  and  counterstained  with  DAPI  to  highlight  the  nuclei  (blue  in  the  
merged  panels).  Scale  bar,  20  µm.  
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4.2.6  HPV  E6  induction  of  IL-­6  expression  is  required  for  the  induction  
of  STAT3  phosphorylation  
The   data   from   chapter   3   demonstrated   that   the   increased   STAT3   phosphorylation  
observed   in   HPV   containing   keratinocytes  was   dependent   on   the   E6   oncoprotein.  
Additionally,  HPV16  E6  has  been  previously  demonstrated  to  induce  IL-­6  secretion  in  
non-­small   cell   lung  cancer   (NSCLC)  cells   (416,417).  Therefore,   the  ability  of  E6   to  
induce  IL-­6  expression  in  cervical  cancer  cells  was  assessed.  To  this  end,  we  firstly  
utilised  an  IL-­6  promoter  luciferase  reporter.  In  C33A  cells,  expression  of  HPV18  E6  
significantly  increased  IL-­6  promoter  activity  by  ~4-­fold  compared  with  the  GFP  control  
(Fig   4.7A;;   p=  0.002).   This   corresponded   to  a  ~4-­fold   increase   in   endogenous   IL-­6  
mRNA  expression  (Fig  4.7B;;  p=  0.01)  and  IL-­6  protein  expression  (Fig  4.7C).  Finally,  
E6  expression  resulted  in  a  significant  increase  in  IL-­6  secretion,  measured  by  ELISA  
(Fig  4.7D;;  p=  0.0245).  To  demonstrate  that  the  E6  protein  expressed  in  HPV+  cancer  
cells  could  induce  IL-­6  expression,  HeLa  cells  were  treated  with  an  E6  specific  siRNA.  
Knockdown  of  E6  expression  led  to  a  significant  reduction  in  IL-­6  mRNA  expression  
(Fig  4.7E;;  p=  0.046),  IL-­6  protein  expression  (Fig  4.7F)  and  secretion  (Fig  4.7G;;  p=  
0.003).  Together,  these  data  demonstrate  that  HPV  E6  increases  the  expression  and  
secretion  of  IL-­6.     
To  confirm  if  IL-­6  expression  was  necessary  for  E6-­mediated  STAT3  phosphorylation,  
E6  was  expressed  in  C33A  cells  which  were  then  treated  with  neutralising  antibodies  
against  either   IL-­6  or   the  gp130  co-­receptor.  As  previously  shown   in  chapter  3,   the  
presence  of  HPV  E6  induced  the  phosphorylation  of  both  Y705  and  S727  residues  in  
STAT3.      However,   treatment   of   E6   expressing   cells   with   neutralising   antibodies  
against  IL-­6  or  gp130  inhibited  of  STAT3  phosphorylation  (Fig  4.7H).  This  suggests  
that  the  E6  induction  of  IL-­6  expression  is  essential  for  the  autocrine  phosphorylation  
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and  activation  of  STAT3  in  cervical  cancer  cells.       
  
  
Figure   4.7.      HPV   E6   induced   IL-­6   expression   is   required   for   STAT3  
phosphorylation.  A)  Representative   luciferase  reporter  assay   from  C33A  cells  co-­
transfected  with  GFP  tagged  E6  and  an  IL-­6  promoter  reporter.  Promoter  activity  was  
measured  using  a  dual-­luciferase  system.  Data  are  presented  as  relative  to  the  GFP  
transfected   control.     B)  C33A   cells   were   transiently   transfected  with  GFP   or  GFP  
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tagged  HPV18  E6  and  RNA  was  extracted  for  qRT-­PCR  analysis  of  IL-­6  expression.  
Samples   were   normalized   against   U6   mRNA   levels.   Representative   data   are  
presented  relative  to  the  GFP  control.  C)  Representative  western  blot  of  C33A  cells  
transiently   transfected  with  GFP   or  GFP   tagged  HPV18  E6   and   analysed   for   IL-­6  
expression.  Expression  of  HPV  E6  was  confirmed  using  a  GFP  antibody  and  GAPDH  
served  as  a  loading  control.  D)  C33A  cells  were  transiently  transfected  with  GFP  or  
GFP  tagged  HPV18  E6.  The  culture  medium  was  analysed  for  IL-­6  protein  by  ELISA.  
E)  HeLa  cells  were  transfected  with  a  pool  of  two  specific  siRNAs  against  HPV18  E6  
and   analysed   for   IL-­6   mRNA   expression   by   qRT-­PCR.   Samples   were   normalized  
against   U6  mRNA   levels.   Representative   data   are   presented   relative   to   the   GFP  
control.  F)  Representative  western  blot  of  HeLa  cells  transfected  with  a  pool  of  two  
specific   siRNAs   against   HPV18   E6   and   analysed   for   the   expression   of   IL-­6.  
Knockdown  of  HPV18  E6  was  confirmed  using  an  antibody  against  HPV18  E6  and  
p53.    GAPDH  served  as  a  loading  control.  G)  HeLa  cells  were  transfected  with  a  pool  
of  two  specific  siRNAs  against  HPV18  E6.  The  culture  medium  was  analysed  for  IL-­6  
protein  by  ELISA.  H)  Representative  western  blot  of  C33A  cells  transiently  transfected  
with  GFP  or  GFP  tagged  HPV18  E6  and  treated  with  IgG,  anti-­IL6  or  anti-­gp130  for  4  
hours  before  harvest.  Cell   lysates  were  then  analysed  for  phosphorylated  and  total  
STAT3.  Expression  of  HPV  E6  was   confirmed  using  a  GFP  antibody  and  GAPDH  
served  as  a  loading  control.  Bars  represent  the  means  ±  standard  deviation  from  at  
least  three  independent  biological  repeats.  *P<0.05,  **P<0.01  (Student’s  t-­test).  
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4.2.7  HPV  E6  activates  NFκB  to  increase  IL-­6  expression  
Several  signalling  pathways  can  induce  IL-­6  expression  (352).  One  key  host  factor  is  
the  transcription  factor  NFκB,  which  is  activated  in  response  to  a  range  of  extracellular  
ligands  including  TNFα  (418).  HPV  E6  has  previously  been  shown  to  activate  NFκB  
signalling,  particularly  in  hypoxia  (173,413).  To  assess  if  NFκB  was  required  for  E6-­
mediated  IL-­6  expression,  we  firstly  tested  whether  expression  of  E6  in  isolation  could  
activate   NFκB   in   C33A   cells.   Using   an   NFκB   driven   luciferase   reporter   plasmid,  
overexpression  of  E6  induced  NFκB  activity  ~3-­fold  compared  to  a  GFP  control  (Fig  
4.8A;;  p=  0.001).       
Canonical  NFκB  signalling  results   in   the  phosphorylation  of   the  p65  subunit  and   its  
nuclear   translocation  where   it   is   transcriptionally  active   in  complex  with  other  NFκB  
subunits  including  p50  (Fig  4.1).  Over  expression  of  E6  in  C33A  cells  induced  robust  
p65  phosphorylation  (Fig  4.8B).  In  contrast,  siRNA  mediated  knockdown  of  E6  in  HeLa  
cells   led   to  a  reduction   in  p65  phosphorylation  (Fig  4.8C),   together  suggesting   that  
HPV  E6  activates  the  NFκB  signalling  pathway.  
To  assess  if  NFκB  activity  was  required  for  the  increase  in  IL-­6  production  observed  
in  E6  expressing  cells,  we  firstly  employed  a  dual  approach  to  prevent  NFκB  activation  
in   C33A   overexpressing   E6   cells.      For   this,   cells   were   treated   either   with   a   small  
molecule   inhibitor   targeting   the   IKKα/b   (IKKi)   complex,   which   is   required   to  
phosphorylate  and  activate  NFκB,  or   transfected  with  a  plasmid  encoding  a  mutant  
IκBα   protein   (IkBm),   which   cannot   be   degraded   and   as   such   retains   NFκB   in   the  
cytosol  in  an  inactive  conformation.  As  previously  shown,  expression  of  E6  increased  
IL-­6  mRNA  production,  and  significantly  inhibition  of  NFκB  using  either  IKKi  or  IkBm  
led  to  a  reduction  in  IL-­6  mRNA  expression  (Fig  4.8D;;  IKKi,  p=0.00001;;  IkBm,  0.04).  
Importantly,  inhibition  of  NFκB  by  either  strategy  led  to  a  reduction  in  IL-­6  protein  levels  
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(Fig  4.8E)  and  secretion  (Fig  4.8F;;  IKKi,  p=  0.02;;  IkBm,  p=0.007).  To  confirm  if  NFκB  
activity   was   also   required   for  mediating   the   increased   IL-­6   levels   observed   in   the  
context  of  HPV+  cancer  cells,  NFκB  activity  was  blocked  in  HeLa  cells.  Inhibition  of  
NFκB  led  to  a  reduction  in  IL-­6  mRNA  expression  (Fig  4.8F;;  IKKi,  p=  0.03;;  IkBm,  p  
=0.02),   IL-­6  protein   levels  (Fig  4.8H)  and  secretion  (Fig  4.8I;;  IKKi,  p=  0.007;;   IkBm,  
p=0.007).  Collectively,  these  data  demonstrate  that  HPV  E6  mediated  IL-­6  expression  
is  dependent  on  an  active  NFκB  transcription  factor  in  cervical  cancer  cells.  
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Figure   4.8.      HPV   E6   mediated   IL-­6   expression   requires   NF-­κB   activity.   A)  
Representative   luciferase   reporter   assay   from  C33A  cells   co-­transfected  with  GFP  
tagged   E6   and   a   ConA   reporter,   which   contains   tandem   κB   binding   sites   (419).  
Promoter  activity  was  measured  using  a  dual-­luciferase  system.  Data  are  presented  
as  relative   to   the  GFP  transfected  control.  B)  Representative  western  blot  of  C33A  
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cells   transiently   transfected  with  GFP  or  GFP   tagged  HPV18  E6  and  analysed   for  
phosphorylated  and  total  p65  expression.  Expression  of  HPV  E6  was  confirmed  using  
a  GFP  antibody  and  GAPDH  served  as  a  loading  control.  C)  Representative  western  
blot  of  HeLa  cells  transfected  with  a  pool  of  two  specific  siRNAs  against  HPV18  E6  
and   analysed   for   the   expression   of   phosphorylated   and   total   p65.   Knockdown   of  
HPV18  E6  was  confirmed  using  an  antibody  against  HPV18  E6  and  p53.     GAPDH  
served   as   a   loading   control.  D-­F)  C33A   cells   were   co-­transfected  with  GFP,  GFP  
tagged  HPV18  E6  or  GFP  tagged  HPV18  E6  and  mutant  IκBα  (IkBm).  Cells  were  then  
either  left  untreated  or  treated  with  IKK  inhibitor  VII  (IKKi).  E)  Total  RNA  was  extracted  
for  qRT-­PCR  analysis  of  IL-­6  expression.  Samples  were  normalized  against  U6  mRNA  
levels.  Representative  data  are  presented  relative  to  the  GFP  control.  F)  Cell  lysates  
were  analysed  for  the  expression  of  phosphorylated  and  total  p65  and  IL-­6.  Expression  
of  HPV  E6  was  confirmed  using  a  GFP  antibody  and  GAPDH  served  as  a   loading  
control.  G)  The  culture  medium  was  analysed  for  IL-­6  protein  by  ELISA  G-­I)  HeLa  cells  
transfected  with  a  pool  of  two  specific  siRNAs  against  HPV18  E6.  H)Total  RNA  was  
extracted  for  qRT-­PCR  analysis  of  IL-­6  expression.  Samples  were  normalized  against  
U6  mRNA  levels.  Representative  data  are  presented  relative   to   the  GFP  control.   I)  
Cell  lysates  were  analysed  for  the  expression  of  phosphorylated  and  total  p65  and  IL-­
6.  Expression  of  HPV  E6  was  confirmed  using  a  GFP  antibody  and  GAPDH  served  as  
a  loading  control.  J)  The  culture  medium  was  analysed  for  IL-­6  protein  by  ELISA.  Bars  
represent  the  means  ±  standard  deviation  from  at  least  three  independent  biological  





4.2.8   NFκB   is   required   for   STAT3   phosphorylation   in   HPV   E6  
expressing  cells    
As  NFκB  was  absolutely  required  for  the  increase  in  IL-­6  expression  observed  in  HPV+  
cancer  cell  lines,  it  was  necessary  to  next  test  whether  NFκB  was  also  required  for  the  
activation  of  STAT3.  First,  we  tested  the  ability  of  an  inducer  of  NFκB  activation,  TNFα,  
to  cause  STAT3  phosphorylation.  Treatment  of  serum  starved  C33A  cells  with  TNFα  
led  to  an  increase  in  p65  phosphorylation,  which  peaked  at  0.5  hours  after  treatment  
(Fig  4.9A;;  lane  3).  TNFα  treatment  also  induced  IL-­6  expression;;  starting  at  0.5  hours  
post  treatment  and  remaining  high  up  to  24  hours  post  treatment.  Interestingly,  TNFα  
treatment  also  led  to  an  increase  in  STAT3  phosphorylation  at  both  Y705  and  S727  
residues;;   however,   this   peaked   much   later,   at   2   hours   (Fig   4.9A;;   lane   5).   TNFα  
treatment  also  led  to  the  nuclear  translocation  of  STAT3,  2  hours  post  treatment  (Fig  
4.9B).  
To  assess  the  importance  of  NFκB  activation  for  STAT3  phosphorylation  in  cervical  
cancer  cells,  HPV  E6  was  firstly  overexpressed  in  C33A  cells,  with  or  without  treatment  
with  the  NFκB  inhibitor  IKKi,  or  co-­expression  of    IkBm.  E6  overexpression  noticeably  
increased   p65   and   STAT3   phosphorylation   and   inhibition   of   NFκB   using   either  
approach  led  to  a  loss  of  STAT3  phosphorylation  (Fig  4.9C),  Additionally,  blockade  of  
NFκB  also  led  to  a  reduction  in  STAT3  phosphorylation  in  HeLa  cells  (Fig    4.9D  and  
E),   suggesting   that   E6   mediated   STAT3   phosphorylation   is   depended   on   NFκB.  
Finally,   to  ascertain   if  NFκB  was  essential   for   the  paracrine  activation  of  STAT3   in  
C33A  cells,  we  took  conditioned  media  from  HeLa  cells  in  which  NFκB  was  inhibited  
and   added   this   to   C33A   cells.   This   conditioned   media   failed   to   induce   STAT3  
phosphorylation  (Fig  4.9F)  and  nuclear  translocation  (Fig  4.9G).  Importantly,  inhibition  
of   NFκB   activity   had   no  effect   on   STAT3   phosphorylation   or   nuclear   translocation  
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mediated  by  treatment  with  exogenous  IL-­6  (Fig  4.10A  and  9B),  demonstrating  that  
NFκB  is  upstream  of  IL-­6  secretion.  Together,  the  data  suggests  that  NFκB  activity  is  
required  for  the  autocrine  and  paracrine  activation  of  STAT3  in  HPV+  cervical  cancer  
cells.  
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Figure  4.9.  NF-­κB  activity  is  required  for  HPV  E6  mediated  STAT3  signalling.  A)  
Representative  western  blot  of  C33A  cells  treated  with  20  ng/mL  recombinant  human  
TNFa  for  the  indicated  time  points.  Cell  lysates  were  analysed  for  phosphorylated  and  
total  p65,  phosphorylated  and  total  STAT3  and  IL-­6  expression.  GAPDH  served  as  a  
loading   control.   Data   are   representative   of   at   least   three   biological   independent  
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repeats.  B)  C33A  cells  treated  with  20  ng/mL  recombinant  human  TNFa  for  60  mins  
were  fixed  and  were  analysed  by  immunofluorescence  staining  for  total  STAT3  (green)  
and  total  p65  (red)  and  counterstained  with  DAPI  to  highlight  the  nuclei  (blue  in  the  
merged  panels).  Scale  bar,  20  µm.  C)  C33A  cells  were  co-­transfected  with  GFP,  GFP  
tagged  HPV18  E6  or  GFP  tagged  HPV18  E6  and  mutant  IκBα  (IkBm).  Cells  were  then  
either   left   untreated   or   treated  with   IKK   inhibitor   VII   (IKKi).   Cell   lysates  were   then  
analysed   for   phosphorylated   and   total   p65,   phosphorylated   and   total   STAT3  
expression.  Expression  of  HPV  E6  was  confirmed  using  a  GFP  antibody  and  GAPDH  
served  as  a  loading  control.  D)  Representative  western  blot  from  HeLa  cells  treated  
with  increasing  doses  of  the  IKKα/b  inhibitor  IKK  inhibitor  VII  (IKKi).  Cell  lysates  were  
analysed  for  the  expression  of  phosphorylated  and  total  p65,  phosphorylated  and  total  
STAT3  and  IL-­6  expression.  GAPDH  served  as  a  loading  control.  E)  Representative  
western  blot  from  HeLa  cells  transfected  with  mutant  IκBα  (IkBm).  Cell  lysates  were  
analysed  as  in  D).  F)  C33A  cells  were  serum  starved  for  24  hours.  Cells  were  then  
treated  with  HeLa   condition  media   from  HeLa   cells   treated  with  DMSO  or   IKKi,   or  
transfected  with  pcDNA  or  IkBm.  Cell  lysates  were  analysed  for  phosphorylated  and  
total  STAT3  expression.  GAPDH  served  as  a   loading   control.  G)  C33A  cells  were  
serum  starved  for  24  hours.  Cells  were  then  treated  with  HeLa  condition  media  from  
HeLa  cells  treated  with  DMSO  or  IKKi,  or  transfected  with  pcDNA  or  IkBm.  Cells  were  
analysed  by  immunofluorescence  staining  for  total  STAT3  (green)  and  counterstained  
with  DAPI  to  highlight  the  nuclei  (blue  in  the  merged  panels).  Scale  bar,  20  µm.  
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Figure  4.10.    NF-­κB  inhibition  does  not  affect  exogenous  IL-­6  mediated  STAT3  
signalling.  A)  C33A  were  treated  with  DMSO  or  IKKi  or  transfected  with  pcDNA  or  
IkBm  before  treatment  with  20  ng/mL  recombinant  human  IL-­6  for  30  mins.  Cell  lystaes  
were  analysed  for  phosphorylated  and  total  p65  and  phosphorylated  and  total  STAT3  
expression.  GAPDH  served  as  a  loading  control.  Data  are  representative  of  at  least  
three  biological   independent   repeats.  B)  C33A  were   treated  with  DMSO  or   IKKi  or  
transfected  with  pcDNA  or  IkBm  before  treatment  with  20  ng/mL  recombinant  human  
IL-­6  for  30  mins.  Cells  were  analysed  by  immunofluorescence  staining  for  total  STAT3  
(green)   and   counterstained   with   DAPI   to   highlight   the   nuclei   (blue   in   the  merged  
panels).  Scale  bar,  20  µm.  
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4.2.9   IL-­6  expression   correlates  with   disease  progression   in  cervical  
cancer  
The   IL-­6/STAT3   signalling   axis   is   deregulated   in   several   cancers   (420-­422).  
Additionally,   IL-­6   is   over   expressed   in   lung   cancer   and   head   and   neck   cancers  
(423,424).   We   analysed   cervical   liquid-­based   cytology   samples   from   a   cohort   of  
HPV16+  patients  representing  the  progression  of  disease  development  (CIN1-­CIN3)  
and  HPV  negative  normal  cervical  tissue  controls.  Levels  of  IL-­6  mRNA  significantly  
correlated  with  disease  progression   through  CIN1-­CIN3  (Fig  4.11A;;  CIN1,  p=  0.01;;  
CIN2,   p=   0.004;;   CIN3,   p=0.00005),   with   the   greatest   increase   observed   in   CIN3  
samples  when  compared  with  normal  cervical  tissue.  Additionally,  IL-­6  protein  levels  
also  correlated  with  disease  progression  (Fig  4.11B  and  C;;  CIN1,  p=  NS;;  CIN2,  p=  
0.0003;;  CIN3,  p=0.04),  again  showing  the  largest  increase  in  CIN3.  Finally,  we  mined  
a  publicly  available  database  of  microarray  data  of  normal  cervical  samples  against  
cervical  cancer  samples(425).     There  was  a  statistically  significant   increase   in   IL-­6  
mRNA  expression  in  the  cervical  cancer  samples  (Fig  4.11D;;  p=0.03).  Together,  these  
data  demonstrated  that  IL-­6  levels  are  regulated  at  the  mRNA  level  in  HPV+  cervical  
cancer.     
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Figure  4.11.    IL-­6  expression  correlates  with  cervical  disease  progression  and  is  
up  regulated  in  cervical  cancer.  A)  Scatter  dot  plot  of  qRT-­PCR  analysis  of  RNA  
extracted  from  a  panel  of  cytology  samples  of  CIN  lesions  of  increasing  grade.  Five  
samples  from  each  clinical  grade  (neg,  CIN  I-­III)  were  analysed  and  mRNA  levels  were  
normalized   to   neg   samples.   Samples   were   normalized   against   U6   mRNA   levels.  
Representative  data  are  presented  relative  to  the  HPV-­  cervical  cancer  cells.  Bars  are  
the   means   ±   standard   deviation   from   at   least   three   biological   repeats.   *P<0.05,  
**P<0.01,  ***P<0.001  (Student’s  t-­test).  B)  Representative  western  blots  from  cytology  
samples  of  CIN  lesions  of  increasing  grade  analysed  IL-­6  expression.  GAPDH  served  
as  a  loading  control.  C)  Scatter  dot  plot  of  densitometry  analysis  of  a  panel  of  cytology  
samples.  Twenty  samples  from  each  clinical  grade  (neg,  CIN  I-­III)  were  analysed  by  
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western  blot  and  densitometry  analysis  was  performed  using   ImageJ.  GAPDH  was  
used   as   a   loading   control.  D)   Scatter   dot   plot   of   data   acquired   from   the   dataset  
GSE9750  on  the  GEO  database.  Arbitrary  values  for  the  mRNA  expression  of  IL-­6  in  
normal   cervix   (n=23)   and   cervical   cancer   (n=28)   samples  were   plotted.  Error   bars  
represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  three  biological  repeats.  
*P<0.05,   **P<0.01,   ***P<0.001   (Student’s   t-­test).   E)   Schematic   diagram   of   E6  
mediated  NF-­κB/IL-­6/STAT3  signalling  in  HPV+  cervical  cancer  cells.  
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4.3  Discussion  
The  cytokine   IL-­6   is  over-­expressed   in  diverse  cancers  and   is  often  correlated  with  
activation  of  STAT3  (410).  IL-­6  displays  many  pleiotropic  functions,  being  both  pro-­
inflammatory  and  immunosuppressive  by  interacting  with  the  surrounding  stroma  of  
tumours   (426).   In  HNSCC  and  oral  squamous  cell   carcinoma,  serum   levels  of   IL-­6  
level   are   significantly   higher   than   control   patients   and   serum   IL-­6   is   a   potential  
biomarker   for   these   cancers   (355).   Additionally,   targeting   IL-­6   in   combination  with  
EGFR  inhibitors  such  as  Erlotinib  is  currently  being  investigated  as  a  potential  therapy  
for  HNSCC  due  to  the  resistance  to  EGFR  inhibition  seen  in  many  tumours  (427).  In  
cervical   cancer,   IL-­6   expression   promotes   tumour   proliferation   by   inducing   VEGF-­
dependent  angiogenesis   in  a  STAT3  dependent  manner      (428)  and  has  also  been  
suggested   as   a   potential   biomarker   for   cervical   cancer   (429)   Here,   STAT3  
phosphorylation   and   IL-­6   expression   has   been   shown   to   be   increased   in   HPV+  
cervical  cancer  cell  lines  when  compared  with  normal  keratinocytes  and  HPV-­  cervical  
cancer  cells  (Figure  4.1).  Additionally,  IL-­6  expression  correlates  with  cervical  disease  
progression  and   is   increased   in   cervical   cancer   (Figure   4.11).   This   surplus   of   IL-­6  
expression  may  contribute  to  the  increased  level  of   immune  suppressive  Th17  cells  
and  Treg  seen  in  the  stroma  of  cervical  cancer  tumours  (430).  
The  HPV  E6  oncoprotein  has  been  demonstrated  to  be  required  for  the  expression  
and   secretion   of   IL-­6   NSCLC   cells   (416);;   however,   the   role   of   E6   in   driving   IL-­6  
expression   in   cervical   cancer   is   unknown.   Furthermore,   the   contribution   of   IL-­6   to  
STAT3  activation  in  cervical  cancer  is  poorly  defined.  In  this  chapter,  the  increased  
phosphorylation  of  STAT3  in  HPV  cervical  cancer  cells  was  attributed  to  an  increase  
in   IL-­6   expression   by   HPV   E6   and   the   induction   of   autocrine/paracrine   IL-­
6/gp130/STAT3  signalling   (Figure  4.11E).   In  cervical  cancer  cells,  EGFR  signalling  
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can  induce  STAT3  activation  (431)  However,  the  data  here  identified  that  blockade  of  
IL-­6   or   gp130   signalling   using   neutralising   antibodies   abolished   STAT3  
phosphorylation   (Figure   4.6),   suggesting   that   IL-­6/gp130   is   required   for   STAT3  
phosphorylation  in  HPV+  cervical  cancer  cells.      
To   further   investigate   the   regulation   of   IL-­6   by   E6   in   HPV+   cervical   cancer,   the  
transcription   factor  NFκB  was   identified   as   an  essential   upstream  mediator   of   IL-­6  
expression.  NFκB  is  a  key  component  of  the  inflammatory  response,  which  is  a  key  
hallmark   of   cancer   (283,352,418).   The   induction   of   inflammation   by   diverse  
mechanisms  contributes  to  around  20%  of  cancers,  including  the  role  of  inflammatory  
bowel   disease   in   the   development   of   colorectal   cancer   (CRC)   (432).   Importantly,  
infection  also  plays  an  important  role  in  inflammation-­driven  cancer;;  H.  pylori  can  lead  
to   the   induction  of  stomach  cancers,  whilst  Hepatitis  B  and  C   infection  can   lead   to  
hepatocellular   carcinoma   development   (433-­435).   Previous   data   suggests   that  
inflammation   induced   by   HPV   infection   may   contribute   to   HPV   induced   cervical  
cancers  (436,437).  Indeed,  several  genes  known  to  be  induced  by  the  inflammatory  
response,  including  COX-­2  (438),  are  up-­regulated  in  cervical  cancer.  
The   role   of   NFκB   in   cervical   remains   controversial,   with   HPV   implicated   in   both  
activation   and   inhibition   of   the   transcription   factor   (173,413,439).   HPV   E6   was  
demonstrated  to  increase  the  expression  of  NFκB  components  and  induce  NFκB  DNA  
binding  activity,   increasing  pro-­inflammatory  cytokine  expression  (413).  Additionally,  
E6  reduces  the  expression  of  the  deubiquitinase  CYLD,  a  known  negative  regulator  of  
NFκB  signalling,  in  hypoxic  cells  (173).  In  contrast,  E6  has  been  shown  to  inhibit  NFκB  
transcriptional  activity,  whilst  HPV  E7  can  attenuate  p65  nuclear  translocation  (439).  
The  data  presented  here  demonstrates  that  HPV18  E6  increases  the  phosphorylation  
of  p65,  essential  for  its  nuclear  translocation  and  transactivation.  Additionally,  NFκB  is  
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essential  for  IL-­6  expression  in  HPV+  cervical  cancer  cells.     
The  link  between  NFκB  and  STAT3  has  been  observed  in  many  cancers.  STAT3  and  
NFκB  share  many  target  genes  implicated  in  cancer  progression,  including  cyclin  D1  
and  Bcl  xL  (440).  In  addition,  STAT3  and  NFκB  can  interact  directly,  resulting  in  the  
retention  of  NFκB   in   the  nucleus  and  the  binding  of  unique  DNA  target  sites  (440).  
Furthermore,   STAT3   activation   can   also   induce   NFκB   activation   (441).   In  
glioblastoma,  the  activation  of  STAT3  by  an  NFκB/IL-­6  signalling  axis  is  required  for  
cancer  aggressiveness   (442).  The  data  presented  here  demonstrates   that  NFκB   is  
essential   for   the   induction   of   IL-­6   and   the   autocrine/paracrine   induction   of   STAT3  
phosphorylation  in  HPV+  cervical  cancer  cells.  Therefore,  the  IL-­6/STAT3  signalling  
axis  may  be  an  attractive  therapeutic  target  in  HPV+  cervical  cancer.  
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Chapter  5.  The  role  of  STAT3  signalling  in  cervical  cancer  
5.1  Introduction     
As   an   oncogenic   virus,   HPV   infection   accounts   for   5%   of   human   cancer   cases  
worldwide  (398).  Despite  the  availability  of  vaccines  against  HPV  infection,  these  are  
preventative  and  not  therapeutic  (39).  There  is  currently  no  direct  acting  anti-­viral  that  
targets  HPV,  with  the  most  common  treatment  for  cervical  cancer  being  with  platinum-­
based  chemotherapeutics  such  as  cisplatin  (443).  Additionally,  many  cancers  develop  
resistance   to   such   chemotherapeutics   (444).   Therefore,   there   is  a   need   to   identify  
novel  therapeutic  targets  for  the  treatment  of  HPV-­mediated  cervical  cancer.  
The  transcription  factor  STAT3  has  been  demonstrated  to  be  an  attractive  therapeutic  
target  in  a  diverse  range  of  cancers,  including  bladder  (345),  ovarian  (445)  and  head  
and   neck   squamous   cell   carcinoma   (HNSCC)   (446).   In   bladder   cancer,   STAT3   is  
essential   for   cell   proliferation   and   survival,  whereas   in   pancreatic   cancer   it   also   is  
required  for  angiogenesis  and  metastasis  (347).  
In  cervical  cancer,  inhibition  of  STAT3  has  been  shown  to  be  detrimental  to  cervical  
cancer   cell   proliferation   and   to   increase   the   expression   of   the   tumour   suppressor  
proteins  p53  and  pRb  (369).  In  another  study,  knockdown  of  STAT3  using  siRNA  led  
to  a  similar  reduction  in  cervical  cancer  cell  proliferation  (370).  However,  a  detailed  
investigation  in  to  the  role  of  STAT3  in  cervical  cancer  is  currently  lacking.  
In   this  chapter,   the  effect  of  STAT3   inhibition  and  depletion  on  cervical  cancer  cell  
proliferation,  migration  and  invasion  was  investigated.  Additionally,  the  role  of  STAT3  
in  epithelial-­to-­mesenchymal  transition  (EMT)  was  investigated.  
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5.2  Results    
5.2.1  STAT3   is   required   for   the  proliferation  of  HPV+  cervical  cancer  
cells  
To  investigate  the  role  of  STAT3  during  HPV+  cervical  cancer  cell  proliferation,  STAT3  
was   inhibited   using   the   specific   small  molecule   inhibitor   cryptotanshinone.   In   both  
HPV18+   HeLa   and   HPV16+   CaSKi   cells,   inhibition   of   STAT3   activation   led   to   a  
significant   reduction   in  cell  proliferation  (Fig  5.1A;;  HeLa,  p  =  0.0009  for  crypto,  p  =  
0.0009  for  S3I-­201  at  day  5;;  CaSKi,  p  =  0.002  for  crypto,  p  =  0.002  for  S3I-­201  at  day  
5).   To   confirm   that   this   effect   was   due   to   the   specific   inhibition   of   STAT3,   STAT3  
protein  expression  was  next  depleted  using  a  pool  of  four  validated  STAT3  specific  
siRNAs.   Depletion   of   STAT3  also   led   to   a   reduction   in   cell   proliferation   (Fig   5.1B;;  
HeLa,  p  =  0.009  at  day  5;;  CaSKi,  p  =  0.01  at  day  5.),   indicating   that   the  observed  
effects  on  cell  proliferation  were  specific  to  STAT3.    Next,  the  effect  of  STAT3  inhibition  
on  the  expression  of  key  mediators  of  cell  proliferation  was  examined.  Treatment  of  
cells   with   increasing   doses   of   cryptotanshinone   led   to   a   gradual   decrease   in  
appearance  of   the  phosphorylated   forms  of  STAT3  at  both  Y705  and  S727  without  
affecting  the  total  levels  of  STAT3  protein  (Fig  5.1C).  Additionally,  inhibition  of  STAT3  
led   to   a   reduction   in   cyclin   D1   protein   expression,   a   key   mediator   of   cell   cycle  
progression,   and   the   appearance   of   the   p21   protein,   a   cyclin   dependent   kinase  
inhibitor.  STAT3   inhibition  also   led   to   the   reduction  of  HPV  E6  and  E7  expression,  
which  are   important  virus  coded  regulators  of  proliferation   in  HPV+  cervical  cancer  
cells  (Fig  5.1C).  In  line  with  this,  depletion  of  STAT3  led  to  a  similar  reduction  in  cyclin  
D1,  HPV  E6  and  E7,  and  a  corresponding  increase  in  p21  (Fig  5.1D).       
To   confirm   these   findings,   the   effect   of   STAT3   inhibition   using   two   STAT3   small  
molecule  inhibitors,  cryptotanshinone  and  S3I-­201,  or  the  depletion  of  STAT3  using  
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siRNA  on  the  clonogenicity  of  HPV+  cervical  cancer  cells  was  assessed.  In  both  HeLa  
and  CaSKi   cells,   there  was  a   significant   decrease   in  anchorage-­dependent   colony  
formation  ability  after  STAT3   inhibition   (Fig  5.1E;;  HeLa,  p  =  5x10-­11   for  crypto,  p  =  
1x10-­6   for  S3I-­201;;  CaSKi,  p  =  7x10-­5  for  crypto,  p  =  9x10-­6      for  S3I-­201)  or  STAT3  
depletion  (Fig  5.1F;;  HeLa,  p  =  0.02;;  CaSKi,  p  =  0.004).  Additionally,  STAT3  activity  
(Fig  5.1G;;  HeLa,  p  =  0.002    for  crypto,  p  =  0.003  for  S3I-­201;;  CaSKi,  p  =  0.002  for  
crypto,  p  =  0.003     for  S3I-­201)  and  protein  expression  (Fig  5.1H;;  HeLa,  p  =  0.001;;  
CaSKi,  p  =  0.0003)  was  also  required  for  the  ability  of  HPV+  cervical  cancer  cells  to  
form  colonies  in  an  anchorage-­independent  manner  in  a  soft  agar  assay).  Together,  
these  data  show  that  STAT3  is  required  for  cell  proliferation  and  the  ability  of  HPV+  
cervical   cancer   cells   to   form   colonies   in   an   anchorage   dependent   or   independent  
manner.    
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Fig  5.1.    STAT3  is  required  for  the  proliferation  of  HPV+  cervical  cancer  cells.  A)  
Growth  curve  analysis  of  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  24  hours.  
B)  Growth  curve  analysis  of  HeLa  (left)  and  CaSKi  (right)  cells  after  transfection  of  a  
pool  of   four  specific  STAT3  siRNA   for  72  hours.  C)  Representative  western  blot  of  
cryptotanshinone  dose  response  after  24  hours.  D)  Representative  western  blot  after  
transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  72  hours.  E)  Colony  formation  
assay   (anchorage   dependent   growth)   of   HeLa   and   CaSKi   cells   after   addition   of  
inhibitors  for  24  hours.  E)  Colony  formation  assay  (anchorage  dependent  growth)  of  
HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  72  
hours.  G)  Soft  agar  assay  (anchorage  independent  growth)  of  HeLa  and  CaSKi  cells  
after  addition  of  inhibitors  for  24  hours.  H)  Soft  agar  assay  (anchorage  independent  
growth)  of  HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  
siRNA   for   72   hours.   Error   bars   represent   the   mean   +/-­   standard   deviation   of   a  













5.2.2  STAT3  inhibition  or  depletion  results  in  cell  cycle  arrest  in  HPV+  
cervical  cancer  cells  
Cyclin  D1  is  a  key  cell  cycle  regulator  that  is  over-­expressed  in  several  cancers  (351).  
As  the  inhibition  of  STAT3  activation  or  depletion  of  total  STAT3  protein  both  led  to  a  
reduction  in  cyclin  D1  expression,  the  role  of  STAT3  in  regulation  of  the  cell  cycle  was  
analysed   by   flow   cytometry.   Treatment   with   cryptotanshinone   led   to   a   significant  
increase  in  the  number  of  cells  in  the  S  phase  of  the  cell  cycle  (Fig  5.2A:  HeLa,  p  =  
0.05  for  crypto,  p  =  0.027  for  S3I-­201;;  CaSKi,  p  =  0.03  for  crypto,    p  =  0.02  for  S3I-­
201)  with  a  concomitant  decrease  in  cells  in  G2/M  (Fig  5.2A;;  not  significant)  A  similar  
effect  was  seen  upon  depletion  of  STAT3  protein  levels  by  siRNA  treatment  (Fig  5.2B;;  
HeLa  S  phase,  p  =  0.003;;  CaSKi  S  phase,  p  =  0.002),  indicating  that  STAT3  is  required  
for  cell  cycle  progression  from  S  phase  to  G2/M,  potentially  through  the  regulation  of  
cyclin  D1  expression.  
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Fig  5.2.    STAT3  inhibition  or  depletion  results  in  cell  cycle  arrest  in  HPV+  cervical  
cancer  cells.  A)  Flow  cytometric  analysis  of  cell  cycle  profile  of  HeLa  and  CaSKi  cells  
after  addition  of  inhibitors  for  24  hours.  B)  Flow  cytometric  analysis  of  cell  cycle  profile  
of  HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  
72  hours.  Error  bars  represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  three  









5.2.3   STAT3   regulates   apoptosis   through   the   expression   of   the   pro-­
survival  genes,  Bcl  xL  and  Survivn  in  HPV+  cervical  cancer  
As  well  as  being  a  driver  of  cancer  cell  proliferation,  in  some  circumstances  STAT3  is  
also  required  for  cell  survival  (345).  In  cervical  cancer  cells,  inhibition  of  STAT3  has  
been  shown  to  induce  caspase  activation  and  PARP  cleavage  (370).  Therefore,  the  
effect  of  STAT3  inhibition  or  depletion  on  apoptosis  of  HPV+  cervical  cancer  cells  was  
assessed.   To   look   at   the   early   stages   of   apoptosis,   an   Annexin   V   assay   was  
performed,   which   measures   phospholipid   flipping   in   the   cell   membrane,   an   early  
indicator   for  cell  apoptosis   (447).   In  both  HeLa  and  CaSKi  cells,   the  percentage  of  
early  apoptotic  cells  significantly  increased  after  STAT3  inhibition  for  6  hours  (Fig  5.3A;;  
HeLa,  p  =  0.02  for  crypto,  p  =  0.003  for  S3I-­201;;  CaSKi,  p  =  0.01  for  crypto,  p  =  0.005  
for   S3I-­201).   By   24   hours,   the   percentage   of   cells   in   late   apoptosis   increased  
significantly  (HeLa,  p  =  0.0001  for  crypto,  p  =  0.001  for  S3I-­201;;  CaSKi,  p  =  0.0007  for  
crypto,      p   =   7x10-­5   for   S3I-­201),   whilst   there  was   also   a   significant   percentage   of  
necrotic  cells  (HeLa,  p  =  0.002  for  crypto,  p  =  0.005  for  S3I-­201;;  CaSKi,  p  =  0.00006  
for  crypto,    p  =  0.0004  for  S3I-­201).  Depletion  of  STAT3  had  a  similar,  although  less  
pronounced  effect  on  cell  apoptosis  (Fig  5.3B).    
To   further   investigate   the  role  of  STAT3   in  cell  survival,  an  assay   to  measure  DNA  
condensation,   another   hallmark   of   apoptosis,   was   performed.   STAT3   inhibition   or  
depletion  resulted  in  a  significant  percentage  of  apoptotic  and  necrotic  cells  in  both  
HeLa  and  CaSKi   cells   (Fig   5.3C  and  D).   To   investigate   the  molecular  mechanism  
involved   in   the   induction   of   apoptosis   due   to   STAT3   inhibition   or   depletion,  
immunofluorescence  staining  was  performed  to  measure  the  activity  of  caspase  3,  a  
key   caspase   involved   in   the   initiation   of   apoptosis(448).   At   6   hours   post   STAT3  
inhibition,  cleaved  caspase  3,   indicative  of   the  active   form  of   the  caspase  enzyme,  
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was  detected   in  cells   that  displayed  rounded  up  or  fragmented  nuclei  (Fig  5.3E).  A  
similar  effect  was  seen  after  STAT3  depletion  at  24  hours  (Fig  5.3F),  indicating  that  
STAT3  inhibition  or  depletion  results  in  the  activation  of  caspase  dependent  apoptosis.  
To  confirm   this,   the  activity  of  caspase  3  was  analysed  by  western  blotting   for   the  
presence   of   the   cleaved   form   of   the   caspase   3   substrate   PARP-­1.   After   24   hours  
inhibition  (Fig  5.3G),  or  48  hours  of  STAT3  depletion  (Fig  5.3H),  PARP-­1  cleavage  
was  readily  detectable,  indicating  that  caspase  3  was  activated.  
Several  pro-­survival  genes  are  known  to  be  direct  STAT3  targets,  including  Bcl  xL  and  
Survivin.  Therefore,   the  expression  of   these  genes  was  analysed  by  RT-­qPCR  and  
western  blot.  In  both  HeLa  and  CaSKi  cells,  inhibition  or  depletion  of  STAT3  led  to  a  
reduction  in  Bcl  xL  protein  expression  as  indicated  by  western  blotting  (Fig  5.3G  and  
H).  Furthermore,  the  mRNA  expression  of  both  Bcl  xL  and  Survivin  was  decreased  
(Fig  5.3I  and  J).  Together,  these  data  suggest  that  STAT3  is  essential  for  the  survival  
of  HPV+  cervical  cancer  cells,  potential  through  the  regulation  of  pro-­survival  genes  
such  as  Bcl  xL  and  Survivin.  
  
     
 183 
     
 184 
     
 185 
Fig  5.3.  STAT3  regulates  apoptosis  through  the  expression  of  the  pro-­survival  
genes,  Bcl  xL  and  Survivn  in  HPV+  cervical  cancer.  A)  Flow  cytometric  analysis  of  
Annexin  V  assay  in  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  6  and  24  hours.  
B)   Flow   cytometric   analysis   of   Annexin   V   assay   in   HeLa   and   CaSKi   cells   after  
transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  24  hours.  C)  Flow  cytometric  
analysis  of  Vybrant™  DyeCycle™  Violet/SYTOX™  AADvanced™  apoptosis  kit  assay  
in  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  24  hours.  D)  Flow  cytometric  
analysis  of  Vybrant™  DyeCycle™  Violet/SYTOX™  AADvanced™  apoptosis  kit  assay  
in  HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  
24  hours.  E)  Immunofluorescence  analysis  of  HeLa  and  CaSKi  cells  after  addition  of  
inhibitors  for  6  hours.  Cover  slips  were  stained  for  Cleaved  caspase  3  (green).  Nuclei  
were   visualised   using   DAPI   (blue).   F)   Immunofluorescence   analysis   of   HeLa   and  
CaSKi  cells  after   transfection  of  a  pool  of   four  specific  STAT3  siRNA  for  24  hours.  
Cover  slips  were  stained  for  Cleaved  caspase  3  (green).  Nuclei  were  visualised  using  
DAPI  (blue).  Images  were  acquired  using  identical  exposure  times.  Scale  bar,  20  µm.  
G)  Representative  western  blot  of  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  
24  hours  and  analysed  for  PARP  cleavage  and  Bcl  xL  expression.  GAPDH  served  as  
the   loading   control.  H)  Representative  western   blot   of  HeLa  and  CaSKi   cells   after  
transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  72  hours.  I)  Quantitative  PCR  
analysis  of  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  24  hours  and  analysed  
for  PARP  cleavage  and  Bcl   xL   expression.  GAPDH  served  as   the   loading   control.  
Cells  were  analysed  for  the  pro-­survival  genes  BCL2L1  and  BIRC5.  U6  served  as  a  
loading  control.  Error  bars  represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  
three   biological   repeats.   *P<0.05,   **P<0.01,   ***P<0.001   (Student’s   t-­test).   J)  
Quantitative  PCR  analysis  of  HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  
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specific  STAT3  siRNA  for  72  hours.  Cells  were  analysed  for  the  pro-­survival  genes  
BCL2L1  and  BIRC5.  U6  served  as  a  loading  control.  Error  bars  represent  the  mean  
+/-­  standard  deviation  of  a  minimum  of  three  biological  repeats.  *P<0.05,  **P<0.01,  























5.2.4  STAT3  is  required  for  the  migration  and  invasion  of  HPV+  cervical  
cancer  cells  
STAT3  activity  has  been  demonstrated  to  be  essential  for  the  migration  and  invasion  
of  hepatocellular  carcinoma  cells   (449).  Additionally,  STAT3  knockout  mice  have  a  
compromised  wound   healing   response   (315).   Therefore,   the   role   of   STAT3   in   the  
migration   and   invasion   of   HPV+   cervical   cancer   cells   was   investigated.   Using   a  
standard   wound   healing   assay,   chemical   inhibition   of   STAT3   or   depletion   of   total  
STAT3  protein  levels  both  led  to  a  significant  reduction  in  would  closure  in  either  HeLa  
or  CaSKi  cells  (Fig  5.4A  and  B;;  HeLa,  p  <  5x10-­5  for  all  conditions;;  CaSKi,  p  <  0.006  
for  all  conditions).  To  build  on  these  findings,  the  migration  and  invasion  properties  of  
HPV+  cervical  cancer  cells  were   tested  after  STAT3   inhibition  or  depletion  using  a  
TranswellÒ  Assay.  STAT3  inhibition  or  depletion  led  to  a  significant  reduction  in  the  
number   of   migrated   cells   through   the   uncoated   TranswellÒ   membrane   (Fig   5.4C;;  
HeLa,  p  <  2x10-­7  for  all  conditions;;  CaSKi,  p  <  2x10-­7  for  all  conditions).  In  addition,  
STAT3   was   also   required   for   the   invasion   of   HPV+   cervical   cancer   cells   through  
MatrigelÒ   coated   TranswellÒ   membranes   (Fig   5.4D;;   HeLa,   p   <   2x10-­7   for   all  
conditions;;  CaSKi,  p  <  2x10-­7  for  all  conditions).  These  data  demonstrate  that  STAT3  
is  required  for  the  migration  and  invasion  of  HPV+  cervical  cancer  cells.  
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Fig   5.4.   STAT3   is   required   for   the   migration   and   invasion   of   HPV+   cervical  
cancer   cells.   A)  Wound   healing   assay   in   HeLa   and  CaSKi   cells   after   addition   of  
inhibitors  for  24  hours.  Confluent  cells  were  then  wounded  and  imaged  immediately  
and  after  24  hours.  B)  Wound  healing  assay  in  HeLa  and  CaSKi  cells  after  transfection  
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of   a   pool   of   four   specific   STAT3   siRNA   for   72   hours.   Confluent   cells   were   then  
wounded   and   imaged   immediately   and   after   24   hours.   C)   Quantification   of   the  
migration  of  HeLa  and  CaSKi  cells  over  expressing  after  addition  of  inhibitors  for  24  
hours  by  Transwellâ  migration  assay.  The  average  number  of  invaded  cells  per  field  
was  calculated  from  five  representative  fields  per  experiment.  D)  Quantification  of  the  
invasion  of  HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  
siRNA  for  72  hours  by  Transwellâ   invasion  assay.  The  average  number  of   invaded  
cells  per  field  was  calculated  from  five  representative  fields  per  experiment.  Error  bars  
represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  three  biological  repeats.  

















5.2.5  STAT3  is  essential  for  epithelial  to  mesenchymal  transition  (EMT)  
through   the   regulation   of   the   EMT   associated   transcription   factors  
Snail  and  Slug  in  HPV+  cervical  cancer  cells  
In  oesophageal  cancers  and  HNSCC,  STAT3  is  required  to  drive  EMT  and  cancer  cell  
metastasis  (346,450).  Additionally,  IL-­6  mediated  STAT3  signalling  has  been  shown  
to  induce  the  expression  of  the  key  EMT  related  transcription  factors  Snail  and  Slug,  
as  well  as  the  mesenchymal  gene  vimentin  (451).  
To  investigate  if  STAT3  was  required  for  the  EMT  observed  in  HPV+  cervical  cancer  
cells,  the  expression  of  key  genes  involved  in  EMT  was  first  analysed  by  RT-­qPCR.  
Chemical   inhibition  of  STAT3  activation  reduced  the  mRNA  expression  of   the  Snail  
and  Slug  transcription  factors,  as  well  as  the  mesenchymal  markers  vimentin  and  ZEB-­
1   (Fig   5.5A).   Additionally,   mRNA   expression   of   the   epithelial   marker   ZO-­1   was  
increased   upon   STAT3   inhibition.   Similar   results   were   obtained   by   STAT3   siRNA  
depletion  (Fig  5.5B).  Western  blotting  confirmed  that  STAT3  also  regulated  the  protein  
expression  of  these  EMT  markers  (Fig  5.5C  and  D).  Additionally,  the  expression  and  
localisation   of   vimentin   was   assessed   by   immunofluorescence.   Vimentin   is   highly  
expressed  in  HeLa  and  CaSKi  control  cells,  with  a  filamentous  cytosolic  expression  
pattern  throughout  a  cell.  Inhibition  or  depletion  of  STAT3  led  to  a  reduced  expression  
of  vimentin,  with  a  reduction  in  visible  fibrous  vimentin  structures  (Fig  5.5F).     
  
A   key   characteristic   of   EMT   is   cadherin   switching,   in   which   cancer   cells   lose  
expression   of   E-­cadherin   and   instead   preferentially   express   N-­cadherin   (452).  
Blockade  of  STAT3  activity,  either  by  inhibition  or  siRNA  depletion  led  to  an  increase  
in  E-­cadherin   expression  and  a   reduction   in  N-­cadherin   expression,   indicating   that  
STAT3   is   required   for   cadherin   switching   in   HPV+   cervical   cancer   cells.   Western  
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blotting   or   immunofluorescence   staining   could   not   confirm   the   expression   of   E-­
cadherin  and  N-­cadherin  protein  after  STAT3  inhibition  or  depletion.  Therefore,  flow  
cytometry  was  used  to  analyse  the  expression  of  cell  surface  E-­cadherin.  After  STAT3  
inhibition,   the  surface  expression  of  E-­cadherin   increased  by  an  average  of  72%  in  
HeLa  cells  and  44%  in  CaSKi  cells  (Fig  5.5E).      
Together,  these  data  demonstrate  that  STAT3  is  essential  for  EMT  in  HPV+  cervical  
cancer  cells.  
  
     
 192 
     
 193 
Fig   5.5.   STAT3   is   essential   for   epithelial   to   mesenchymal   transition   (EMT)  
through   the   regulation  of   the  EMT  associated   transcription   factors  Snail   and  
Slug   in   HPV+   cervical   cancer   cells.   A)  Quantitative   PCR   analysis   of   HeLa   and  
CaSKi  cells  after  addition  of  inhibitors  for  24  hours.  Cells  were  analysed  for  the  EMT  
marker  expression.  U6  served  as  a  loading  control.  B)  Quantitative  PCR  analysis  of  
HeLa  and  CaSKi  cells  after  transfection  of  a  pool  of  four  specific  STAT3  siRNA  for  72  
hours.  Cells  were  analysed  for  the  EMT  marker  expression.  U6  served  as  a  loading  
control.  C)  Representative  western   blot   of   HeLa   and  CaSKi   cells   after   addition   of  
inhibitors  for  24  hours.  Cells  were  analysed  for  the  EMT  marker  expression.  GAPDH  
served  as  a  loading  control.  D)  Representative  western  blot  of  HeLa  and  CaSKi  cells  
after   transfection   of   a   pool   of   four   specific  STAT3   siRNA   for   72   hours.  Cells  were  
analysed  for  the  EMT  marker  expression.  GAPDH  served  as  a  loading  control.  E)  Flow  
cytometric  analysis  of  E-­cadherin  expression  in  HeLa  and  CaSKi  cells  after  addition  
of  inhibitors  for  24  hours.  F)  Immunofluorescence  analysis  of  vimentin  expression  in  
HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  24  hours.  Cover  slips  were  stained  
for   vimentin   (green).   Nuclei   were   visualised   using   DAPI   (blue).   G)  
Immunofluorescence  analysis  of  vimentin  expression  in  HeLa  and  CaSKi  cells  after  
transfection  of  a  pool  of   four  specific  STAT3  siRNA  for  72  hours.  Cover  slips  were  
stained   for   vimentin   (green).   Nuclei   were   visualised   using  DAPI   (blue).   Error   bars  
represent  the  mean  +/-­  standard  deviation  of  a  minimum  of  three  biological  repeats.  






5.2.6   Inhibition  of  JAK2  reduces  STAT3  phosphorylation  and   impairs  
HPV+  cervical  cancer  cell  proliferation,  migration  and  invasion  
Although  there  is  substantial  evidence  that  STAT3  transactivation  function  is  activate  
in  many  cancers,  there  are  currently  no  clinically  available  STAT3  inhibitors.  The  main  
issue  preventing  development  of  such  inhibitors  has  been  toxicity  in  early  stage  animal  
models   (350);;   therefore,   targeting   other   components   in   the   core   STAT3   signalling  
pathway  is  an  attractive  alternative.  The  data  presented  in  Chapter  3  demonstrated  
that  HPV  E6  induces  STAT3  tyrosine  phosphorylation  by  activating  Janus  Kinase  2  
(JAK2).  Therefore,  the  effect  of  JAK2  inhibition  in  HPV+  cervical  cancer  cells  was  also  
investigated.  Ruxolitinib   is  a  clinically  available  JAK1/2   inhibitor   for   the   treatment  of  
high-­risk  myelofibrosis  and  Fedratinib  is  a  JAK2  specific  inhibitor  currently  in  Phase  III  
trials  for  high-­risk  myelofibrosis  (382,383).  In  both  HPV18+  Hela  and  HPV16+  CaSKi  
cells,   inhibition   of   JAK2   activation,   as   judged   by   its   phosphorylation,   resulted   in   a  
significant  reduction  in  cell  proliferation  (Fig  5.6A;;  HeLa,  p  =  0.0007  for  ruxo,  p  =  0.001  
for   fed  at  day  5;;  CaSKi,  p  =  0.001  for   ruxo,  p  =  0.005  for   fed  at  day  5),  which  was  
comparable  to  that  observed  with  the  STAT3  small  molecule  inhibitors  (Fig  1A).  To  
confirm   that   treatment   with   the   JAK2   inhibitors   reduced   STAT3   phosphorylation,  
western  blotting  was  performed.  In  these  experiments,  treatment  with  the  inhibitor  led  
to   a   dose-­dependent   reduction   in   JAK2   phosphorylation,   confirming   the   action   of  
ruxolitinib   (Fig   5.6B).   Importantly,   inhibition   of   JAK2   also   led   to   a   dose-­dependent  
reduction  in  STAT3  tyrosine  phosphorylation,  whilst  having  only  a  minimal  effect  on  
STAT3   serine   phosphorylation   at   the   higher   doses.   The   inhibition   of   JAK2   also  
resulted   in  a   reduction   in  cyclin  D1  expression  and  an   increase   in  p21  expression,  
consistent   with   the   results   obtained   upon   STAT3   inhibition.   Furthermore,   JAK2  
inhibition  resulted  in  a  significant  decrease  in  anchorage-­dependent  (Fig  5.6C;;    HeLa,  
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p  =  0.0002  for  ruxo,  p  =  2x10-­5  for  fed;;  CaSKi,  p  =  0.003  for  ruxo,  p  =  0.01  for  fed)  and  
anchorage  independent  colony  formation  (Fig  5.6D;;  HeLa,  p  =  6x10-­6  for  ruxo,  p  =  0.03  
for  fed;;  CaSKi,  p  =  2x10-­5  for  ruxo,  p  =  0.07  for  fed).       
  
JAK2   has   been   demonstrated   to   be   required   for   the   migration   and   invasion   of  
glioblastoma  cells  (453).  Therefore,  a  TranswellÒ  Assay  was  performed,  and  in  this  
assay  the  inhibition  of  JAK2  led  to  a  significant  reduction  in  the  number  of  migrated  
cells  through  the  uncoated  TranswellÒ  membrane  (Fig  5.6E;;  HeLa,  p  <  2x10-­7  for  all  
conditions;;  CaSKi,  p  <  2x10-­6   for  all   conditions)  and   the   invasion  of  HPV+  cervical  
cancer  cells  through  MatrigelÒ  coated  TranswellÒ  membranes  (Fig  5.6F;;  HeLa,  p  <  
2x10-­7   for  all  conditions;;  CaSKi,  p  <  2x10-­9   for  all  conditions).  Together,  these  data  
demonstrate  that  targeting  JAK2  generates  a  similar  phenotype  to  that  observed  when  
STAT3  is  inhibited  in  HPV+  cervical  cancer  cells.  
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Fig   5.6.   Inhibition   of   JAK2   inhibits   STAT3   phosphorylation   and   impairs   cell  
proliferation,  migration  and  invasion  in  HPV+  cervical  cancer  cells.  A)  Growth  
curve  analysis  of  HeLa  and  CaSKi  cells  after  addition  of   inhibitors   for  48  hours.  B)  
Representative  western  blot  of   ruxolitinib  dose   response  after  48  hours.  C)  Colony  
formation  assay  (anchorage  dependent  growth)  of  HeLa  and  CaSKi  cells  after  addition  
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of  inhibitors  for  48  hours.  D)  Soft  agar  assay  (anchorage  independent  growth)  of  HeLa  
and   CaSKi   cells   after   addition   of   inhibitors   for   48   hours.   E)   Quantification   of   the  
migration  and  invasion  of  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  48  hours  
by  Transwellâ   invasion  assay.  The  average  number  of   invaded  cells  per   field  was  
calculated   from   five   representative   fields   per   experiment.  Error   bars   represent   the  
mean   +/-­   standard   deviation   of   a   minimum   of   three   biological   repeats.   *P<0.05,  




















5.2.7  JAK2   inhibitors   induce  cell  cycle  arrest  and  apoptosis   in  HPV+  
cervical  cancer  cells  
JAK2  is  involved  in  the  regulation  of  the  cell  cycle  in  cancer  cells  through  the  direct  
phosphorylation  of  the  cyclin-­dependent  kinase  inhibitor  p27  (454).  In  contrast  to  the  
effect  of  role  of  STAT3  on  the  cell  cycle,  JAK2  inhibition  resulted  in  a  decrease  in  cells  
in  the  S  and  G2/M  phase  of  the  cell  cycle  and  a  significant  increase  of  cells  in  G0/G1  
(Fig  5.7A;;  HeLa  G0/G1,  p  =  0.017  for  ruxo,  p  =  0.03  for  fed;;  CaSKi  G0/G1,  p  =  0.035  
for  ruxo,  p  =  0.027  for  fed).  
To  identify  if  this  accumulation  of  cells  in  G0/G1  resulted  in  apoptosis,  cells  treated  
with  the  JAK2  inhibitors  were  analysed  by  Annexin  V  staining  and  flow  cytometry.  In  
both   HeLa   and   CaSKi   cells,   the   percentage   of   early   apoptotic   cells   significantly  
increased  after  STAT3  inhibition  for  6  hours  (Fig  5.7B;;  HeLa,  p  =  0.09  for  ruxo,  p  =  
0.001  for  fed;;  CaSKi,  p  =  8x10-­5  for  ruxo,  p  =  .003  for  fed).  By  24  hours,  the  percentage  
of  cells  in  late  apoptosis  increased  significantly  (HeLa,  p  =  0.05  for  ruxo,  p  =  0.03  for  
fed;;  CaSKi,  p  =  0.03  for  ruxo,  p  =  0.05  for  fed),  whilst  there  was  also  an  increase  in  
necrotic  cells  (HeLa,  p  =  0.009  for  ruxo,  p  =  0.32  for  fed;;  CaSKi,  p  =  0.19  for  ruxo,  p  =  
0.03  for  fed).  Inhibition  of  JAK2  also  resulted  in  a  significant  increase  in  apoptotic  and  
necrotic  cells  as  detected  in  the  DNA  condensation  assay  (Fig  5.7C).  
As  demonstrated   for  STAT3   inhibition  or  depletion,   the   induction  of  apoptosis  upon  
JAK2  inhibition  involved  the  activation  of  caspase  3,  as  determined  by  the  induction  of  
cleaved  caspase  3   (Fig  5.7D)  and  PARP  cleavage   (Fig  5.7E).  JAK2   inhibition  also  
resulted   in   the  reduction   in  Bcl  xL  protein  expression,  suggesting   that   the   inhibition  
JAK2  reduced  the  ability  of  STAT3  induce  the  expression  of  pro-­survival  genes.  
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Fig  5.7.  JAK2  inhibitors  induce  cell  cycle  arrest  and  apoptosis  in  HPV+  cervical  
cancer  cells.  A)  Flow  cytometric  analysis  of  cell  cycle  profile  of  HeLa  and  CaSKi  cells  
after  addition  of  inhibitors  for  24  hours.  A)  Flow  cytometric  analysis  of  Annexin  V  assay  
in   HeLa   and   CaSKi   cells   after   addition   of   inhibitors   for   6   and   24   hours.  C)   Flow  
cytometric   analysis   of  Vybrant™   DyeCycle™  Violet/SYTOX™   AADvanced™  
apoptosis  kit  assay  in  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  for  24  hours.  
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D)  Immunofluorescence  analysis  of  HeLa  and  CaSKi  cells  after  addition  of  inhibitors  
for   6   hours.  Cover   slips  were   stained   for  Cleaved   caspase  3   (green).  Nuclei  were  
visualised  using  DAPI  (blue).  E)  Representative  western  blot  of  HeLa  and  CaSKi  cells  
after  addition  of  inhibitors  for  24  hours  and  analysed  for  PARP  cleavage  and  Bcl  xL  
expression.  GAPDH  served  as  the  loading  control.  Error  bars  represent  the  mean  +/-­  
standard   deviation   of   a   minimum   of   three   biological   repeats.   *P<0.05,   **P<0.01,  




















5.2.8  JAK2  phosphorylation  correlates  with  cervical  disease  severity  
and  is  increased  in  HPV+  cervical  cancer  cells 
JAK2  phosphorylation  is  increased  in  several  haematological  cancers  (455).  As  the  
data  suggests  that  JAK2  activity  is  critical  for  HPV+  cervical  cancer  cell  proliferation  
and  survival,   the  phosphorylation  status  of  JAK2   in  cervical  disease  was  analysed.  
Cervical  liquid-­based  cytology  samples  representing  pre-­cancerous  cervical  disease  
progression   (CIN1-­3)  and  normal  cervical   tissue  were  analysed   for  phosphorylated  
and  total  JAK2  expression  by  western  blot.  JAK2  phosphorylation   increased   in   line  
with   cervical   disease   grade   from  CIN1   to  CIN3,   whilst   total   JAK2   levels   remained  
confirming   that   JAK2  phosphorylation   significantly   increases  upon   cervical   disease  
grade  (Fig  5.8B;;  CIN1,  p  =  6.5x10-­5;;  CIN2,  p  =  6.6x10-­6;;  CIN3,  p  =  8.1x10-­6). 
Finally,  to  confirm  if  JAK2  phosphorylation  was  elevated  in  cervical  cancer  cells,  the  
phosphorylation   status   in   cervical   cancer   cell   lines   was   also   assessed.   Increased  
JAK2  phosphorylation  was  observed  in  both  HPV16+  and  HPV18+  cervical  cancer  cell  
lines  when  compared  to  HPV-­  cervical  cancer  cells.  These  data  suggest   that  JAK2  
phosphorylation   correlates   with   cervical   disease   severity   and   JAK2   is   aberrantly  
phosphorylated  in  HPV+  cervical  cancer  cells.  
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Fig  5.8.  JAK2  phosphorylation  correlates  with  cervical  disease  severity  and  is  
increased   in   HPV+   cervical   cancer   cells.   A)  Representative   western   blots   from  
cytology   samples   of   CIN   lesions   of   increasing   grade   analysed   IL-­6   expression.  
GAPDH  served  as  a  loading  control.  B)  Scatter  dot  plot  of  densitometry  analysis  of  a  
panel  of  cytology  samples.  Twenty  samples  from  each  clinical  grade  (neg,  CIN  I-­III)  
were   analysed   by   western   blot   and   densitometry   analysis   was   performed   using  
ImageJ.  GAPDH  was  used  as  a   loading  control.  C)  Representative  western  blot  of  
from  six  cervical  cancer  cell  lines  –  two  HPV-­  (C33A  and  Dotc2  4510),  two  HPV16+  
(SiHa   and   CaSKi)   and   HPV18+   (SW756   and   HeLa)   –   for   the   expression   of  
phosphorylated   and   total   JAK2.   GAPDH   served   as   a   loading   control.   Data   are  
representative  of  at   least  three  biological   independent  repeats.  Error  bars  represent  
the  mean  +/-­  standard  deviation  of  a  minimum  of  three  biological  repeats.  *P<0.05,  




The  transcription  factor  STAT3  is  activated  in  many  haemopoietic  and  solid  cancers,  
including  HNSCC,  glioblastoma  and  pancreatic  cancer  (347,442,446).  STAT3  controls  
the   expression   of   genes   that   contribute   to   the   hallmarks   of   cancer,   including  
proliferation,   survival,   angiogenesis,   immune   evasion   and   inflammation(283).   In  
cervical   cancer,   STAT3   has   previously   been   shown   to   be   required   for   viral   gene  
expression  and  for  cell  growth  (370).  However,  these  studies  were  undertaken  using  
the   plant   metabolite   curcumin   that   has   broad   effects   on   a   multitude   of   signalling  
pathways.  Therefore,  data  gained  from  this  study  must  be   further  validated  using  a  
more   targeted  approach  using   specific   small  molecule   inhibitors.  Both   of   the   small  
molecule  inhibitors  used  in  this  study,  cryptotanshinone  and  S3I-­201,  bind  to  the  SH2  
domain  of  STAT3  to  inhibit  its  dimerisation  and  nuclear  translocation  (456,457);;  these  
compounds  offer  higher  levels  of  specificity  in  inhibiting  the  STAT3  signalling  pathway.  
Additionally,   the   authors   used  a  STAT3   siRNA   to   study   the   role   of  STAT3   in   viral  
oncogene  expression  and  cell  growth  (370).  Whilst  their  results  using  STAT3  siRNA  
correlate  with  the  pharmacological  data,  they  did  not  extend  the  siRNA  studies  to  look  
at  other  cancer  phenotypes  after  STAT3  depletion,  limiting  the  scope  of  their  study.  
In   this   study,   the   role   of  STAT3   in   cervical  cancer   proliferation,   survival  migration,  
invasion  and  EMT  was  investigated  using  two  highly  specific  small  molecule  inhibitors  
and  a  pool  of  STAT3  specific  siRNA.  The  results  demonstrate  that  STAT3  is  essential  
for   cell   proliferation   and   cell   cycle   progression   in   HPV+   cervical   cancer   cells   and  
inhibition  or  depletion  of  STAT3  resulted  in  caspase-­mediated  apoptosis.  Additionally,  
STAT3  is  required  for  the  migration  and  invasion  of  HPV+  cervical  cancer  cells  and  
the  expression  of  key  transcription  factors  and  cellular  markers  involved  in  EMT.  
A  number  of  validated  STAT3  target  genes  are  key  drivers  of  cell  proliferation.  Cyclin  
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D1  is  an  important  oncogenic  driver  of  cell  cycle  progression  and  its  expression  is  up-­
regulated  in  many  cancers,  often  in  a  STAT3  dependent  manner  (458).  Additionally,  
STAT3  signalling  can  repress  the  expression  of  p53  and  its  downstream  target  p21,  
proteins  that  are  essential  in  modulation  of  the  cell  cycle  and  inducing  growth  arrest  
(458).   The   data   here   demonstrates   that   in   HPV+   cervical   cancer   cells,   STAT3   is  
required  for  the  expression  of  cyclin  D1  and  repression  of  p21  (Fig  5.1C  and  D),  and  
this  could  be  one  of  the  mechanisms  utilised  by  STAT3  to  drive  cells  proliferation  and  
cell  cycle  progression  (Fig  5.2).  However,  as  both  HPV  E6/E7  expression  up-­regulates  
cyclin  D1  to  drive  transformation  (ref),  studies  in  which  cyclin  D1  is  overexpressed  in  
STAT3  silenced  cells  would  be  required  in  order  to  confirm  that  cyclin  D1  is  required  
for  the  proliferative  effects  associated  with  aberrant  STAT3  activation.    
A  key  hallmark  of  cancer  is  the  ability  to  avoid  apoptosis  (459).  As  p53  is  important  in  
inducing  apoptosis  after  genotoxic  stress  (460)  and  STAT3  regulates  a  number  of  pro-­
survival   genes,   the   role   of   STAT3   in   cell   survival   in   HPV+   cervical   cancer   was  
assessed.   Short   term   inhibition   or   depletion   of   STAT3   resulted   in   the   induction   of  
caspase  3  activation  (Fig  5.3E  and  F)  and  an  increase  in  early  apoptosis  as  indicated  
by  Annexin  V  assay  (Fig  5.3A  and  B).    After  24  hours,  cells  underwent  the  later  stages  
of  apoptosis  (Fig  5.3A-­D),  PARP-­1  cleavage  (Fig  5.3G  and  H)  and  necrotic  cell  death.  
At   the  molecular   level,   STAT3  was   required   for   the   expression   of   the   pro-­survival  
genes   Bcl   xL   and   Survivin   (Fig   5.3G-­H),   suggesting   that   STAT3   may   confer   cell  
survival  through  the  regulation  of  key  proteins  involved  in  cell  survival.  
The  ability   of   cancer   cells   to  migrate   and   invade   into   the   lumen  of   blood   vessel   is  
critical   for   cancer  metastasis   (459).  STAT3  controls   several   key   genes   involved   in  
these  processes,  such  as  matrix  metallopeptidase   family  members   (280).   In  HPV+  
cervical  cancer  cells,  STAT3  is  required  for  the  migration  of  cells  (Fig  5.4A-­C)  and  the  
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invasion  of  cells  through  a  Matrigelâ  membrane  (Fig  5.4D).  To  identify  if  this  is  due  to  
the  regulation  of  genes  involved  in  these  process,  further  experiments  will  be  required  
to  look  at  the  expression  of  such  genes.    
Another   key   component   of   cell   metastasis   is   epithelial   to   mesenchymal   transition  
(EMT).   This   process   is   controlled   by   the   expression   of   key   transcription   factors,  
including   Snail,   Slug   and   Twist,   that   act   to   activate   or   repress   key   epithelia   or  
mesenchymal  genes    (452).  Snail,  Slug  and  Twist  have  all  been  demonstrated  to  be  
involved   in   EGF-­stimulated   EMT   in   cervical   cancer   cells   (461).   Additionally,   IL-­6  
stimulated   EMT   has   been   shown   to   be   STAT3   dependent   in   cervical   cancer   cells  
(462).  The  data  presented  here  showed  that  STAT3  is  required  for  the  expression  of  
the  EMT  transcription  factors  Snail  and  slug,  the  mesenchymal  markers  vimentin  and  
ZEB-­1  and  the  repression  of   the  epithelial   tight   junction  protein  ZO-­1   (Fig  5.5A-­D).  
STAT3  inhibition  or  depletion  also  resulted  in  ‘cadherin  switching’,  where  N-­cadherin  
expression   is   decreased   and   E-­cadherin   expression   is   increased   (Fig   5.5A-­B).  
Additionally,   surface  expression  of   these   cadherin  markers   is   altered  upon  STAT3  
inhibition  or  depletion  (Fig  5.5E),  together  suggesting  that  STAT3  is  essential  for  the  
EMT  program  in  HPV+  cervical  cancer  cells.  Further  experiments  would  be  required  
to  demonstrate  if  STAT3  contributes  to  EMT  driven  by  key  cytokine  and  growth  factor  
stimulations,  such  as  EGF,  IL-­6  or  TGF-­b. 
STAT3  as  a  target  for  cancer  therapeutics  has  been  of  wide  interest  for  the  last  15  
years,   due   to   the   ability   to   generate   potent,   specific   inhibitors   and   the   number   of  
cancers   that   have   deregulated   STAT3   signalling.   However,   the   main   issue   with  
developing  a  clinically  available  STAT3  inhibitor  has  been  toxicity  in  early  stage  clinical  
trials.  Therefore,  a  better  approach  in  targeting  the  STAT3  signalling  pathway  may  be  
to   target   upstream   components   in   the   hope   of   reducing   toxicities   associated   with  
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STAT3  inhibition.  The  tyrosine  kinase  JAK2  is  key  for  STAT3  tyrosine  phosphorylation  
and   consequent   activation.   JAK2   is   phosphorylated   in   many   cancers,   particularly  
those  of  a  haematopoietic  origin  (455).  Several  of   these  cancers  harbour   the  JAK2  
V617F  mutant,  which   is   able   to   drive   cell  proliferation   and  enable   immune  escape  
(362,463).   Inhibition   of   JAK2   using   the   non-­selective   compound   AG490   has  
demonstrated   that   JAK2   activity   is   required   for   STAT3   phosphorylation   and   viral  
oncogene   expression   in   HPV+   cervical   cancer   cells   (370).   Here,   the   well-­
characterised  JAK1/2  inhibitor  Ruxolitinib,  which  has  been  approved  for  the  treatment  
of  Polycythemia  Vera   (PV),  and   the  JAK2   inhibitor  Fedratinib,  which   is  currently   in  
Phase  III  trials  for  myeloproliferative  disorders,  were  utilised  to  specifically  inhibit  JAK2  
in  HPV+  cervical  cancer.    In  these  cells,  use  of  either  inhibitor  resulted  in  a  significant  
inhibition  in  cell  proliferation  (Fig  5.6A)  and  colony  formation  potential  (Fig  5.6C-­D).  
JAK2   inhibition   also   decreased   STAT3   tyrosine   phosphorylation,   and   reduced  
expression   of   the   STAT3   target   cyclin   D1,   with   a   corresponding   increase   in   p21  
expression.  JAK2  inhibition  also  resulted  in  an  arrest  of  the  cell  cycle  and  the  induction  
of  apoptosis   in  HPV+  cervical  cancer  cells.  However,  whereas  STAT3   inhibition  or  
depletion  resulted  in  an  accumulation  of  cells  in  the  S  phase  of  the  cell  cycle  (Fig  5.2),  
JAK2  inhibition  resulted  in  an  accumulation  of  cells  in  G0/G1  (Fig  5.7A).  This  is  likely  
due   to   the   fact   that   JAK2   feeds   into   other   signalling   pathways   besides   STAT3,  
including   STAT5,   MAPK   and   PI3K/AKT   (464).   JAK2   inhibition   also   resulted   in  
apoptosis   with   the   induction   of   caspase   3   activation   (Fig   5.7B-­D)   and   PARP-­1  
cleavage  (Fig  5.7E).  As  JAK2  inhibition  also  resulted  in  the  reduced  expression  of  Bcl  
xL  (Fig  5.7E),  the  mechanism  of  apoptosis  induction  upon  JAK2  inhibition  may  be  due  
to  the  reduction  in  STAT3  dependent  Bcl  xL  expression.  Further  work  would  need  to  
demonstrate  that  STAT3  is  the  essential  downstream  target  of  JAK2  inhibition  Finally,  
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JAK2   phosphorylation   correlated  with   disease   severity   in   liquid   biopsy   samples   of  
cervical  disease  and  was  shown  to  be  in  aberrantly  phosphorylated  in  HPV+  cervical  
cancer  cells.    
In  conclusion,  the  data  presented  here  demonstrates  that  STAT3  is  essential  for  the  
proliferation,   migration   and   invasion   of   HPV+   cervical   cancer   cells.   Additionally,  
inhibition  or  depletion  of  STAT3  results  in  the  induction  of  apoptosis.  Furthermore,  the  
upstream  kinase  JAK2  is  aberrantly  phosphorylated  in  HPV+  cervical  cancer  cells  and  
targeting   JAK2  using   clinically  available   inhibitors   results   in  a   similar   phenotype   to  
STAT3   inhibition,   identifying   JAK2   a   potential   therapeutic   target   in   HPV+   cervical  
cancer.  
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Chapter  6.  Final  Discussion  and  Summary    
The  work  presented  in  this  thesis  represents  the  most  detailed  characterised  of  the  
role  of  the  STAT3  transcription  factor  both  during  the  differentiation-­dependent  HPV  
life  cycle  and  in  HPV+  cervical  cancer.  It  identifies  STAT3  as  an  essential  host  factor  
in  both  in  the  HPV  life  cycle  and  in  HPV-­mediated  transformation.    
As   an   obligate   intracellular   pathogen,   HPV   must   manipulate   host   cell   factor   and  
signalling   pathways   in   order   to   drive   is   own   replication   (375).   Previous   work   has  
identified  several  transcription  factors  and  signalling  pathway  modulated  by  HPV  to  
drive  viral  replication  and  persistence.  For  example,  the  transcription  factor  KLF4  has  
been  shown  to  regulate  keratinocyte  differentiation  and  cell  cycle  progression  and  is  
upregulated  by  HPV  to  drive  viral  transcription  (55).  Furthermore,  the  MAP  kinase  p38  
and  its  downstream  target  MAPKAP2  have  been  identified  as  critical  for  viral  genome  
amplification(397).  Extensive  studies  have  also  elucidated  a  critical  role  for  the  DNA  
damage  response  (DDR)  in  driving  viral  genome  amplification    (404).  Both  the  E6  and  
E7  proteins  can  activate  the  ATM  and  ATR  arms  of  the  DDR  (465),  with  several  key  
genes   involved   in   this   response  activated  by  HPV.  One  of   these  genes   involved   in  
HPV   mediated   activation   of   the   DDR   is   the   transcription   factor   STAT5.   STAT5  
activation   is   essential   for   HPV   induced   ATM   phosphorylation      (150)   and   the  
acetyltransferase  Tip60  is  a  key  regulator  of  STAT5  mediated  ATM  activation  (466).  
The  activation  of  the  ATR  arm  of  the  DDR  is  also  dependent  on  STAT5,  through  the  
regulation  of  Topoisomerase  IIb-­Binding  protein  1  (TopBP1)  (264).  
In  this  study,  the  transcription  factor  STAT3  was  identified  as  a  host  cell  factor  that  is  
essential   for   the  productive  HPV   life  cycle  (Chapter  3).  The  activation  of  STAT3  by  
HPV  E6  is  required  for  viral  transcription  and  oncogene  expression  and  is  critical  for  
cell   cycle  progression   in  keratinocytes.     Additionally,  a  phosphorylation  null  STAT3  
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mutant  displayed  a  profound  reduction   in  the  suprabasal  hyperplasia  seen   in  HPV-­
containing   organotypic   rafts,   demonstrating   the   requirement   of   STAT3   for   the   full,  
productive  HPV  life  cycle.  
STAT3  is  a  bona  fide  oncogene  that  can  induce  tumours  in  nude  mice    (272).  Of  the  
STAT  proteins,  STAT3  is  most  strongly  associated  with  tumour  formation  and  is  the  
only   STAT   family   member   that   is   embryonic   lethal   upon   genetic   deletion   (273).  
Aberrantly   phosphorylated   STAT3   is   found   in   several   cancers   of   diverse   origin  
(345,347,449,456)  and  the   targeting  of  constitutive  STAT3  signalling   is  a  promising  
therapeutic  target  in  oncology  (194).  The  activation  of  STAT3  occurs  primarily  through  
cytokine   and   growth   factor   signalling,   resulting   in   the   activation   of   JAK   proteins  
(194,467).  The  data  shows  that  JAK2  phosphorylation  is  increased  in  HPV  containing  
keratinocytes   and   this   is   induced   by   the   E6   oncogene.   Use   of   the   two   well  
characterised  small  molecule  inhibitors  of  JAK1/2  (ruxolitinib)  and  JAK2  (Fedratinib)  
demonstrated   that   the   tyrosine   phosphorylation   of   STAT3   in   HPV   containing  
keratinocytes   is   primarily   mediated   by   JAK2.   Importantly,   Ruxolitinib   is   a   clinically  
approved  inhibitor  of  JAK1/2  in  the  treatment  of  myeloproliferative  disorders;;  therefore,  
the  use  of  Ruxolitinib  or  other  JAK  inhibitors  may  have  therapeutic  potential  in  treating  
HPV  infection  and  this  line  of  research  warrants  further  investigation.     
Additionally,   the   identification   of   the   kinase   responsible   for   STAT3   serine  
phosphorylation  was   identified.  Many  candidate  kinase  have  been  shown  to   induce  
the  serine  phosphorylation  of  STAT3  and  this  appears  to  be  tissue-­specific  (191).  In  T  
cells,  the  kinase  CDK5  phosphorylates  STAT3  at  S727  and  this  is  required  to  supress  
the  development  of  Treg  cells(293),  whereas  in  the  liver  cancer  cell  line  HepG2,  Protein  
Kinase  C  (PKC)  induces  STAT3  S727  phosphorylation  in  an  IL-­6  dependent  manner  
(290,291)  However,   the   serine   727   residue  of  STAT3   sits   in   a   strong  MAP  kinase  
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consensus   sequence   (725PMSP728),   suggesting   that   MAP   kinase   may   play   an  
important  role  in  serine  phosphorylation  of  STAT3.  Indeed,  the  three  canonical  MAP  
kinases  p38,  ERK  and  JNK  have  all  been  demonstrated  to  induce  STAT3  S727  (287-­
289)Using  specific  small  molecule   inhibitors,  all   three  canonical  MAP  kinases  were  
identified  to  be  important  in  the  serine  phosphorylation  of  STAT3  in  HPV  containing  
keratinocytes.  Interestingly,  S727  phosphorylation  was  only  abolished  upon  inhibition  
of  all  three  MAP  kinases,  suggesting  a  level  of  redundancy  between  the  kinases  and  
demonstrating  the  critical   important  of  this  post-­translational  modification  of  STAT3.
     
The   upregulation   of   STAT3   phosphorylation   during   the   primary   life   cycle   of   HPV  
suggests  that  this  pathway  may  play  an  important  role  in  HPV-­driven  tumourigenesis.  
In  order  to  target  the  pathways  that  are  required  for  the  proliferative  environment  that  
HPV  induces  in  order  to  drive  its  own  replication,  it   is  essential  that  the  mechanism  
HPV  uses  to  regulate  these  pathways  is  understood.  STAT3  is  activated  in  response  
to  receptor  mediated  signalling.  The  most  well-­studied  signalling  axis  leading  to  the  
downstream   activation   of   STAT3   is   IL-­6/gp130   signalling   (194).   This   pathway   is  
deregulated   in   many   cancers   such   as   lung   cancer   (423),   chronic   lymphocytic  
leukaemia  (CLL)  (276)  and  glioblastoma  (468).  In  these  cancers,  STAT3  activation  is  
often  mediated  by  autocrine  IL-­6  signalling.  The  constitutive  activation  of  IL-­6/STAT3  
signalling  is  mostly  due  to  over-­production  of  IL-­6;;  this  is  primarily  due  to  the  loss  of  
key  negative  regulators  of  the  pathway,  such  as  SOCS3,  PIAS3  and  members  of  the  
protein   tyrosine  phosphatase  (PTPs)   family   (304,469,470).  Additionally,  constitutive  
activation  of  receptor  tyrosine  kinases,  such  as  EGFR,  or  tyrosine  kinases,  such  as  c-­
SRC,   can   induce   STAT3   activation   in   certain   cancers   (365).   Interestingly,   gain-­of-­
function  mutations   in   STAT3   are   relatively   rare   (471,472).   Recently,   a   number   of  
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mutations   in   the   SH2   domain   were   identified   in   Granular   Lymphocytic   Leukaemia  
(GLL)  and  these  were  suggested  to  promote  STAT3  phosphorylation  (473).     
In  HPV  associated  cancers,  it  is  well  studied  that  the  EGFR  is  over  expressed  and  can  
result   in   the  activation  of  key   tumourigenic  signalling  pathways,  such  as  MEK-­ERK  
signalling.   Additionally,   treatment   of   cervical   cancers  with   EGF   can   induce   STAT3  
phosphorylation  (431).  However,  the  data  here  suggests  that  IL-­6  is  the  main  driver  of  
STAT3  phosphorylation  in  HPV+  cervical  cancers.       
The  up-­regulation  of  IL-­6  and  autocrine  IL-­6  signalling  in  cancer  cells  is  often  involved  
in  constitutive  activation  of  STAT3  (474).  IL-­6  is  regulated  at  the  transcriptional  level  
and  contains  transcription  factors  binding  sites  for  AP-­1,  NF-­κB  CREB  and  SP-­1  (475).  
The  activity  of   the   transcription   factor  NF-­κB  often  coincides  with  STAT3  activity   in  
cancer(440).   Both   pathways   are   involved   in   promoting   a   pro-­inflammatory  
environment  and  this  has  been  demonstrate  to  promote  the  development  of  cancers,  
including  cervical  cancer  (173,370).  Like  STAT3,  the  deregulated  activation  of  NF-­κB  
is  attributed  to  several  mechanisms.  The  loss  of  negative  regulators  of  NF-­κB,  such  
as  the  deubiquitinases  CYLD  and  A20,  allow  uncontrolled  NF-­κB  signalling,  and  this  
results  in  the  expression  of  pro-­inflammatory  and  pro-­proliferative  genes  that  can  drive  
tumourigenesis  (476,477).   Indeed,   reduced  CYLD  expression   in  cervical  cancer  by  
the  over  expression  of  miR-­501  promotes  cell  proliferation  by  the  activation  of  NF-­κB  
(478).  The  regulation  of  IL-­6  by  NF-­κB  occurs  in  many  cancer  and  this  can  drive  an  
inflammatory  state  and  induce  the  autocrine/paracrine  activation  of  STAT3  (442,479).    
In  cervical  cancer,  the  E6  oncoprotein  has  previously  been  demonstrated  to  induce  
STAT3  phosphorylation  (369)  and  can  induce  IL-­6  expression  and  secretion  in  non-­
small   cell   lung   cancer   (NSCLC)   cells   (416).  However,   whether   or   not   IL-­6   directly  
contributes  to  STAT3  phosphorylation  in  cervical  cancer  cells  is  currently  unknown.  
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The  data  presented  in  Chapter  4  demonstrates  that  IL-­6  is  the  key  mediator  of  STAT3  
phosphorylation  in  HPV+  cervical  cancer  cells.  Additionally,  the  data  showed  that  NF-­
κB  is  essential  for  IL-­6  production  induced  by  E6.       
The  exact  mechanism  used  by  HPV  E6  to  drive  this  is  signalling  axis  is  still  currently  
unknown.  E6  has  been  demonstrated  to  induce  the  proteosomal  degradation  of  the  
deubiquitinase  CYLD,  resulting  in  the  activation  of  NF-­κB  in  hypoxic  cells    (173).  This  
may  contribute  to  the  increased  expression  and  secretion  of  IL-­6  and  the  subsequent  
activation   of   STAT3.   Further   studies   will   be   needed   to   identify   if   CYLD   plays   a  
significant  role  in  this  pathway.  Additionally,  the  tumour  suppressor  PTEN  has  been  
demonstrated  to  be  down  regulated  in  cervical  cancers  (480).  HPV  E6  has  also  been  
shown  to  induce  PTEN  phosphorylation,  thus  reducing  the  ability  of  PTEN  to  inhibit  
AKT  signalling    (481).  Again,  whether  PTEN  is  involved  in  this  pathway  requires  further  
studies.     
  
Currently,  there  is  still  no  targeted  therapeutic  for  the  virus.  Despite  the  availability  of  
vaccines  for  HPV,  the  efficacy  of  these  vaccines  in  reducing  HPV-­mediated  cancers  
is   only   just   becoming   apparent   (39).   In   addition,   men   and   women   who   reached  
adolescence  before  the  vaccine  was  available  and  are  thus  unlikely  to  be  given  the  
opportunity  to  receive  the  vaccine  are  still  susceptible  to  several  HPV  induced  cancers.  
Thus,  there  is  still  a  requirement  for  novel  therapeutics  to  treat  HPV  mediated  disease.  
Whilst  a  number  of  studies  have  shown  a  dependence  on  STAT3  for  cervical  cancer  
proliferation  and  survival  (369,370),  whether  STAT3  is  also  needed  for  cell  migration,  
invasion  and  EMT  induction  is  lacking.  The  data  in  chapter  5  demonstrated  that  STAT3  
essential  for  cell  proliferation  and  survival,  as  well  as  being  required  for  the  migration  
and  invasion  of  HPV+  cervical  cancer  cells.  Additionally,  STAT3  was  essential  for  the  
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expression  of   key   genes   involved   in  EMT.  The  mesenchymal   protein   vimentin   has  
previously  been  demonstrated  to  be  over  expressed  in  cervical  cancers  and  correlates  
with  an  invasive  phenotype  (482).  Furthermore,  nuclear  localisation  of  the  transcription  
factor  Snail  is  associated  with  the  downregulation  for  E-­Cadherin,  an  essential  part  of  
EMT  (483).  As  STAT3  regulates   the  expression  of  these  key  genes   involved   in   the  
initiation  of  EMT  and  the  maintenance  of  the  EMT  phenotype,  the  therapeutic  targeting  
of   STAT3   may   result   in   the   reversal   of   EMT   and   a   less   metastatic   phenotype.  
  
A   current   problem   in   developing   targeted   therapies   for   STAT3   is   the   high   level   of  
toxicity   seen   in   pre-­clinical   trials   (350).  Due   to   the   availability   of   clinically   available  
therapies   to  other  components  of   the   IL-­6/STAT3  signalling  pathway,  one  option   to  
target  STAT3  in  cervical  cancer  may  be  to  target  JAK2.  There  are  currently  clinically  
available  drugs  targeting  JAK2,  such  as  Ruxolitinib,  and  others  such  as  Fedratinib,  in  
late  stage  clinical  trials  (484).  The  targeting  of  JAK2  resulted  in  a  similar  phenotype  to  
the  inhibition  or  depletion  of  STAT3,  suggesting  that  JAK2  may  be  a  viable  target  for  
HPV+  cervical  cancer.  However,  further  is  required  to  identify  if  this  effect  is  seen  in  
vivo,   for   example   in   a   mouse   model   using   cervical   cancer   cell   xenografts.  
  
In   conclusion,   STAT3   is   essential   for   the   productive  virus   life   cycle   and   the  
activation   of   STAT3   by   HPV   E6   is   essential   for   the   tumorigenesis   of   HPV+  
cervical   cancer   cells.   Further   research   should   focus   on   the   feasibility   of  
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Table   2.   Primer   sequences   used   in   this   study   for   quantitative,   reverse  







pEGFP-­c1   pEGFP-­c1   Transient   Addgene  
pEGFP-­18E5   pEGFP-­c1   Transient  
Cloned  by  David  Kealy,  Macdonald  
lab  
pEGFP-­18E6   pEGFP-­c1   Transient  
pEGFP-­18E7   pEGFP-­c1   Transient  
pEGFP-­18E6DPDZ   pEGFP-­c1   Transient  
pEGFP-­18E6(F4V)   pEGFP-­c1   Transient  
pEGFP-­18E6(L52A)   pEGFP-­c1   Transient   Genewizâ  




pGL3   Transient   Addgene  
pcDNA3.1   pcDNA3.1   Transient   Addgene  
pcDNA3-­IkBa  (S32/36A)   pcDNA3.1   Transient  
Lab  of  Ronald  T  Hey  (University  of  
Dundee)  
pRc/CMV   pRc/CMV   Transient   Addgene  
pRc/CMV-­STAT3  S727A   pRc/CMV   Transient   Addgene  








pCMV   Lentiviral   Lab  of  Greg  Towers  (University  
College  London  (UCL))  
pUMVC3-­gag-­pol   pUMVC   Lentiviral  
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CCND1   CCGCTGGCCATGAACTACCT   ACGAAGGTCTGCGCGTGTT  
HIF1A   TGCATCTCCATCTTCTACCCAAGT   CCGACTGTGAGTGCCACTGT  
BIRC5   TCCACTGCCCCACTGAGAAC   TGGCTCCCAGCCTTCCA  
HPV18  E6   TGGCGCGCTTTGAGGA   TGTTCAGTTCCGTGCACAGAT  
HPV18  E7   GACCTAAGGCAACATTGCA   GCTCGTGACATAGAAGGTCAA  
IL6   GGCACTGGCAGAAAACAACC   GCAAGTCTCCTCATTGAATCC  
IL10   GGCATGCACAGCTCAGCACTG     GTTTCGTATCTTCATTGTCATG    
IL11   GACATGAACTGTGTTTGCCGC     CAGCCGAGTCTTCAGCAGCAG    
IL17   CGCTGATGGGAACGTGGACTAC     GGTGGACAATCGGGGTGACA    
LIF   CATAATGAAGGTCTTCGCGG     GAAGGCCTGGGCCAACACG    
OSM   AGTACCGCGTGCTCCTTG     CCCTGCAGTGCTCTCTCAGT    
SNAI1   TCGGAAGCCTAACTACAGCGA     AGATGAGCATTGGCAGCGAG    
SNAI2   TGTTGCAGTGAGGGCAAGAA     GACCCTGGTTGCTTCAAGGA    
Gene  Name   Forward  Primer   Reverse  Primer  








TPJ1   C TC TCT AGC GTA      GGATCTACATGCGACGACAA    
CDH1   GCCGAGAGCTACACGTTCA     GACCGGTGCAATCTTCAAA    
CDH2   TG GG ACAGTGTAACTG G     GAAACCGGGCTATCTGCTCG    
U6   CTCGCTTCGGCAGCACA   AACGCTTCACGCATTTGC  
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Table  3.  Primary  and  secondary  antibodies  used  in  this  study  for  western  blot  
(WB)  and  immunofluorescent  analysis  (IF).     
Antibody  Target   Manufacturer  
Antibody  
Type  
Antibody  Use  (dilution)  
STAT3   CST  (#9139)   Mouse  mAb   WB  (1:1000);;  IF  (1:400)  
pSTAT3  (Y705)   CST  (#9131)   Mouse  mAb   WB  (1:1000)  
pSTAT3  (S727)   Abcam  (ab32143)   Mouse  mAb   WB  (1:1000);;  IF  (1:400)  
Involucrin   SCBT  (sc-­21748)   Mouse  mAb   WB  (1:500);;  IF  (1:250)  
Filaggrin   Abcam  (ab81468)   Rabbit  pAb   WB  (1:1000)  
HPV18  E7   Abcam  (ab100953)   Mouse  mAb   WB  (1:1000)  
HPV18  E6   SCBT  (sc-­365089)   Mouse  mAb   WB  (1:1000)  
HPV16  E7   SCBT  (sc-­6981)   Mouse  mAb   WB  (1:500)  
HPV16/18  E6   Abcam  (ab70)   Mouse  mAb   WB  (1:500)  
HPV18  E1^E4   Provided  by  Dr  Sally  
Roberts   (University  
of  Birmingham)  
Mouse  mAb   IF  (1:100)  
GAPDH   SCBT  (sc-­365063)   Mouse  mAb   WB  (1:5000)  
GFP   SCBT  (sc-­9996)   Mouse  mAb   WB  (1:2000)  
p53   SCBT  (sc-­126)   Mouse  mAB   WB  (1:1000)  
p21   CST  (#2947)   Rabbit  mAb   WB  (1:1000)  
Bcl  xL   CST  (#2764)   Rabbit  mAb   WB  (1:1000)  
Cyclin  D1   Abcam  (ab134175)   Rabbit  mAb   WB  (1:1000)  
Cyclin  B1   SCBT  (sc-­594)   Rabbit  pAb   IF  (1:400)  
FLAG   Sigma  (F3165)   Mouse  mAb   WB  (1:1000)  
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Antibody  Target   Manufacturer  
Antibody  
Type  
Antibody  Use  (dilution)  
IL-­6   Abcam  (Ab6672)   Rabbit  pAb   WB  (1:1000),  
Neutralisation  (1:250)  
gp130   R&D  Systems  
(MAB628)  
Mouse  mAb   Neutralisation  (1:500)  
pJAK2  
(Y1007/Y1008)  
CST  (#3776)   Rabbit  mAb   WB  (1:500)  
JAK2   CST  (#3230)   Rabbit  mAb   WB  (1:1000)  
pERK1/2  
(T202/Y204)  
CST  (#43705)   Rabbit  mAb   WB  (1:1000)  
ERK1/2   CST  (#9102)   Rabbit  mAb   WB  (1:2000)  
p-­p38  
(T180/Y182  
CST  (#9211)   Rabbit  mAb   WB  (1:1000)  
p38   CST  (#8690)   Rabbit  mAb   WB  (1:1000)  
pJNK1/2  
(T183/Y185)  
CST  (#4668)   Rabbit  mAb   WB  (1:1000)  
JNK1/2   CST  (#9252)   Rabbit  mAb   WB  (1:1000)  
p-­cJun  (S73)   CST  (#3270)   Rabbit  mAb   WB  (1:1000)  
pMSK1  (T581)   CST  (#9595)   Rabbit  mAb   WB  (1:1000)  
pMK2  (T334)   CST  (#3041)   Rabbit  mAb   WB  (1:1000)  
p-­p65  (S536)   CST  (#3036)   Rabbit  mAb   WB  (1:1000)  
p65   CST  (#8242)   Rabbit  mAb   WB  (1:1000)  
PARP-­1   CST  (#9542)   Rabbit  mAb   WB  (1:1000)    
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Snail   CST  (#3879)   Rabbit  mAb   WB  (1:1000)  
Slug   CST  (#9585)   Rabbit  mAb   WB  (1:1000)  
Vimentin   CST  (#5741)   Rabbit  mAb   WB  (1:1000);;  IF  (1:400)  
ZEB-­1   CST  (#3396)   Rabbit  pAb   WB  (1:1000)  
ZO-­1   CST  (#8193)   Rabbit  mAb   WB  (1:1000)  
E-­cadherin   CST  (#3195)   Rabbit  mAb   Flow  cytometry  (1:200)  
a-­mouse  
secondary  
Sigma  (A4416)   Goat  pAb   WV  (1:5000)  
a-­rabbit  
secondary  
Sigma  (A6154)   Goat  pAb   WV  (1:5000)  
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Cells   Source   Cell  Characteristics  
Normal  human  
keratinocytes  (NHK)  
Lab  of  Dr  Sally  Roberts  
(University  of  Birmingham)  
Primary  keratinocyte  cell  from  human  
foreskin  
3T3  J2  fibroblasts  
Lab  of  Dr  Sally  Roberts  
(University  of  Birmingham)  
Immortalised  mouse  fibroblasts  used  as  
feeder  cells  for  NHKs  
C33A   ATCCâ  
Epithelial  cells,  derived  from  cervical  
cancer  biopsies;;  HPV-­  
DoTc2-­4510   ATCCâ  
Epithelial  cells,  derived  from  cervical  
carcinoma;;  HPV-­  
SiHa   ATCCâ  
Epithelial  cells  of  cervical  SCC,  reported  
to  contain  integrated  HPV16  genomes  
(~1  -­  2  copies  per  cell)  
CaSki   ATCCâ  
Cervical  epithelial  cells  from  metastatic  
site:  small  intestine;;  epidermoid  
carcinoma,  reported  to  contain  integrated  
HPV16  (~600  copies  per  cell)  as  well  as  
sequences  related  to  HPV18  
SW756   ATCCâ  
Epithelial  cells,  derived  from  cervical  
squamous  cell  carcinoma;;  HPV18+  
HeLa   ATCCâ  
Epithelial  cells  from  cervical  
adenocarcinoma,  have  been  reported  to  
contain  HPV18  sequences  
HEK293TT  
Lab  of  Mathew  Reeves  
(UCL)  
Epithelial  kidney  cells  expressing  the  
transforming  gene  of  adenovirus  5  and  a  
SV40  Large  T  expression  cassette  
